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Chapter 1 
INTRODUCTION 
 
For centuries, physicians have pursued effective and selective methods for treating 
diseases. Over just the past two centuries, it was discovered that there are substances in the 
blood that could fight infection, and by the turn of the last century, “magic bullets” were 
envisioned as a new frontier in medicine, particularly microbiology. However, it was not 
until the late 1940s that was provided the first evidence that antibodies developed against 
rodent tumors, and tagged with a radionuclide, could localize specifically to these 
targets.1,2,3,4 Today, we continue to face many of the same challenges that these early 
investigators encountered for radioconjugate targeting, such as antibody specificity, 
radiolabeling, and pharmacokinetics. 
Specificity is the Holy Grail for all targeted compounds. While specificity conjures 
visions of uniqueness between the target and its environment, more often specificity is 
derived from quantitative differences between the target and other host tissues. 
Architectural separation that isolates presentation in the environment from the more 
accessible presentation in the target can also produce a level of specificity. The lack of 
suitably specific antibodies for targeting human tumors was the most prominent factor 
contributing to the waning interest in radioantibody targeting in the 1960s. However, a key 
realization that a human colonic tumor xenografted in a hamster cheek pouch continued to 
express a newly defined human oncofetal antigen, CEA (carcinoembryonic antigen), paved 
the way for resurgence of radioantibody targeting in the 1970s that led to the first 
successful demonstration of tumor localization in patients by external scintigraphy.5,6 
Affinity-purified (monospecific) polyclonal antibodies used in these early clinical studies 
                                                
1 Korngold, L.; Pressman, D. Cancer Res. 1954, 14, 96–99. 
2 Pressman, D. Cancer 1949, 2, 697–700. 
3 Pressman, D.; Eisen, H.N.; Fitzgerald, P.J. J. Immunol. 1950, 64, 281–287. 
4 Bale, W.F.; Spar, I.L.; Goodland, R.L. Cancer Res. 1960, 20, 1488–1494. 
5 Goldenberg, D.M.; Hansen, H.J. Science 1972, 175, 1117–1118. 
6 Goldenberg, D.M.; Preston, D.F.; Primus, F.J.; Hansen, H.J.; Cancer Res. 1974, 34, 1–9. 
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were quickly replaced with murine monoclonal antibodies, and more recently with less 
immunogenic humanized or fully human antibodies and recombinant proteins. Monoclonal 
antibodies enhanced selectivity to a unique conformational determinant within a molecule, 
and recombinant antibodies have greatly amplified the repertoire of targeting structures 
with altered affinity/avidity and pharmacokinetic properties, but all base their binding on 
the guiding principles of antibodies and their specificity. 
Of course, tumor detection and therapy with radiolabeled antibodies could never 
have advanced without the contributions of the radiochemists and chemists, who expanded 
our choices from the staple radionuclide used for many years, 131I, which has poor imaging 
properties, to a host of new radionuclides with diverse imaging and therapeutic 
properties.7,8,9,10 
While specificity has a major role in defining the targeting utility of a given 
compound, its pharmacokinetic and biodistribution properties often have a more profound 
impact on tissue uptake than an agent’s specificity. This is because targeting is a passive 
process, where a molecule injected into the bloodstream wanders in the vascular or 
extravascular fluid, being carried along by the natural flow of body fluids, until it 
encounters a cell bearing a target molecule it can bind to. Once bound, the antibody has the 
potential to be held there until the radionuclide decays, it may be released from the cell and 
return to extracellular fluid volume, it can be catabolized by local peptidases or 
internalized by the tumor cells and catabolized by lysosomal enzymes. From this process, 
the radionuclide is freed from the antibody, where it may be released back into the 
circulation or retained locally by the cells. Many free radionuclides have an affinity for 
certain body tissues, such as radiometals for bone or radioiodine for the thyroid, or they 
can bind to serum proteins and then can be redirected to other tissues. Only a small portion 
of the injected antibody is deposited within a tumor, while the rest of the antibody 
eventually extravasates from the blood, like all other proteins, and is catabolized by the 
body’s tissues, mainly the liver, spleen, and other reticuloendothelial-rich organs. The 
delayed clearance from the tumor creates a differential uptake, where there is a higher 
                                                
7 Scheinberg, D.A.; Strand, M.; Gansow, O.A. Science 1982, 215, 1511–1513. 
8 Meares, C.F.; Moi, M.K.; Diril, H. et al. Br. J. Cancer Suppl. 1990, 10, 21–26. 
9 Deshpande, S.V.; DeNardo, S.J.; Meares, C.F. et al. J. Nucl. Med. 1988, 29, 217–225. 
10 Griffiths, G.L.; Goldenberg, D.M.; Jones, A.L.; Hansen, H.J. Bioconj. Chem. 1992, 3, 91–99. 
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concentration in the target than surrounding tissues, enabling visualization or potentially 
providing a therapeutic window of opportunity. 
The body’s blood vessels lead to well-defined regions of the body, but there are 
many tributaries that divert and dilute the radioimmunoconjugate within the total fluid 
volume of the body. This is where an agent’s properties, such as its size and composition, 
determine its fate. A molecule’s size/shape chiefly determines whether it will pass easily 
through the openings in the vascular channels and percolate into the extravascular space, 
where most diseases (targets) reside. Size also defines how quickly it will be sequestered 
from the blood by the reticuloendothelial system, primarily in the liver, spleen, and lymph 
nodes, where the larger sinusoidal openings between the endothelial cells enable more 
rapid extravasation, or if small enough (e.g., <60 kDa), to be removed via glomerular 
filtration.11 The composition of a molecule defines its charge and hydrophilicity, which can 
result in nonspecific binding to various tissues or even serum components. Composition 
naturally endows the conformational shape of the molecule that is key to binding to a 
target of interest, but other regions within the molecule’s structure might bind 
unintentionally to other tissues that could diminish specificity. Glycosylation also impacts 
tissue uptake and blood clearance.12,13 The high degree of homology in the basic core 
structure of an IgG reduces the potential for variable tissue binding and clearance that 
otherwise might be encountered with de novo targeting agents. Of course, agents can be 
administered in a defined compartment, such as the peritoneal cavity, by hepatic artery 
perfusion into the liver, or by the intrathecal route, or surgically resected cavity within the 
brain, to reduce the impact that a molecule’s pharmacokinetic properties might have on 
targeting.14 Compartmental administration for tumors that are anatomically confined 
allows the antibody to be exposed first to the antigen, but often, a sizable portion of the 
agent escapes into the blood or lymphatic channels, free to travel throughout the body. 
Some innovative methods for circumventing many of the pharmacokinetic 
challenges posed by a directly radiolabeled antibody, are based on the technique called 
pretargeting. 
                                                
11 Trejtnar, F.; Laznicek, M. J. Nucl. Med. 2002, 46, 181–194. 
12 Leung, S.O.; Qu, Z.; Hansen, H.J. et al. Clin. Cancer Res. 1999, 5, 3106s–3117s. 
13 Govindan, S.V.; Griffiths, G.L.; Michel, R.B.; Andrews, P.M.; Goldenberg, D.M.; Mattes, M.J. Cancer 
Biother. Radiopharm. 2002, 17, 307–316. 
14 Sharkey, R.M.; Goldenberg, D.M. Adv. Drug. Deliv. Rev. 2008, 60, 1407–1420. 
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Perhaps, surprisingly, the biggest problem with most radionuclide–antibody 
conjugates is that they are highly stable in the blood, and thus, generally wherever the 
antibody is distributed, the radionuclide follows. A radionuclide that dissociates from the 
antibody would have very unfavourable properties. For example, cyclic DTPA (diethylene 
triamine pentaacetic acid) anhydride was one of the first chelate derivatives used to 
complex a radiometal (111In or 90Y) to an antibody,7,15 but the radiometals, particularly 90Y, 
would slowly dissociate from the chelate, allowing the unbound metal to be taken up by 
other tissues, such as the cortical bone. When other chelates that bound the radiometal 
more tightly were developed (e.g., DOTA), they quickly replaced cyclic DTPA 
anhydride.16 Other chemistries have been developed that allow selective cleavage of the 
chelate–radiometal complex from the antibody when it is catabolized in the liver.17 This 
cleavable linkage improved tumor/liver ratios, but it did not address the high concentration 
of radioantibody remaining in the blood, and thus this method was unable to increase the 
radiation-absorbed dose delivered to the tumor. Molecular engineering has made great 
strides in crafting constructs that try to strike a balance between optimal blood and tissue 
clearance with reasonable tumor uptake and retention,18 but another approach had already 
achieved rapid blood clearance with high tumor uptake/good retention in the mid-1980s. 
This method is pretargeting, a technique that has evolved over the past 20 years to include 
three different approaches based on bispecific monoclonal antibodies (bsMAb) with 
radiolabeled haptens, avidin or streptavidin used for targeting radiolabeled biotin (Figure 
1.1), and antibody–oligonucleotide conjugates for targeting radiolabeled complementary 
oligonucleotides. In this thesis will be discussed only the Avidin/Biotin pretargeting 
system. 
 
                                                
15 Hnatowich, D.J.; Layne, W.W.; Childs, R.L. et al. Science 1983, 220, 613–615. 
16 Camera, L.; Kinuya, S.; Garmestani, K. et al. Eur. J. Nucl. Med. 1994, 21, 640–646. 
17 Peterson, J.J.; Meares, C.F. Bioconj. Chem. 1999, 10, 553–557. 
18 Seitz, K.; Zhou, H. J. Clin. Pharmacol. 2007, 47, 1104–1118. 
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Figure 1.1 Schematic representation of the Pretargeting System 
 
The most significant advance in pretargeting occurred when Hnatowich et al. 
introduced a new method to bridge the antibody and radionuclide targeting steps based on 
the ultrahigh affinity of biotin for avidin/streptavidin.19 Such avidin/biotin binding methods 
were already in use for in vitro immunoassays and immunohistochemistry. These and other 
investigators explored several configurations, using an antibody conjugated with avidin 
paired with radiolabeled biotin, or biotin-conjugated antibodies used to capture 
radiolabeled avidin.20,21,22 This avidin–biotin affinity was nearly 6 logs higher than most 
antibody–antigen interactions (Kd = 10-15 M), which essentially ensured an irreversible 
bond between biotin and avidin. Glycosylated avidin and its non-glycosylated counterpart, 
streptavidin, have four binding sites for biotin, which offers the potential that multiple 
radiolabeled biotins could be captured by a single pretargeted antibody–avidin conjugate. 
Importantly, the radiolabeled biotin had very rapid clearance from the body (biological 
half-life = 30 min), indicating that it had rapid extravasation and minimal binding to tissues 
as well as efficient renal excretion. The initial animal studies showed great potential of this 
method, and 2 years later, the first clinical studies were performed using the human milk 
fat globule-1 (HMFG1) IgG (anti-MUC1) coupled to streptavidin followed 2–3 days later 
with 111In-biotin.23 In addition to establishing important safety data, this study also showed 
that endogenous biotin, which is present in the serum and tissues, did not block the 
streptavidin–IgG conjugate’s ability to bind the subsequently administered 111In-biotin. 
                                                
19 Hnatowich, D.J.; Virzi, F.; Rusckowski, M. J. Nucl. Med. 1987, 28, 1294–1302. 
20 Paganelli, G.; Belloni, C.; Magnani, P. et al. Eur. J. Nucl. Med. 1992, 19, 322–329. 
21 Paganelli, G.; Magnani, P.; Zito, F. et al. Cancer Res. 1991, 51, 5960–5966. 
22 Paganelli, G.; Ferrari, M.; Ravasi, L. et al. Clin. Cancer Res. 2007, 13, 5646s–5651s. 
23 Kalofonos, H.P.; Rusckowski, M.; Siebecker, D.A. et al. J. Nucl. Med. 1990, 31, 1791–1796. 
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This was not the case in mice, where the concentration of endogenous biotin is much 
higher than in humans and requires animals to be fed a biotin-deficient diet for several 
days before initiating pretargeting studies.24,25 Tumor targeting was observed in 8/10 
patients but, disappointingly, similar uptake was seen in at least 5 of these patients given 
111In-biotin alone. This most likely represented blood pool radioactivity with slower 
washout from tumors due to their abnormal physiology. They also found that the 
streptavidin conjugate was immunogenic, with antibodies formed to both the murine IgG 
and the streptavidin. However, the more important finding from this study was the very 
low normal tissue and blood pool radioactivity (i.e., 111In-biotin cleared with an alpha- and 
beta-phase half-life of 2.4 min and 4.2 h, respectively), suggesting that this method, when 
properly optimized, could greatly reduce blood and tissue background radioactivity. 
This particular approach was perfected by the contributions of investigators at 
NeoRx Corp. (Seattle, WA). They focused their efforts on the development of a 
streptavidin conjugate prepared with the murine monoclonal antibody, NR-LU-10, as the 
pretargeting agent with 111In/90Y-DOTA (1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-
tetraacetic acid)-biotin. They also introduced the use of a clearing agent, galactose-
conjugated and biotinylated human serum albumin, to remove excess streptavidin–IgG 
from the blood before the radiolabeled biotin was injected. Hepatocytes have galactose 
receptors that effectively remove galactosylated antibody immune complexes from the 
blood,26,27 and biotin not only serves as a specific binding ligand for the streptavidin 
conjugate but also, in sufficient excess, it would prevent the binding of the subsequently 
administered radiolabeled biotin, allowing it to flow relatively unabated through the body 
until it reaches the tumor. In their procedure, the streptavidin–IgG conjugate was allowed 
2–3 days to achieve maximum tumor uptake, and then the clearing agent was given. One 
day later, the radiolabeled biotin was administered. Using this technique, Axworthy et al.28 
were the first to present provocative animal data indicating not only that a pretargeting 
approach could improve tumor/blood and tumor/tissue ratios, but also that the tumor 
uptake could be similar to that of a directly radiolabeled IgG. In some respects, this finding 
                                                
24 Hnatowich, D.J. Nucl. Med. Commun. 1994, 15, 575–577. 
25 Sharkey, R.M.; Karacay, H.; Griffiths, G.L. et al. Bioconj. Chem. 1997, 8, 595–604. 
26 Mattes, M.J. J. Natl. Cancer Inst. 1987, 79, 855–863. 
27 Ong, G.L.; Ettenson, D.; Sharkey, R.M. et al. Cancer Res. 1991, 51, 1619–1626. 
28 Axworthy, D.B.; Fritzberg, A.R.; Hylarides, M.D. et al. J. Immunother. 1994, 16, 158. 
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was puzzling since the pharmacokinetic behaviour of directly labelled IgG and antibody 
fragments predicted that the more rapidly an agent cleared from the blood, the lower would 
be its tumor accumulation. The radiolabeled biotin cleared more rapidly from the blood 
than any other previously reported directly conjugated antibody fragment, but despite this, 
it was able to achieve IgG-like tumor uptake. So how did this pretargeting procedure 
accomplish this targeting panacea? A comparison of a typical directly radiolabeled 
antibody targeting procedure with pretargeting procedures reveals some very important 
differences. 
With a directly radiolabeled antibody, the main goal should be to administer the 
smallest possible radioantibody protein dose prepared at the highest possible specific 
activity, which increases the probability that each molecule reaching the target would 
deliver a radioactive payload. Unfortunately, pharmacokinetic, biodistribution, and even 
specificity issues often dictate that additional unlabelled antibody be added 
(coadministered or preadministered) with the radiolabeled antibody to improve the 
antibody’s biodistribution or targeting. Any competition for radioantibody with an 
unlabelled antibody runs the risk of reducing the total amount of radioactivity delivered to 
the tumor, with a preinfusion having a greater risk of blocking some of the more accessible 
antigen-rich regions within the tumor before the radioantibody is given. Since uptake and 
tumor/blood ratios for an IgG are already low, it is not surprising that RIT 
(Radioimmunotherapy) with directly radiolabeled antibodies has had limited therapeutic 
impact, except for lymphomas, which have an inherently high radiosensitivity. As 
mentioned, smaller antibody fragments bearing radiometals have exceptionally high renal 
uptake and retention that greatly exceeds that delivered to the tumor. There have been 
animal studies reporting improved therapeutic activity for antibody fragments versus IgG, 
and there even have been methods that reduce renal uptake of radiometals.29,30,31 While 
each of these has been clinically evaluated, neither provided a sufficient therapeutic boost 
to spur further clinical evaluation. 
Pretargeting procedures often start with the injection of relatively high doses of the 
immunoconjugate (e.g., IgG-streptavidin or biotin conjugate) or bsMAb (Recombinant 
                                                
29 Behr, T.M.; Behe, M.; Stabin, M.G. et al. Cancer Res. 1999, 59, 2635–2643. 
30 Behr, T.M.; Blumenthal, R.D.; Memtsoudis, S. et al. Clin. Cancer Res. 2000, 6, 4900–4907. 
31 Behr, T.M.; Memtsoudis, S.; Sharkey, R.M. et al. Int. J. Cancer. 1998, 77, 787–795. 
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bispecific antibodies). This maximizes the conjugate loading in the tumor, which increases 
the number of binding sites available for the radiolabeled biotin or hapten (i.e., effector). 
Because the pretargeting immunoconjugate/bsMAb is not radiolabeled, there are no 
inherent radiotoxicity limitations to the amount administered. However, optimal 
pretargeting conditions do not demand administration of excessively high protein doses at 
levels that might saturate antigen binding sites in the tumor. Instead, optimal conditions 
will occur as long as the amount of conjugate or bsMAb prelocalized to the tumor is 
sufficient to capture the highest fraction of the effector that will ultimately reach the tumor. 
If an effector is radiolabeled at 2 mCi (74 MBq)/nmole, then often only 100 nmoles would 
be given. With such rapid elimination, only a small fraction of the effector will every pass 
through the tumor. Therefore, the administered amount of pretargeting agent needs only to 
be sufficient to optimize the capture of this small quantity of effector. In our experience, 
the optimal bsMAb dose can be reasonably approximated from the amount of hapten 
administered (which in our case is conjugated to a peptide) and is expressed as the mole 
ratio of the bsMAb to peptide-hapten. 
Pagel et al.32 provided additional insight into this point by showing in a human 
lymphoma xenograft model that the uptake of radiolabeled biotin (effector) could not be 
improved by pretargeting with immunoconjugates directed against multiple antigens, as 
compared to the best single antigen (e.g., CD20, CD22, or HLA-DR). By combining one 
immunoconjugate that had the highest uptake in the tumor with others that had lower 
uptake, they effectively reduced the number of moles of individual immunoconjugates in 
the tumor, thereby reducing the effector-capturing efficiency. 
In order to give the radiolabeled effector the best chance of binding to the 
prelocalized immunoconjugate in the tumor, the residual immunoconjugates in the body 
need to be blocked/cleared. The blood is the primary concern since any radiolabeled 
effector introduced by intravenous injection will encounter circulating immunoconjugates 
there first. However, other tissues also need to be considered, such as the liver that is the 
primary organ for removing IgG from the blood. Since most bsMAb studied to date have 
been F(ab’)2 fragments, investigators simply waited for the concentration of the bsMAb in 
the blood to be reduced to a level where interaction with the radiolabeled hapten-peptide 
                                                
32 Pagel, J.M.; Hedin, N.; Subbiah, K. et al. Blood. 2003, 101, 2340–2348. 
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was minimized. The molar ratios of immunoconjugate to hapten and degree of blood 
clearance required to minimize hapten-bsMAb interaction will vary depending on the 
binding affinity of the antihapten portion of bsMAb. Avidin–biotin approaches have relied 
on clearing agents that block and clear the immunoconjugates from the blood following a 
1–3 day period during which the immunoconjugate has an opportunity to reach peak levels 
in the tumor. This is particularly important for these procedures, because the ultrahigh 
affinity of biotin for avidin will ensure stable binding, even if very small amounts of the 
immunoconjugates remain in the blood and tissues. 
The timing requirements for a pretargeting procedure impose a restriction on the 
types of antigens that can be targeted; they must remain accessible (i.e., not internalized or 
catabolized) in sufficient quantity to bind the radiolabeled effector. 
However, the real strength of a pretargeting system is its ability to very efficiently 
trap the radiolabeled effector in the tumor. As with any injected agent, only a small 
fraction will percolate the vasculature of the tumor, so it is important to have the 
pretargeted immunoconjugates accumulate and be retained in the tumor in sufficient 
amounts to maximize the capture of the effector molecules. At least for the radiolabeled 
effectors commonly used in pretargeting, those leaving the vascular space will quickly 
encounter the pretargeted immunoconjugates bound to the surface of tumor cells. Binding 
to the effector-capturing agent, whether it is streptavidin or a bsMAb, will retain the 
effector in the tumor, while within minutes, the unbound effector molecules are rapidly 
eliminated from the body, creating almost immediate and exceptionally high tumor/blood 
ratios. The radiolabeled effector will persist in the tumor as long as it remains bound to the 
bsMAb’s antieffector arm or to streptavidin, and as long as the immunoconjugate remains 
fixed to the tumor antigen. Unlike the initial bsMAb pretargeting configuration, where the 
effector was a single chelate–radiometal complex (i.e., a hapten), LeDoussal et al. found 
that tethering two haptens together with a small peptide linker enhanced uptake and 
retention of the effector; this was referred to as an affinity enhancement system (AES).33 
An antibody or even a fragment, whose larger size impedes its transvascular 
movement into tumors, and rather than being easily eliminated, it continues to circulate in 
the body, awaiting catabolism for excretion of the radioactivity. While this might provide 
                                                
33 LeDoussal, J.M.; Martin, M.; Gautherot, E.; Delaage, M.; Barbet J. J. Nucl. Med. 1989, 30, 1358–1366. 
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the potential for multiple tumor passes, the concentration of the antibody in the blood 
eventually decreases over time, being sequestered by other tissues in the body, thereby 
making it less available for tumor uptake. In addition, the longer the tumor uptake is 
delayed, the more of the radionuclide will be released by catabolism and be redistributed to 
other parts of the body, contributing to toxicity. Thus, pretargeting procedures are more 
highly adept at achieving exceptionally rapid tumor uptake and blood clearance than direct 
targeting of radioimmunoconjugates. The end result is that tumor radionuclide delivery is 
maximized, with possible higher radiation dose rates and often increased radiation- 
absorbed doses, while most normal tissues are spared prolonged radiation exposure34,35 
(Figure 1.2). As a consequence, significantly improved antitumor responses have been 
observed in a variety of animal models with pretargeting procedures compared to direct 
RIT.36 
 
 
Figure 1.2 Radiolabeled antibodies (a) vs. radiolabeled biotin (b). 
 
                                                
34 Axworthy, D.B.; Reno, J.M.; Hylarides, M.D. et al. Proc. Natl. Acad. Sci. USA 2000, 97, 1802–1807. 
35 Sharkey, R.M.; Karacay, H.; Cardillo, T.M. et al. Clin. Cancer Res. 2005, 11, 7109s–7121s. 
36 Pagel, J.M.; Pantelias, A.; Hedin, N. et al. Cancer Res. 2007, 67, 5921–5928. 
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A different pretargeting procedure based on streptavidin-biotin was first proposed by 
Paganelli et al.,37 who compared a two-step and a three-step method for delivering either 
131I-streptavidin or 111In-biotin, respectively, to athymic mice bearing peritoneal implants 
of a human colon cancer cell line (LoVo) pretargeted with a biotinylated antibody 
(AUA1). Radiolabeled streptavidin was localized to tumors pretargeted 1 day earlier with 
the biotinylated antibody. In the second case, instead of using a streptavidin–IgG conjugate 
to localize the radiolabeled biotin, the same antibody conjugated instead to biotin was 
administered. One day later, animals were injected with a 10-fold molar excess of 
unlabeled avidin, and then 2 h later with 111In-biotin. 111In-biotin was used to evaluate the 
procedure, but it is not a therapeutic analogue of biotin (90Y-biotin would be required for 
treatment). All injections were given intraperitoneally. Tumors isolated from the peritoneal 
cavity 4 h after the radiopharmaceutical injection had an uptake of approximately 24% 
ID/g with the pretargeted approach and using 131I-streptavidin; this was four times higher 
than with a directly radiolabeled IgG (MAb AUAI), and with improved tumor/blood ratios 
(!3.5:1 versus <1:1). However, 131I-streptavidin uptake in the liver was elevated, because 
streptavidin formed complexes with circulating biotinylated antibody in the blood, which 
were then deposited in the liver. They found that an intraperitoneal injection of unlabelled 
avidin could reduce the concentration of the biotinylated antibody in the blood, and so they 
decided in the second approach to administer an excess of unlabelled avidin 2 h before 
administering 111In-biotin. In this procedure, the unlabelled avidin would bind first to the 
biotinylated antibody prelocalized to the peritoneal tumors, and as the excess avidin enters 
the bloodstream from the peritoneal cavity, it would bind to the circulating biotin IgG that 
would then be removed quickly by the liver (avidin is glycosylated, which accelerates its 
clearance by hepatic asialoglycoprotein receptors). When 111In-biotin was subsequently 
injected i.p. 2 h later, tumor/blood and tumor/liver ratios were improved to approximately 
50:1 and 35:1 just 2 h after radiopharmaceutical administration. However, tumor/kidney 
ratios were decreased to <1:1, reflecting the higher retention of 111In-biotion in the kidneys 
compared to 125I-streptavidin in the former approach. 
This method was quickly examined in patients, but with all injections given 
intravenously (i.v.). In this first clinical study, patients with a variety of CEA-producing 
                                                
37 Paganelli, G.; Pervez, S.; Siccardi, A.G. et al. Int. J. Cancer 1990, 45, 1184–1189. 
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tumors received 1mg of a biotinylated anti-CEA IgG (murine MAb FO23C5), followed 3 
days later by 4–6 mg of avidin, and finally 2 days later by 111In-biotin. Tumor visualization 
was apparent on gamma camera scans with tumor/blood and tumor/liver ratios exceeding 
5:1 within 20 min (tumor/kidney ratios were !1:1). Two patients were imaged 1 month 
later without the benefit of pretargeting with the biotinylated antibody; one was 
administered 111In-biotin alone, the other given the same dose of avidin followed by 111In-
biotin. In these follow-up studies, there was no obvious tumor targeting, whereas the 
pretargeting procedure localized their lesions. Imaging of one patient with 111In-FO23C5 
anti-CEA F(ab’)2 2 weeks prior to the pretargeting study failed to disclose metastatic 
deposits in the liver because of elevated normal liver uptake, but with the pretargeting 
approach, these lesions were seen subsequently. These studies established the proof-of-
principle for this new alternative cross-linking method based on streptavidin–biotin 
binding, and set the stage for future therapeutic use. 
The first radiotherapeutic trial with the avidin–biotin pretargeting system was 
subsequently reported using this method but with a slight modification.38,39 The trial, 
performed in patients with high-grade gliomas, involved the intravenous injection of an 
antitenascin IgG-biotin immunoconjugate (35 mg/m2). The clearing step was modified to 
include first an injection with avidin (30 mg) that was followed 30 min later by 
streptavidin (50 mg). This modification first allowed avidin to clear the biotin conjugate 
from the blood by forming complexes that would be removed by the liver (avidin’s 
glycosylation aids in hepatic removal of the complexes). By administering streptavidin 
later, when most of the circulating biotinylated antibody conjugate was already complexed 
with avidin and shuttled to the liver, it would circulate somewhat longer in the blood, 
allowing it enough time to bind to the pretargeted biotin immunoconjugate in the tumor. 
The next day, patients received 111In or 90Y-labeled biotin for binding to the streptavidin 
now prelocalized to the tumor and bound to the biotinylated antibody. Given the potential 
for limited transport across the blood-brain barrier, it was interesting to note that the 
investigators chose to administer all these agents intravenously. However, imaging studies 
clearly showed the tumors were localized. Even 12 months after treatment, 17% of the 
                                                
38 Paganelli, G.; Grana, C.; Chinol, M. et al. Eur. J. Nucl. Med. 1999, 26, 348–357. 
39 Cremonesi, M.; Ferrari, M.; Chinol, M. et al. Eur. J. Nucl. Med. 1999, 26, 110–120. 
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patients still showed tumor reduction, and one patient was alive and without evidence of 
disease after a 10-year follow-up. 
These promising results led to a follow-up pretargeted RIT trial in grade III/IV 
glioma patients using the same protocol as above immediately after primary surgery and 
radiotherapy, to determine time to relapse and overall survival. 
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Chapter 2 
BIOTIN DERIVATIVES 
 
2.1 The radioimmunotherapy 
In the recent years, large experience has been accrued through the clinical 
applications of radiolabeled monoclonal antibodies in diagnosis and therapy of malignant 
diseases. Currently, the cancer treatments involve surgery often followed by chemotherapy 
and radiation therapy. The therapy depends on the differences in sensitivity from the 
normal tissue compared to the tumor. Radiation and chemotherapy have the disadvantage 
that they destroy both healthy and malignant cells thus causing severe side-effects. A new 
type of radiation therapy, called radioimmunotherapy (RIT), uses monoclonal antibodies 
(MoAbs) to address the radiation on the tumor. The radioimmunotherapy can be used to 
treat metastases otherwise difficult to detect and to treat by other diagnostic means because 
in RIT method the radiation comes from inside of the tumor differently from the 
conventional external radiation therapy. The RIT, in fact, is a clinical technique allowing, 
through radiopharmaceuticals, the radionuclide to bind a tumor-associated antigen on the 
membrane of tumor cells. 
 
2.2 Radiopharmaceuticals 
A radiopharmaceutical is a radioactive compound used for diagnosis and/or 
therapeutic treatment of human diseases. Usually radiopharmaceuticals have not 
pharmacologic effects, because in most cases they are used in traces. 
A radiopharmaceutical is made up of two parts: 1) the vector, i.e. the drug, which 
localises itself in the target area, and 2) the radioisotope, i.e. 99Tc, 111In, 131I. 
Radiopharmaceuticals are administered by intravenous or intra-peritoneal way. For this 
reason they must be sterile, pyrogen free, not toxic and are made according to the GMP of 
conventional drugs. 133Xe itself, for example, can be considered as a radiopharmaceutical; 
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on the other side, radiolabeled compounds are considered radiopharmaceuticals, i.e. 
proteins labelled with 131I. Radiopharmaceuticals must have some preset characteristics: 
• Easy availability: the synthesis must be cheap and easy. 
• Short effective half-life: the physical half-life (Tp) is the time necessary the activity 
of a radiopharmaceutical to be halved. Tp is characteristic for each radionuclide and 
independent from the chemical and physical features. The constant decay is 
correlated with Tp by the formula "p = 0.693/Tp. The biologic half-life (Tb) is the 
time necessary to eliminate from the body the moiety of the administered dose. 
Radiopharmaceuticals can be excreted in several ways, for example through 
excrements or urine. The elimination of a radiopharmaceutical from an alive 
organism depends both on the physical decay of the radionuclide and on the 
biological clearance. The effective half-life (Te), for this reason, is lower than Tp 
and Tb and it must be lower as possible. 
• Particle emission: the choice of radioisotope is important. For diagnosis, a "-
emitting radioisotope with a short half-life will give the clearest images and the 
lowest radiation dose to the patient. In a therapeutic radiolabeled drug, ideal 
radioisotopes are characterised by an abundance of non-penetrating radiations (i.e., 
! or # particle emitters). 
• High target-to nontarget activity ratio: the main aim is to obtain the high 
concentration of the radiopharmaceutical, in the target organ, both for therapeutic 
and diagnostic applications. The surrounding tissues might have a lower 
concentration of radiopharmaceutical. In this case the instrumentation can measure 
the radioactivity distribution with high accuracy. The organ involved in the 
pathology is so detected. 
• Metabolic stability: obviously a radiopharmaceutical must be stable in vivo. In the 
most cases the organism metabolizes the drug during the diagnostic text; in other 
circumstances the metabolism can give important information after accumulation in 
the organ. 
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2.3 Radionuclides 
Radionuclides are defined by several physical parameters: type of particles emitted, 
energy and physical half-life (Table 2.1). Chemical parameters are also important, as the 
chemistry involved in radiolabeling largely imparts on in vivo stability of the conjugates. 
Finally, the radiochemical purity and the specific activity that may be achieved in clinical 
practice are also important. 
 
Table 2.1 Radionuclides physical half-life, decay and maximum penetration. 
Radionuclide Physical 
half-life 
Particle energy 
(MeV) 
Maximum 
tissue range 
32P 14.3 d # (1.71) 8.7 mm 
67Cu 2.58 d # (0.54), $ (0.185) 1.8 mm 
90Y 2.67 d # (2.28) 12.0 mm 
105Rh 1.48 d # (0.57), $ (0.320) 1.9 mm 
109Pd 13.6 h # (1.0) 4.6 mm 
111Ag 7.47 d # (1.05), $ (0.34) 4.8 mm 
125I 60.0 d $ (0.027) 10 nm 
131I 8.04 d # (0.6), $ (0.364) 2.0 mm 
177Lu 6.7 d # (0.497), $ (0.208) 1.5 mm 
186Re 3.77 d # (1.08), $ (0.131) 5.0 mm 
188Re 16.95 h # (2.13), $ (0.155) 11.0 mm 
198Au 2.7 d # (0.97), $ (0.411) 4.4 mm 
211At 7.2 h % (6.8) 65 µm 
212Bi 1 h % (7.8), $ (0.72) 70 µm 
99mTc 6 h $ (0.143) 6.7 mm 
64Cu 12.7 h # (0.573), $ (1.34) 10 µm 
 
The kind of particles emitted by the radionuclide is the most important parameter. 
Depending on their decay, radionuclides can be divided into two primary classes: 
diagnostics and therapeutics. Diagnostic radiopharmaceuticals (radioimmunoscintigraphy) 
are molecules labelled with "-emitting isotopes. Gamma rays (high energy photons) can be 
detected by appropriate instruments (Gamma cameras); they are electromagnetic radiations 
and provide a non-invasive method of assessing the disease showing ill tissues and 
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monitoring the effect of treatment. !-emitters and #-emitters are used mainly for 
radioimmunotherapy. # particles, because of its very large mass and its charge, have a very 
short range. They are not suitable for radiation therapy for their great destructive power 
within a short range. In contact with fast-growing membranes and living cells, they cause 
maximum damage. The !-emitters have a greater radius penetration than #-particles, but 
still much less than gamma rays (Figure 2.1). They show ideal characteristics for treatment 
of solid tumours. 
 
 
Figure 2.1 Penetration range. 
 
The path lengths of !-particles are significantly greater than the diameter of cancer 
cells. The radiation effect of beta particles from the site of antibody binding on the 
neighbouring cells is the so-called ‘crossfire effect’ (Figure 2.2). This effect allows a 
therapeutic radiation doses to cells in bulky, poorly vascularised tumors, or even in tumors 
with heterogeneous antigen expression. This phenomenon reduces the requirement to 
target every single tumour cell, thereby bypassing tumour antigen heterogeneity and 
inadequate tumour vascularisation. 
 
 
Figure 2.2 Crossfire effect. 
Chapter 2. Biotin derivatives 
 22 
While the range of radioisotope for diagnostic application is broad enough (In, I, Te, 
etc.), for therapeutic application is limited as only two radionuclides are used, Yttrium-90 
and Renium-186. In particular Yttrium-90 (90Y) has been applied with success to the 
treatment of several malignancies, it is easily obtained by a generator 90Sr/90Y; 90Y has an 
half-life of 2.7 days and it is a pure !-emitter. 
 
2.3.1 Radionuclides and chelating agents 
In the past, biological macromolecules like enzymes, antibodies or other kinds of 
peptides, were radiolabeled binding the radioactive metal directly on the molecule. In 
particular the most frequently used radioisotope has been iodine (125I and 131I), due to its 
abundance and to its easy introduction into aminoacidic residues of proteins. 
Currently it is preferred to proceed through indirect method. This involves the use of 
a chelator (specific to the particular metal) and a linker to covalently attach the chelator to 
the biomolecule. It is necessary to pay attention so that the label does not modify the zones 
appointed for the binding to the receptor and does not negatively influence therefore the 
affinity of the biological system. For example the chelating agent generally links to some 
part of the antibodies through a modified group of lysine. This random interaction risks to 
modify the receptor site of the antibody and consequently to alter its affinity for the 
antigen. In order to obviate to the problem, the chelator is attached to sulphur residues, far 
from the zone of tie with the antigen.40 
The peraza-crown macrocycles constitute the greatest group among multidentate 
macrocyclic compounds.41 These ligands are involved in numerous applications as 
selective complexing agents of transition and heavy metals and other metallic ions like 
alkaline earths.42,43 The peraza-crown generally forms strong complexes when they have at 
least three nitrogen atoms on the ring. Two cyclic tetraamines have played a key role in 
                                                
40 Aftab, E.; Stoldt, H.S.; Testori, A.; lmperatori, A.; Chinol, M.; Paganelli, G.; Geraghty, J. Eur. J. Surg. 
Oncol. 1996, 22, 381-396. 
41 Bradshow, J.S.; Krakowiak, K.E.; Izatt, R.H. “Aza-crown macrocycles” in “The chemistry of heterocyclic 
compounds” Edward, C., Taylor, Ed., Wiley, J. & Sons Inc., New York, 1993. 
42 Bianchi, A.; Micheloni, M.; Paoletti, P. Coord. Chem. Rev. 1991, 110, 17. 
43 Tsukube, H.; Yamashita, K.; Iwachido, T.; Zenki, M. Tetrahedron Lett. 1989, 39, 3983. 
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this field: the 12-membered 1,4,7,10-tetraazacyclododecane (cyclen) and the 14-membered 
1,4,8,11-tetraazacyclotetradecane (cyclam)44 (Figure 2.3). 
 
 
Figure 2.3 Cyclen and Cyclam structures. 
 
These macrocycles have the advantage being N- and C-functionalized with side 
chains carrying ligating groups.45,46 In particular, the respective tetraacetic acids: 1,4,7,10,-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic (H4-DOTA or DOTA) and 1,4,8,11-
tetraazacyclotetradecane-N,N’,N’’,N’’’-tetraacetic (H4-TETA or TETA) (Figure 2.4) were 
prepared from the previously mentioned macrocycles. 
 
 
Figure 2.4 DOTA and TETA structures. 
 
The first publication about the synthesis of these ligands has been described by 
Stetter et al.; their use have led to some improvements in stability in vivo compared to 
EDTA.47,48 
Desreux et al. also conducted 1H and 13C-NMR studies on complexes of DOTA with 
lanthanides49 and potentiometric measurements on this and other chelates.50 Other studies 
                                                
44 Richmann, J.E.; Atkins, T.J. J. Am. Chem. Soc. 1974, 96, 2268. 
45 Di Vaira, M.; Mani, F.; Stoppioni, P. J. Chem. Soc. Dalton Trans 1998, 1879-1884. 
46 Bu, X.H.; Cao, X.C.; Zhang, W.Q.; Zhang, R.H.; Clifford, T. Transition Met. Chem. 1997, 22, 513-515. 
47 Stetter, H.; Frank, W. Angew. Chem. 1976, 88, 760. 
48 Stetter, H.; Frank, W.; Mertens, R. Tetrahedron 1981, 37, 767. 
49 Desreux, J.F. Inorg. Chem. 1980, 19, 1319-1324. 
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on tetraaza-cyclams and their derivatives, as DOTA and TETA, investigated the 
connection between cavity size and ability to complex calcium51 and trivalent lanthanides 
as La(III), Eu(III), Pr(III), Yb(III).52 
The research work on the complexing ability of DOTA and TETA towards In(III) 
and Y(III) salts was particularly important. In fact 111In ($-emitter) and 90Y (#-emitter) 
isotopes were already used for medical applications such as tracers.53 In particular the 
stability of 90Y-DOTA complex in physiological conditions appears very high.  
In order to understand the importance of these results, it is appropriate to remember 
that since ‘70 Meares and his group tried to introduce binding sites for metal ions into the 
protein using modified chelating agents.54  
The successful attempt in this field opened the possibility to use radioactive ions as 
tracers. In the following years monoclonal antibodies, labeled with macrocyclic chelates 
bind to radioactive metal ions as 111In, 90Y, 67Cu, were introduced in the organism for 
tumors therapy and diagnosis.55 
In order to favour the coupling with the specific immunoglobulin, one of the 
carboxylic groups of the N-tetraazamacrocycles was activated in the following way56 
(Figure 2.5). 
 
 
Figure 2.5 Activation of a chelating tetraazamacrocycle. 
 
                                                                                                                                              
50 Desreux, J.F.; Merciny, E.; Loncin, M.F. Inorg. Chem. 1981, 20, 987-991. 
51 Stetter, H.; Frank, W. Angew. Chem. Int. Ed. Engl. 1976, 15, 686. 
52 Desreux, J.F.; Barthelemy, P.P. Nucl. Med. Biol. 1988, 15, 9. 
53 Wu, C.; Virzi, F.; Hnotovich, D.J. Nucl. Med. Biol. 1992, 19, 239. 
54 Meares, F.; Goodwin, D.A.; Lenny, C.S.H.; Girgis, A.Y.; Silvester, D.J.; Nunn, A.D.; Lovender, P.J. Proc. 
Natl. Acad. Sci. USA 1976, 73, 3803. 
55 Hnatowich, J.; Layne, R.L.; Lanteigne, D.; Davis, M.A. Science 1982, 220, 613; Hnatowich, D.J.; Virzi, 
F.; Doherty, P.W. J. Nucl. Med. 1985, 26, 503; Cox, P.L.; Jankowski, K.J.; Kataki, R. J. Chem. Soc. 
Chem. Comm. 1989, 12, 797; Hnatowich, D.J. Nucl. Med. Biol. 1990, 17, 49; Deshpende, S.V.; De 
Nardo, S.J.; Kukis, D.L.; Mori, M.K; McCall, M.J.; De Nardo, C.L.; Meares, C.F. J. Nucl. Med. 1990, 31, 
473. 
56 Buckeley, R.C.; Searle, F. FEBS 1984, 166, 202. 
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The carboxylic group, so activated, was reacted with the suitable monoclonal 
antibody of the class IgG and the compound obtained was labelled with halogen metal. 
Subsequent development of these chelating agents was the synthesis of bifunctional 
molecules. This type of molecules carried on one side strong chelate groups and on the 
other a pendant arm with a reactive functional group.57 Among these, 2-(p-nitrobenzyil)-
1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (p-nitrobenzyl-DOTA) 
(Figure 2.6) was particularly important. 
 
 
Figure 2.6 Structure of p-nitrobenzyl-DOTA. 
 
This molecule is able to coordinate 90Y strongly also in presence of biological 
ligands58 and can binds G immunoglobulin (IgG) directly. 
More recently, somatostatin analogues were used for carrying radioactive metals 
complexed with macrocyclic ligands on the human cancer cells59,60 exploiting the fact that 
some classes of tumors were known to over-express certain receptors for the somatostatin. 
Among these compounds there is the eight amino acid somatostatin analogue octreotide 
(Figure 2.7). 
 
                                                
57 Meares, F.; Wensel, T.G. Acc. Chem. Res. 1984, 17, 202. 
58 Mori, M.K.; Meares, C.F.; De Nardo, S.J. J. Am. Chem. Soc. 1988, 110, 6266; Renn, O.; Meares, C.F. 
Bioconjugate Chem. 1992, 3, 563. 
59 Albert, R.; Smith-Jones, P.; Stolz, B.; Simeon, C.; Knecht, H.; Bruns, C.; Pless, J. Bioorg. Med. Chem. 
Lett. 1998, 8, 1207-1210. 
60 Heppeler, A.; Froidevaux, S.; Mäcke, H.R.; Jermann, E.; Béhé, M.; Powell, P.; Hennig, M. Chem. Eur. 
1999, 5, 1974-1981. 
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Figure 2.7 DOTA-Octreotide. 
 
This compound was linked to DOTA to obtain the [DOTA°] adducts octreotide 
which were successful in for tumors individuation (if complexed with 111In $-emitter) but 
also in therapeutic applications with #-emitters such as 90Y complexes.61,62 
 
2.4 Radiolabeled monoclonal antibodies 
The antibodies are glycoproteins produced by B-lymphocytes in the bone marrow; 
they help fight against foreign substances called antigens. When an antigen enters the 
body, it stimulates the immune system to produce antibodies. They can be divided into five 
classes (IgG, IgM, IgA, IgD and IgE) based on physical characteristics including the 
structure of the heavy chain, size, valency, and amino acid sequence.  
The antibody consists of four polypeptide chains connected by disulfide and 
noncovalent bonds: two identical light (low molecular weight) chains and two identical 
heavy (high molecular weight) chains. At the end of these chains there is the amino 
terminal variable domain that is the binding site of antigens (Figure 2.8). 
 
                                                
61 De Jong, M.; Bakker, W.H.; Breeman, W.A.P.; Bernard, B.F.; Hofland, L.J.; Visser, T.J.; Srinivasan, A.; 
Schmidt, M.; Béhé, M.; Mäcke, H.R.; Krenning, E.P. Int. J. Cancer 1998, 75, 406-411. 
62 De Jong, M.; Breeman, W.A.P.; Bakker, W.H.; Kooij, P.P.M.; Bernard, B.F.; Hofland, L.J.; Visser, T.J.; 
Srinivasan, A.; Schmidt, M.; Erion ,J.L.; Bugaj, J.E.; Mäcke, H.R.; Krenning, E.P. Cancer Research, 
1998, 58, 437-441. 
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Figure 2.8 Antibody structure. 
 
The production of monoclonal antibodies (MoAbs) (Figure 2.9) requires the use of 
animals, usually mice. The immunization of a mouse with an antigen is the first step in the 
production of MoAbs. When the mouse begins to produce antibodies against the antigen, 
its spleen is removed. Antibody-producing cells of the spleen are then fused with a 
myeloma tumor cells. That kind of cells can grow indefinitely in culture (myeloma is a B-
cell cancer). They have lost the ability to produce antibodies. The fused hybrid cells (called 
hybridomas), are cancer cells and they will multiply rapidly and indefinitely. In this way it 
is possible to produce a large amounts of antibodies. The desired fusions are between 
healthy B-cells, producing antibodies against the antigen of interest, and myeloma cells. 
The production of the right hybridoma is not a simple process. The major problem is that 
some hybridomas produce wrong antibodies, constituted by two different antibodies: the 
first deriving from B-lymphocytes, the other one from unspecific antibody of tumoral cell. 
To solve this problem are used only myeloma cells that have lost a specific enzyme 
(hypoxanthine-guanine phosphoribosyltransferase, HGPRT). This enzyme enables cells to 
synthesize purines, using an extracellular source of hypoxanthine as a precursor. 
Ordinarily, the absence of HGPRT is not a problem for the cell because cells have an 
alternative pathway that they can use to synthesize purines. When cells are exposed to 
aminopterin (a acid folic analogue), they are unable to use this other pathway and are now 
fully dependent on HGPRT for survival. Therefore cannot grow under certain conditions 
(namely in the presence of HAT medium). Unfused myeloma cells cannot grow because 
they lack HGPRT. Unfused normal spleen cells cannot grow indefinitely because of their 
Chapter 2. Biotin derivatives 
 28 
limited life span. Hybridoma cells (produced by successful fusions) are able to grow 
indefinitely because the spleen cell partner supplies HGPRT and the myeloma partner is 
immortal. Hybridoma cultures can be maintained indefinitely: in vitro (culture vessels) or 
in mice. 
 
 
Figure 2.9 Production of monoclonal antibodies. 
 
Monoclonal antibodies are important agents used in biomedical research, in 
diagnosis of diseases and in treatment of such diseases as infections and cancer.63 
When they are used in therapy, monoclonal antibodies can react against specific antigens 
on cancer cells and may enhance the patient's immune response. They can be conjugated or 
linked to anticancer drugs, radioisotopes, biologic response modifiers, or toxins. 
Antibodies are used in several diagnostic tests to detect small amounts of drugs, toxins or 
hormones and for AIDS diagnosis. They can be used to treat viral diseases, to classify 
strains of a single pathogen, to identify and to trace specific cells or molecules in an 
organism. Furthermore they are used in the radioimmunodetection and 
radioimmunotherapy of cancer.64,65,66,67 Radiopharmaceuticals based on monoclonal 
                                                
63 Zalutsky, M.R. C.R.C. Press, Boca Raton, Florida 1989. 
64 Mach, J.P.; Buchegger, F.; Forni, M. Immunol. Today 1981, 2, 239. 
65 Epenotos, A.A.; Britton, K.E.; Mather, S. Lancet 1982, 2, 999. 
66 Larson, S.M. J. Nucl. Med. 1985, 26, 538. 
67 Buraggi, G.L.; Callegaro, L.; Mariani, G.; Turrin, A.; Cascinelli, N.; Attili, A.; Bombardieri, E.; Terno, G.; 
Plassio, G.; Dovis, M. Cancer Res. 1985, 45, 3378. 
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antibodies require validation and quality control. The tests are performed on compounds 
radiolabeled before their administration. In several studies, some authors showed that a big 
amount of radioactivity recovered in blood and normal tissues was caused by radiolabeled 
monoclonal antibodies denatured or with any immunogenic property. 
Radiochemical purity is defined as the total radioactivity percentage bounded to 
antibody and it is measured by simple chromatographic techniques. 
There are many limitations when using radiolabeled monoclonal antibodies for 
treating solid tumors in humans.68 One of the most limitation using MoAbs in RIT is an 
abnormal high interstitial pressure of the tumor. This characteristic belongs overall to the 
center of tumor where, moreover, the vascularization is reduced or absent. In particular the 
diffusion of the smallest MoAbs (150 kDa) from blood-vessels to interstitial matrix is 
decelerate by high interstitial pressure. In addition, directly labelled MoAbs circulate for 
days with maximum tumor concentration occurring at 1-2 days with continuing high blood 
concentration for several more days. Therefore, even when properly selected MoAbs are 
employed, only a small percentage (usually not more than 1%) actually localizes on the 
tumor. The remaining 99% continues to circulate in the blood stream and diffuses to 
different parts of the organism, accumulating radioactivity in healthy tissues particularly in 
the kidneys, liver and bone marrow, causing possible damage. The accumulation of 
radioactive dose in tumor models obtained from mice is about 20-30% of the administered 
dose per gram of tumor, while 0,1% is obtained in human models.69,70 
This low tumor-background ratio remains the main problem of the 
Radioimmunotherapy strategy. In attempt to overcome the low uptake of label by the 
tumor and improve the tumor-to-blood ratio, at the end of ’80 years many pretargeting 
systems were studied.33,71,72,73 The concept of tumor pretargeting is based on the separate 
administration of MoAbs and radiolabel. Such systems need a modified monoclonal 
antibody (first conjugates) that permits a second component (second conjugates) to bind 
specifically to it. Pretargeting protocols, based on the Av/biotin system, are currently used 
                                                
68 Epenetos, A.A.; Snook, D.; Durbin, H. Cancer Res 1986, 46, 3183-3191. 
69 Strand, S.E.; Zanzonico, P.; Johnson, T.K. Med. Physics 1993, 20, 515. 
70 Mann, D.B.; Cohen, M.B.; Saxton, R.E.; Morton, D.L.; Benedict, W.F.; Korn, E.L.; Spolter, L.; Graham, 
L.S.; Chang, C.C.; Burk, M.W. Cancer 1984, 54, 1318. 
71 Paganelli, G.; Malcovati, M.; Fazio, F. Nucl. Med. Commun. 1991, 12, 211. 
72 Goodwin, D.A.; Meares, C.F.; McCall, M.J.; McTigue, M.; J. Nucl. Med. 1988, 29, 226-234. 
73 Goodwin, D.A. J. Nucl. Med. 1995, 36, 876-879. 
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for applications in clinical oncology because the specific MoAbs are easily biotinilated and 
can bind the avidin with high affinity. 
 
2.5 Pretargeting approaches: rationale for Pretargeting 
Pretargeting techniques have been first proposed by Goodwin et al.74,75 to improve the 
performances of radioimmunodetection (immunoscintigraphy) and RAIT. Instead of 
chemically coupling the radioactive isotope to the antibody itself, or to a fragment of the 
antibody, a tumor- seeking agent (an immunoconjugate) bearing a binding site for a small 
molecule is used to target tumor cells. This immunoconjugate, which is not labeled, is 
injected first. It diffuses and tags the target cells with specific binding sites for the small 
molecule that carries the active payload. After partial excretion of the immunoconjugate, 
the labelled molecule is injected in a second step and binds to the tumor bound 
immunoconjugate (Figure 2.10). In pretargeting techniques, the slow antibody plasma 
clearance, which favours tumor uptake, is not associated with increased radiation dose to 
normal tissues since the antibody is not labelled. The small labelled molecule has a fast 
diffusion in body tissues and a rapid plasma clearance which should result in fast tumor 
uptake and low circulating activity. Obviously, antigen shedding and antibody 
internalization are potential limitations to pretargeting approaches. Antibodies or antibody 
fragments usually constitute the tumor-specific ligands, but any substance capable of 
binding specifically to tumor cells in vivo could be used. Many different systems have been 
proposed to ensure the recognition between the antibody and the tracer: another antibody 
(usually an anti-hapten antibody), the avidin-biotin system23,76 or complementary 
nucleotides. 
                                                
74 Goodwin, D.A.; Mears, C.F.; McTigue, M.; David, G.S. Nucl. Med. Commun. 1986, 7, 569. 
75 Goodwin, D.A.; Meares, C.F.; David, G.F.; McTigue, M.; McCall, M.J.; Frincke, J.M.; Stone, M.R.; 
Bartholomew, R.M.; Leung, J.P. Int. J. Rad. Appl. Instrum. B. 1986, 13, 383. 
76 Paganelli, G.; Magnani, P.; Zito, F.; Villa, E.; Sudati, F.; Lopalco, L.; Rossetti, C.; Malcovati, M.; 
Chiolerio, F.; Seccamani, E. Cancer Res. 1991, 51, 5960-5966. 
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Figure 2.10 Schematic of a three-step procedure. 
 
If pretargeting was used just as described above, it would not achieve much higher 
targeting efficacy than directly-radiolabeled antibodies. Indeed, excess immunoconjugate 
present in the circulation binds the labelled molecule and reduces its clearance. With high-
affinity systems, large immunoconjugate doses or short time intervals between 
immunoconjugate and labelled molecule injections, high irradiation doses are delivered to 
normal tissues because of extended whole-body retention of the activity. Conversely, if the 
labelled molecule is injected only when most antibody conjugate has cleared or if its 
affinity for the antibody conjugate is weak, it disappears rapidly from the circulation, 
usually through the kidneys and only a small fraction of the injected activity binds the 
tumor. High tumor-to-non-tumor contrast ratios can be obtained, but tumor uptake and 
radiation exposure are low.77,78 Using sophisticated pharmacokinetic computer models, 
Jain et al.79 and Weinstein et al.80 concluded that simple pretargeting techniques afford 
                                                
77 Kranenborg, M.H.; Boerman, O.C.; Oosterwijk-Wakka, J.C.; de Weijert, M.C.; Corstens, F.H.; Oosterwijk, 
E. Int. J. Cancer 1998, 75, 74. 
78 Klivenyi, G.; Schuhmacher, J.; Patzelt, E.; Hauser, H.; Matys, R.; Moock, M.; Regiert, T.; Maier-Borst, W. 
J. Nucl. Med. 1998, 39, 1769. 
79 Zhu, H.; Jain, R.K.; Baxter, L.T. J. Nucl. Med. 1998, 39, 65. 
80 Sung, C.; van Osdol, W.W.; Saga, T.; Neumann, R.D.; Dedrick, R.L.; Weinstein, J.N. Cancer Res. 1994, 
54, 2166. 
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only limited improvement over directly-labelled antibodies. For these reasons, the basic 
concept of pretargeting has been further improved as described below. 
 
2.5 Avidin-biotin system 
This biological system has long been widely used for in vitro applications, in ELISA 
(Enzyme-Linked Immunosorbent Assay) tests and in molecular biology. The system takes 
advantage from the extremely high affinity between avidin and biotin in order to form 
macromolecular complexes on target molecules, which are thus made detectable by 
physical or chemical means.81,82 
The avidins are functionally defined by their ability to bind biotin with high affinity 
and specificity, without recognising or binding any other physiological compound with any 
strength. Avidins are small oligomeric proteins made up of four identical subunits, each 
bearing a single binding site for biotin.  
Avidin (Table 2.2) is a 66 KDa glycosylated protein, commonly isolated from hem 
egg white, and positively charged with an isoelectric point of approximately 10.5. 
Streptavidin, a non glycosilated analogue, isolated from Streptomyces avidinii, is 
nearly neutral at physiological pH, in contrast to avidin, with an isoeletric point 
approximately 6. 
 
Table 2.2 Avian Avidin and Streptavidin characteristics. 
Characteristics Avian Avidin Streptavidin 
Molecular weight 66.000 65.000 
Number of subunits 4 4 
Subunit M.W. 16.000 16.000 
Biotin binding sites/mole 4 4 
Kd of biotin complex 10-15 10-15 
Oligosaccharide subunit 1 0 
Mannose subunit 4.5 - 
Glucosamine subunit 3 - 
Isoelectric point 10.5 6 
 
                                                
81 Wilchek, M.; Bayer, E.A. Anal. Biochem. 1988, 171, 1. 
82 Wilchek, M.; Bayer, E.A. Immunol. Today 1984, 5, 39. 
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Biotin (vitamin H) (Figure 2.11) is a 244 Da molecule, constituted by a functional 
“head” region (bicyclic ring) which binds avidin and a functionally irrelevant carboxyl 
“tail” end (valeric acid), which can be chemically altered with little or no effect on the 
molecule. 
 
Figure 2.11 Biotin (vitamin H). 
 
The latter can be differently functionalized. Biotin is the coenzyme for four 
carboxylases. Through its carboxyl group, biotin is linked covalently to epsilon-amino 
group of lysine in four carboxylases that play critical roles in intermediary metabolism. 
The avidin can inhibit these reactions because “seizes” the biotin. A large series of biotin 
derivatives, obtained by modifying the carboxyl group, are commercially available and can 
be used to covalently bind to a variety of molecules containing primary amines, thiol 
groups aldehydes and so on. The biotinylation of MoAbs does not usually alter the 
biodistribution of antibodies and in general many properties of the molecules.76 The 
avidin-biotin binding is noncovalent but for the dissociation is required a value of pH 
superior to 13 or inferior to 2, very improbably in physiological conditions. The studies of 
crystal structures of the biotin-avidin (A) and biotin-streptavidin (B) complexes (Figure 
2.12) showed many hydrogen-bond networks of the respective proteins with the native 
ligand.83 In particular the biotin ring system shows a similar network of interactions in both 
proteins, whereas the respective biotin carboxylates show distinct differences. 
 
 
Figure 2.12 Biotin-avidin and biotin-streptavidin complexes. 
                                                
83 Pazy, Y.; Kulik, T.; Bayer, E.A.; Wilchek, M.; Livnah, O. J. Biol. Chem. 2002, 277, 30892-30900. 
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The external part of the binding site is covered essentially from non-polar 
aminoacids, as moreover the head of the biotin is non-polar. The advantages of the biotin-
avidin system are: 
• Avidin binding to biotin is specific enough to ensure the binding is directed 
only to the target of interest. 
• The affinity of avidin for biotin is extremely high, with a dissociation 
constant of the avidin-biotin complex of 10-15 M. For practical purposes, their 
binding can be regarded as irreversible.84,85 
• The avidin is not toxic for the animals. 
However the avidins, xenomolecules, can give an immune response. A study about 
this problem showed that 20% of the patients treated with avidin develops an antibody 
response. 
2.5.1 Strategies of pretargeting 
Two major methods, 2 steps and 3 steps, are presently used in the clinical settings 
with the aim to improve the delivery of radionuclides to tumors.71,72,86 
The 2 Step Pretargeting System (Figure 2.13) has been used mainly to target 
intraperitoneal tumors. In a typical protocol, biotinylated MoAbs are injected 
intraperitoneally (first step). In this way MoAbs recognize rapidly the target tissue: the 
immunoglobulines not bound to the tumor leave the intraperitoneal cavity trough the 
lymphatic system and than trough the blood stream. To obtain diagnostic images with high 
resolution, it is necessary that the metabolic systems discharge free MoAbs from the 
organism. 3-5 days later a solution of radiolabeled streptavidin is injected intraperitoneally 
(second step). After 3 hours from the second administration, SPECT (Single Photon 
Emission Computed Tomography) exam is performed. This approach originated very high 
radioactivity distribution tumor to normal tissue (9:1) and tumor to blood ratios (14:1) 
suggesting that this two-step strategy might be superior to conventional radiolabeled 
MoAbs for intraperitoneal targeting of tumors. 
                                                
84 Green, N.M. Biochem. J. 1963, 89, 585. 
85 Green, N.M. Adv. Protein Chem. 1975, 29, 85-133. 
86 Paganelli, G.; Riva, P.; Deleide, G.; Clivio, A.; Chioleiro, F.; Scasselati, G.A.; Malcovati, M.; Siccardi, A. 
Int. J. Cancer. 1988, 2, 121. 
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Figure 2.13 2-Step Pretargeting System. 
 
The locoregional approach is useful when tumor is confined into the peritoneal 
cavity or in other locoregional approaches. In the presence of widespread disease, a 
systemic injection of the tracer is nonetheless required. A three-step approach has been 
designed for these cases, where conjugates need to be cleared not only from a well-defined 
body cavity, but also from the entire blood pool. 
A typical three protocol (Figure 2.14) involves the systemic injection of biotinylated 
MoAbs (first step). These antibodies will reach their target (the tumor) in 24 to 48 hours. 
1-2 days after the first injection, the patient receives an endovenous injection of avidin. 
Due to the high affinity between these two molecules, avidin will bind to the biotin, which 
is already on the tumor. The excess circulating biotinylated antibodies in the form of cold 
complexes via avidin will be metabolised by the liver. On the third day, when dispersed 
antibodies have been eliminated, the patient receives the last injection: a dose of biotin, 
which has been previously labelled with a radioactive isotope. In this way, the radioactive 
biotin is strongly attracted by the avidin on the tumor and reaches its specific target in few 
minutes, destroying it. Radioactive biotin not bound to the tumor is rapidly excreted 
through the kidneys thus it is a very small molecules. 
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The rapid blood clearance of the radiolabeled biotin allows imaging to be performed 
short time (90-120 minutes) after injection and with very low background activity. 
 
Figure 2.14 3-Step Pretargeting System. 
 
In both Pretargeting Systems (2 and 3 step), the label does not alter any avidins 
properties and their affinity is maintained (approximately 90%). 
The new strategies based on pretargeting techniques have shown many advantages 
compare to the use of directly labelled antibodies:87 
• Fast clearance of the labelled molecule. With small radiopharmaceuticals the 
background radioactivity levels are very low and this allows to perform imaging in 
a few minutes after injection. 
• The removal of circulating antibodies. In the 3-step the excess of circulating 
biotinylated MoAbs are removed as cold complexes, which are taken up and 
metabolized by the liver. This is the major factor in background reduction and it is 
obtained prior to label injection. 
                                                
87 Magnani, P.; Paganelli, G.; Modorati, G. J. Nucl. Med. 1995, 37, 967-971. 
      
  
             
              
            
               
  
            
           
  
 
                
                   
                     
 
    
1° STEP 
Avidin 
Biotinylated 
MoAbs 
Radiolabeled 
biotin  
 
Antigen 
express on the 
tumor cell  
2° STEP 
3° STEP 
Chapter 2. Biotin derivatives 
 37 
• Retention of immunoreactivity of MoAbs. The biotinylation does not usually alter 
many properties of the antibodies. 
• Signal amplification. In this strategy, because of each avidin has four small pockets 
where biotin molecules can be bound, the signal is triplicate. 
The disadvantages are mainly two: 
• The request of reiterated injections with particular attention to doses and times of 
administration. 
• The immunogenicity of the avidin: an immune response is observed in 20% of 
patients.  
At the first time the 3-step pretargeting system was tested in 20 patients with CEA-
expressing tumors, using antibodies anti-CEA (anticarcinoembryonic). 
Presently, this system has been used for melanomas, gliomas, carcinomas and other 
types of tumors but, in theory, it can be applied to all types of tumor for which specific 
antibodies are available. It requires, however, a specially equipped area for the 
manipulation of radioisotopes. 
 
2.6 Previous results in the production of radiolabelled biotin 
derivatives 
The conjugation of the biotin with a chelating agent is obtained trough the reactivity 
of the carboxyl group tail end. The –COOH group can react with almost all types of 
compounds. At first the carboxylic chains of DOTA or of 1,4,7,10-tetraazacyclo-tridecane-
N,N’,N’’,N’’’-tetraacetic acid (TRITA) were used to link the macrocycle to biotin. 
Than, structures with different spacer arms were studied. Among the compounds 
synthesized on a large scale, the 2-(p-nitrobenzyil)-1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid (p-nitrobenzyl-DOTA) gives the respective derivative p-
aminobenzylic (Figure 2.15) by hydrogenation in the presence of a catalytic amount of 
Pd/C. This derivative, trough its amino group, can be linked to biotin molecule, directly or 
trough a spacer arm.88 
                                                
88 Renn, O.; Soodwin, D.A.; Studer, M.; Moran, J.K.; Jacques, V.; Meares, C.F. J. Control. Release 1996, 39, 
239. 
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Figure 2.15 Structure of a biotinyl derivative conjugated with p-aminobenzyl-DOTA. 
 
The spacer arm between the carboxyl group and the chelating agent has the function 
to maintain the ‘head’ of biotin at the right distance from the azamacrocycle. This is a 
suitable distance for binding the biotin moiety to the Av pocket and for using the best 
activity of the labelled part. 
A biotin derivative containing an azamacrocycle as chelating agent has been recently 
prepared in our laboratory:89 10-[2-[[6-[[5-[(3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-
d]imidazol-4-yl]pentyl]amino]hexyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-
1,4,7-triacetic Acid (MonoDOTA) (Figure 2.16), conjugated trough one of the four N-
carboxymethyl chains of DOTA to a six carbon atoms alkylamino spacer. The –COOH 
groups of the macrocycle are involved in the radionuclide coordination. But literature dates 
demonstrated which the metallic ion is coordinated via carboxylic oxygen atoms of only 
two of the four functionalized chains; so the amide bond with the spacer arm does not have 
important effect on the coordination capacity of the DOTA for radioisotopes. 
 
   1 
Figure 2.16 MonoDOTA. 
 
This biotinyl derivative, compared to compounds synthesized in the past, can also 
overcome the limitations due to instability in physiologic environment. The amide bond 
between the sidearm of biotin and the spacer carrying the chelating moiety, are per se 
                                                
89 Sabatino, G.; Chinol, M.; Paganelli, G.; Papi, S.; Chelli, M.; Leone, G.; Papini, A.M.; De Luca, A.; 
Ginanneschi, M. J. Med. Chem. 2003, 46, 3170-3173. 
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easily hydrolysable by the serum biotinidase,90 an enzyme that is also able to break biotinyl 
peptides. At the same time, molecular changes of the biotin side arm, carrying the 
radionuclide chelating unity, can affect the binding to Av or Sav, diminishing the affinity 
and causing loss of the radiating power on cancer cells. The pivotal work of Wilbur’s 
group91 and of other researchers92 has highlighted some structural characteristics of the 
biotin conjugates, which hamper the action of biotinidase and allow to retain high affinity 
for Av and Sav pockets. Pazy et al. showed that the avidin pocket is much more sensible 
than Sav to structural changes on the biotin side chain, which caused the disordered 
conformation of a critical loop.83 On the basis of these findings, these authors suggested an 
explanation of the fundamental role of streptavidin when administered in the three-step 
procedure. 
The new biotin conjugate, obtained in a few steps synthesis, already described in the 
original work by Sabatino et al., was prepared for reaction of the original carboxyl group 
of the biotin with diamino hexane. Subsequently, the amide CO was reduced to CH2 group 
in order to prevent the recognition at the site of the enzymatic attack and, finally, the N-
hexylamine was coupled to one of the four carboxymethyl chains of DOTA chelator. The 
reduction is an excellent way to prevent the enzimatical degradation but the synthetic step 
is not so simply and occur with very low yield. 
The binding and stability studies in vitro on the new molecule labelled with 90Y and 
111In (labelling yield greater than 97%) with avidin, confirmed its clinic applicability. 
In particular the binding studies of the new 90Y-labeled biotin derivative 1, in the 
presence of a 1:2 Av/1 molar ratio (which is two times the natural 1:4 molar ratio), showed 
that about 85% of 90Y-labeled compound 1 was bound to Av, whereas at the natural 1:4 
molar ratio only about 50% was bound. Data at 2 and 24 hours at 37 °C were similar, 
indicating that the binding occurs rapidly and is almost irreversible despite the linkage with 
the bulky DOTA molecule. Stability studies showed that in both saline and diluted human 
serum the activity was almost completely associated to the labelled 1 molecule up to 48 
                                                
90 Wilbur, D.S.; Hamlin, D.K.; Chyan, M.K.; Kegley, B.B.; Pathare, P.M. Bioconjugate Chem. 2001, 12, 
616-623. 
91 Wilbur, D.S.; Hamlin, D.K.; Chyan, M.K.; Kegley, B.B.; Quinn, J.; Vessella, R.L. Bioconjugate Chem. 
2004, 15, 601-616, and references therein. 
92 Axworthy, D.B.; Theodore, L.J.; Gustavson, L.M.; Reno, J.M. United States Patent 1997, 5, 608-660. 
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hours. Consequently, we can affirm that biotinidase are not able to break the 1 conjugate in 
a significant extent. 
Due to the good results obtained in vitro experiments, in particular the high affinity 
to avidin, the 111In-labeled compound 1 (a radionuclide $-emitter) was used in a clinical 
study in order to verify the bio distribution into health and ill tissues. 
A therapy trial based on the 3-step pretargeting has been conduced in a patient with 
histologically confirmed grade III or IV glioma and documented residual disease or 
recurrence after conventional treatment. The first step of the protocol consisted of 
biotinylated anti-tenascin monoclonal antibodies, injected i.v., at a dose of 2 mg. Avidin 
(10 mg) were then administered i.v. 24 hours after the antibody. At the third day 5 mg of 
HAS (Human Serum Albumin) biotinylated were administered, followed, after 15 minutes, 
by 3 mCi of 111In-DOTA-biotin. 
Experimental conditions and procedures will be discussed adequately in Chapter 5.0. 
 
2.7 BisDOTA derivatives 
2.7.1 Solid phase synthesis of BisDOTA 
In this PhD thesis it is described for first the synthesis on solid phase of new mono-
biotin derivatives containing azamacrociclic chelating agents and it is shown the 
preliminary study of their biological activity such as potential radiopharmaceuticals for a 
future application in clinical oncology in according to the pretargeting system.93 In the 
second part of this section will be described the synthesis and preliminary tests in vitro of 
BisBiotin derivatives. 
In the three-step pretargeting technique, the radioactivity is carried on the tumor by 
the radiolabeled biotin, which is functionalized with the DOTA chelator. Since only a 
small percentage really localizes on the tumoral lesion, it is important that the DOTA-
biotin conjugate is labelled at high specific activity. The maximum allowed stoichiometry 
of a DOTA conjugated molecule is one metallic radionuclide per molecule, and this may 
limit the dose effectively delivered to the tumor. Further developments are now being 
                                                
93 Pratesi, A.; Bucelli, F.; Mori, I.; Chinol, M.; Verdoliva, A.; Paganelli, G.; Riveccio, V.; Gariboldi, L.; 
Ginanneschi, M. J. Med. Chem. 2010, 53, 432–440. 
Chapter 2. Biotin derivatives 
 41 
explored and are here presented: new biotin derivatives, carrying two DOTA groups per 
molecule (BisDOTA), have been synthesized and tested. BisDOTA is substantially a 
modified biotin, conjugated with two molecules of DOTA through bi-functional spacers. 
The rationale is to label the BisDOTA-biotin at higher specific activity if compared 
to the MonoDOTA analogue. In fact, each biotin can theoretically bind up to two metallic 
radionuclides. In this way, BisDOTA-Biotin radiolabeled at high specific activity could 
deliver a higher radiation dose to the tumour and then improve the efficacy of targeted 
radionuclide therapy, provided the high affinity for Av is retained. 
We report the synthesis of new biotin derivatives carrying two DOTA groups, 
featured by spacers chosen to have a good compromise between the necessity of a correct 
distance of the bulky DOTA chelating groups from each other and from the biotin head. 
In the solid phase synthesis, activation of carboxylic acids is a key step for the 
formation of amide or ester bonds. 
The coupling reactions, carried out with carbodiimides, (Figure 2.17) proceed by 
conversion to an O-isoacylurea, which is very reactive and can undergo a rearrangement to 
give unreactive species (N-acylurea) or cause loss of chiral integrity. Active species can be 
captured using a hydroxylamine derivative to give the corresponding active ester. In this 
regard, HOBt is less reactive than the O-isoacylurea but is more stable and less prone to 
racemization. HOAt is an additive more expensive compared to HOBt, but gives best 
results. 
 
 
Figure 2.17 Carbodiimide mechanism. 
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Following the growing interest in peptides, numerous coupling reagents have been 
developed and became commercially available, including carbodiimmides,94 alone or plus 
additives (HOBt, HOAt),95 phosphonium salts,96 and uronium (aminium) salts97 (Figure 
2.18). 
 
 
Figure 2.18 Comercially available HOBt-based coupling reagents. 
 
The most valuable approach involves the use of in situ coupling reagents. Most of 
them engaged the benzotriazole,98 or azabenzotriazole99 ring system as crucial chemical 
structures, subsequently transformed into a good leaving group. 
When described for the first time, HBTU was assigned the structure of uronium salt, 
presumably by analogy with the previously described phosphonium salts. Following 
studies showed that the true structures, in both the crystalline state and in solution, were 
the aminium isomers and not the uronium isomers (Figure 2.19). 
  
                                                
94 Sheehan, J.C.; Hess, G.P. J. Am. Chem. Soc. 1955, 77, 1067. 
95 König, W.; Geiger, R. Chem. Ber. 1970, 103, 788; Carpino, L.A. J. Am. Chem. Soc. 1993, 115, 4397. 
96 Castro, B.; Dormoy, J.R.; Evin, G.; Selve, C. Tetrahedron Lett. 1975, 16, 1219-1222; Coste, J.; Le-
Nguyen, B.; Castro, B. Tetrahedron Lett. 1990, 31, 205-208. 
97 Carpino, L.A.; Imazumi, H.; El-Faham, A.; Ferrer, F.J.; Zhang, C.; Lee, Y.; Foxman, B.M.; Henklein, P.; 
Hanay, C.; Mugge, C.; Wenschuh, H.; Klose, J.; Beyermann, M.; Bienert, M. Angew. Chem. Int. Ed. 
2002, 41, 441-445; Li, P.; Xu, J.C. J. Chem. Soc. Perkin 2, 2001, 113-120. 
98 Carpino, L.A.; Henklein, P.; Foxman, B.M.; Abdelmoty, I.; Costisella, B.; Wray, V.; Domke, T.; El-
Faham, A.; Muegge, C. J. Org. Chem. 2001, 66, 5245-5247. 
99 Carpino, L.A.; Xia, J.; Zhang, C.; El-Faham, A. J. Org. Chem. 2004, 69, 62-71; Carpino, L.A.; Ferrer, F.J; 
Albericio, F. J. Org. Lett. 2001, 3, 2793-2795. 
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Figure 2.19 HOBt-based coupling reagents (uronium and aminium isomers). 
 
The carbodiimide reagents, used in the presence of HOBt or HOAt for the inhibition 
of side reactions such as racemization, are mostly replaced by phosphonium and aminium 
salts of HOBt or HOAt.100 
The same active esters formed by the system DCC/HOBt can be prepared with 
onium (aminium/uronium and phosphonium) salts in the presence of a base. Couplings 
with aminium/uronium salts in the presence of base have proven to be more effective than 
those carried out with phosphonium reagents or carbodiimide in the presence of 
hydroxylamine derivatives. On the other hand, reagents based on phosphonium salts are 
preferred to their aminium/uronium counterparts for cyclization, because the latter 
compounds can give guanidilation reactions on the amino group. The tetrafluoroborate or 
the hexafluorophosphate anions, generally used as non-nucleophilic counterions in the 
aminium salts, had no significant influence on the coupling rate or racemization, but only 
in the solubility of the coupling reagents. BOP was one of the first phosphonium salts 
developed for SPPS. However, this reagent generates a poisonous by-product (HMPA, 
hexamethylphosphoramide) (Figure 2.20). 
 
 
Figure 2.20 Mechanism of the BOP. 
                                                
100 Carpino, L.A.; El-Faham, A.; Minor, C.A.; Albericio, F. J. Chem. Soc. Chem Commun. 1994, 201. 
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For this reason, halogeno-phosphonium salts and phosphonium-HOBt reagents, were 
then developed. The progenitor of the aminium salts was HBTU (the mechanism, up to 
now not well defined, is described below in Figure 2.21). 
 
 
Figure 2.21 Mechanism of the aminium salts. 
 
The most common side reactions in peptide coupling reactions are the formation of 
N-carboxyanhydrides, diketopiperazines and guanidines (Figure 2.22). 
 
 
Figure 2.22 Guanidine derivative formation with aminium salts. 
 
The amino group block can happen if the reagent is added directly to amino 
component. For this reason the carboxylic group have to be activated with the uronium salt 
before the addition of the amino component. Anyway the activating reagents have not to be 
in excess compared with the carboxylic function. 
A critical point of synthetic pathways of MonoDOTA and BisDOTA, prepared in 
solution, reduction of the amidic group to an aminic by a suspension of the starting amide 
in THF with BH3$THF reagent. This reaction required a tedious work-up of the crude 
product even if the yield was quite satisfactory. Recently, Wilbur and co-workers claimed 
that biotin amide derivatives which have a carboxylate function % to the biotinamide bond 
R O
O
N
N
N
O
NMe2Me2HN
X
H Base N
N
N
O
R O
O
NMe2
NHMe2
N
N
N
O
O
R
O
NMe2
NMe2
R'H2N
O
RR
' NH
N
N
N
O
H Base X
N
N
N
O
NMe2
Me2N
X
H2N CHC
R
NH-Peptide
O
N CH C
R
NH-Peptide
O
C
Me2N
Me2N
Chapter 2. Biotin derivatives 
 45 
block biotinidase activity.92 These considerations prompted us to prepare %-biotinamido 
lysine derivatives by direct coupling of biotin with L-lysine suitably protected on the &-
amino group. Then, the introduction of the bi-functional spacer and of two DOTA 
molecules should have to complete the synthesis. Aiming to ensure a fast synthetic 
approach, we decided to exploit the solid phase peptide synthesis (SPPS), routinely used in 
our laboratory of peptide chemistry. This technique can rapidly afford the products in the 
range from µM to mM scale. In the SPPS technique the compound is bound to an insoluble 
support: thus at the end of any synthetic step, each unreacted reagent can be removed by a 
simple washing procedure, greatly decreasing the time required for synthesis. A key step in 
that synthetic strategy is the activation of carboxylic acids, as previously. Moreover it is 
necessary to protect the side-chains by using protecting group, like in this case Fmoc, t-Bu 
and MTT groups (Table 2.3).  
 
Table 2.3 Main protecting groups. 
Protecting groups Deprotection conditions Stability conditions 
Fmoc Piperidine 20% in DMF TFA, Pd 
MTT 1% TFA in DCM 1-5% TIS Pd(0), hydrazine, piperidine 
t-Bu 95% TFA TFA<60%, Pd(0), Pd, hydrazine, piperidine 
 
These groups are orthogonal each other, i.e. they are removed in different conditions 
(Figure 2.23), in this way we can deprotect selectively only an amine group. 
 
 
Figure 2.23 Fmoc/MTT/t-Bu strategy. 
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The resin used for the synthesis, commercially available, is a Wang resin, p-
benzyloxybenzyl alcohol, (100-200 mesh) (Figure 2.24) functionalized by a lysine 
protected in % with Fmoc and in & with MTT. 
 
                       
Figure 2.24 Wang resin and Fmoc-Lys-(MTT)-Wang resin. 
 
For the determination of the effective resin loading, it is necessary to weigh exactly 
the dried Fmoc-amino acid resin (about 1 µmol, related to Fmoc) into a 10 mL volumetric 
flask and to add piperidine (0.4 mL) and DCM (0.4 mL) (Scheme 2.1). 
 
 
Scheme 2.1 
 
After 30 min the mixture is diluted with MeOH (1.6 mL) and DCM to 10 mL. 
Absorbance of the solution is measured at 301 nm against a blank reagent (0.4 mL of 
piperidine and 1.6 mL of MeOH diluted to 10 mL with DCM). The substitution ratio is 
calculated from the formula: 
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Uncertain coupling results were checked by the ninhydrin test as described by 
Kaiser.101 
Peptide cleavage from the resin and deprotection of the amino-acids side chains were 
carried for the Wang resin with a solution of TFA/TIS/H2O (95:2.5:2.5). TIS is a 
nucleophilic reagent (known as scavenger) which is added to the cleavage mixture in order 
to prevent the generation of reactive cationic species. These obtained from the protecting 
groups and the handles on the resin, can, unless trapped, react with residues which contain 
nucleophilic functional groups: Trp, Met, Tyr and Cys. In addition to TIS, the most 
commonly used scavengers are EDT, thioanisole and phenol. EDT is not only an extremely 
good scavenger for t-butyl cations, but it assists in the removal of the trityl protecting 
group from cysteine and is particularly effective in preventing acid catalyzed oxidation of 
tryptophan residues. Thioanisole is known to accelerate Arg removal in TFA. Phenol is 
thought to offer some protection to Tyr and Trp residues. 
 
2.7.2 Synthesis of BisDOTALys-C3 
The orthogonally protected Fmoc-L-lysine-(MTT) was purchased already bonded to 
Wang resin (Scheme 2.2). After deprotection of the %-amino group by piperidine, the 
coupling with the activated biotin (HOBt/TBTU/NMM in DMF) was performed only one 
time. The MTT group was removed with a solution of TFA/TIS/DCM (1:2.5:96.5). 
Initially the solution became a fluorescent yellow colour, indicating the presence of MTT 
in solution. Washing was continued until the wash solution became colourless again. 
The Fmoc-protected spacer 5 (Figure 2.25), readily available for SPPS, was activated 
as above and then added to the resin affording the Fmoc-protected diamine. Three 
couplings are necessary to obtain a negative Kaiser test. 
 
 
Figure 2.25 N,N-Bis[3-(Fmoc-amino)propyl]glycin 
 
                                                
101 Kaiser, E.; Colescott, R.L; Bossinger, C.D.; Cook, P.I. Anal. Biochem. 1970, 34, 595. 
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In the case of the SPPS technique, the solid support does not allow the use of 
aqueous solutions and DMF or DCM are the commonly used solvents, ensuring a good 
resin swelling. Therefore, tris(t-butyl) ester of DOTA,102,103 well soluble in DMF, was 
exploited as the coupling agent in the preparation of these bioconjugates. 
 
Scheme 2.2 
 
                                                
102 Bhorade, R.; Weissleder, R.; Nakakoshi, T.; Moore, A.; Tung, C.T. Bioconjugate Chem. 2000, 11, 301-
305. 
103 Cheng, Z.; Chen, Y.; Miao, Y.; Owen, N.K.; Quinn, T.P.; Jurisson, S.S. J. Med. Chem. 2002, 45, 3048-
3056. 
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Figure 2.26 DOTA tris(t-butyl ester). 
 
The tris-protected DOTA derivative appears more advantageous than the not 
protected one: 
• it permits to overcame the mono-activation problem, by reason of only one of the 
carboxylic functions is able to react; 
• it is soluble in the commonly solvents used in the SPPS (DMF). 
The cleavage of the Fmoc protecting groups from 6 gave access to the free amino 
groups prone to conjugate with two mole equiv. of the commercially available DOTA-
tris(t-butyl ester). 
The reaction was performed using the same activating reagents as above described. 
Coupling reaction was controlled by the Kaiser test. The final compound, carrying two 
DOTA moieties, still protected as t-butyl esters, was then cleaved from the resin with a 
solution of TFA/H2O/TIS (95:2.5:2.5). This TFA concentration was also able to hydrolyse 
(2 h) the ester functions at room temperature, affording the expected BisDOTA as the free 
carboxylic acid 7. The crude product was purified by semipreparative RP-HPLC  to give 
pure 7 in 35% yield. The structure was characterized by ESI-MS. 
 
 
2.7.3 Synthesis of BisDOTA-Lys-(pAB)-C3 
In order to move further away from the Av pocket the bulk of the radio labelled 
DOTA moiety, we have designed a new derivative containing a rigid and planar spacer 
(Scheme 2.3). Therefore, the suitably protected p-amino benzoic acid was smoothly 
coupled with the biotinamido lysine anchored to the resin obtained following the synthetic 
procedure previously described (Scheme 2.2). 
HOBt/TBTU/NMM method was used in the coupling reaction and only one coupling 
was necessary to obtain a negative Kaiser test. 
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After Fmoc deprotection, the spacer 5 was added giving the protected bis-amine 10 
(Scheme 2.3). 
 
 
Scheme 2.3 
 
In this coupling reaction the usual HOBt/TBTU/NMM method gave only a small 
quantity of the wanted derivative 9, the remaining product being the starting reagent. This 
is probably due to the lower nucleophilicity of the NH2 group bonded to aromatic ring. 
HATU/NMM method was thus used in this case in order to overcome the coupling 
reaction difficulty. The Kaiser test does not yield useful results with the p-amino benzoic 
acid NH2 group, for this reason the coupling reaction was controlled by subsequent micro 
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cleavages. Four couplings were necessary to observe the complete disappearance of 
starting reagent. 
The conjugation with DOTA-tris(t-butyl ester) followed the same procedure as for 
BisDOTALys-C3. Coupling reaction was controlled by the Kaiser test. Cleavage from the 
resin and removal of the tert-butyl protection was performed using a solution of 
TFA/H2O/TIS (95:2.5:2.5). The crude product was purified by semipreparative RP-HPLC 
to give pure 11 in 20% yield. The final product was identified by ESI-MS and elemental 
analysis. 
Thus the synthetic approach on solid phase resulted very efficient both in terms of 
yield and purification. The yields, calculated on the all reaction steps, are higher if 
compared to the BisDOTA derivatives synthesized in solution, avoiding the isolation and 
purification of intermediate products. However, DOTA tris(t-butyl) ester high cost 
represented, in this approach, the unique disadvantage. 
 
2.8 Design and synthesis of new biotin derivatives 
In this PhD thesis, the creation of new biotin derivatives was carried out through the 
synthesis of compounds mainly characterized by having two molecules of biotin. 
These derivatives were called BisBiotin, and were designed and synthesized with the 
aim to increase the affinity between the radiopharmaceutical drug and avidin: since avidin 
has three pockets available for binding biotin, a compound with two biotin residues, should 
have twice probability to engage the site and this could affect not only the affinity towards 
the protein, but also minimize the amount of radiopharmaceutical dispersed in healthy 
tissue. 
The compounds synthesized in this sense are divided into classes: 
BisBiotinaMonoDOTA (Figure 2.27 and Figure 2.28) and BisBiotinaBisDOTA (Figure 
2.29), the second class includes two residues of biotin and two chelating groups, in order to 
redouble the amount of radiation conveyed by each molecule, and to increase the potency 
of the product. 
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Figure 2.27 BisBiotinMonoDOTA 
 
 
Figure 2.28 Bis BiotinMonoDOTA-(pAB)-C6 
 
 
Figure 2.29 BisBiotinaBisDOTA-(PEG)-C3 
 
2.8.1 Synthesis of BisBiotinMonoDOTA-C3 
The synthesis of BisBiotinMonoDOTA-C3 is made from Fmoc-Lys(MTT)-Wang 
resin, 2, which has two orthogonal protections: the #-amino group is protected with Fmoc, 
that can be removed under basic conditions, whereas the protected %-amino group (MTT) is 
deprotected under weakly acidic conditions. The first step planned for the reaction is the 
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coupling with the bifunctional spacer 5 on the #-amino group of Lys anchored to the Wang 
resin (Scheme 2.4). 
Before carrying out this reaction, it is necessary to remove the Fmoc group, in 
weakly alkaline environment, followed by several washings to completely remove any 
residual solution of deprotection. 
The amino groups are, therefore, free and reactive, so we can introduce a solution of 
the spacer N,N-Bis [3-(Fmoc-amino) propyl] glycine 5 (for simplicity called Spacer-C3), 
properly activated. The Spacer-C3 is in fact an amino acid, functionalized on the #-amino 
group in symmetrical way, it has two amine functions Fmoc-protected and the carboxyl 
groups is free and reactive. 
 
Scheme 2.4 
 
After the obtainment of this first intermediate, 12, we decided to extend the arms of 
the spacer. In fact at the ends of these arms two biotin residues were introduced so that to 
ensure the necessary distance between them to allow the correct disposition into two 
different avidin pockets. 
The necessity to extend the arms of the molecule is accompanied by another 
requirement: the reagent used must have two carboxylic functions, one for the binding with 
the Spacer C3, and the other to form an amide bond with the amine group of Lys side-
chain. The compound identified for this purpose is succinic anhydride, 14, an heterocyclic 
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molecule that, after the reaction, give rise to an amide bond and opens linearly, leaving a 
free carboxyl group. 
The elongation of the chain (Scheme 2.5) involved the Fmoc deprotection of the two 
amino groups of the Spacer C3 and then the reaction with succinic anhydride. The literature 
data shows that long time is required for this coupling and heating conditions not 
appropriate for this kind of products,104,105 for this reason, we chosen to perform the 
reaction in a microwave reactor. 
Under the mild reported conditions the reaction took place in a very short time 
(approx. 30 min.), without adding any activator and using anhydrous THF. 
The choice of the solvent was due to the fact that THF has a relatively low dispersion 
factor, thus avoiding large increases of temperature after irradiation. For this reaction 
temperature remained between 40 and 65 °C. 
 
Scheme 2.5 
 
The intermediate 15 is, in turn, a compound suitable to react with Fmoc-Lys(H)-
OtBu, 17, a building-block specially prepared in order to have the free %-amino group, and 
the #-amino group protected with Fmoc while the and carboxy group was protected as tert-
butyl ester. The preparation of the building block was necessary by the fact that this 
                                                
104 Kappel, J.C.; Barany, G. Letters in Peptide Science 2003, 10, 119-125. 
105 Jagesar, D.C.; Hartl, F.; Buma, W.J.; Brouwer, A.M. Chem. Eur. J. 2008, 14, 1935-1946. 
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product, important for the synthesis, is not a commercial one.106 Masking the carboxyl 
group with tert-butyl ester we obtain an orthogonal protection, which is removed only 
during the final cleavage. The procedure for the synthesis of the protected Lysine is 
described in Experimental Section. 
The function to be activated (i.e. the carboxyl group) is now on resin and therefore 
we introduced for the first the solution containing the activators and after this, the amino 
acid. 
The coupling (Scheme 2.6) not needed to be preceded by deprotection and 
predisposed the molecule to the next step, namely the introduction of biotin. 
 
Scheme 2.6 
 
Compound 18, deprotected from Fmoc groups, was the suitable to react with biotin, 
properly activated: the resulting amide bond is surely resistant to the degradation by 
biotinidases, thanks by the steric hindrance of the carboxylic group on the Lys residue.90 
The coupling (Scheme 2.7) completed the elongation of the of the spacer arms, so the 
next step is the removal of the MTT group from lysine anchored to the Wang resin. 
                                                
106 Kazuyoshi, T.; Akira, A.; Hiroko, N.; So-ichi, T.; Yoshihisa, M.; Hiroaki, T.; Yoshihiro, H. Synthesis 
1994, 10, 1063-1066. 
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Scheme 2.7 
 
The removal of the MTT protecting group, done in weakly acidic conditions, does 
not affected the permanent protective tert-butyl, which was removed within the total 
cleavage, in extremely acidic conditions. 
The compound 19, deprotected from methyltrityl group, is ready for the last reaction 
(Scheme 2.8) of this synthetic procedure, i.e. the coupling with the DOTAtris-tBu, 20, 
suitably activated. After the reaction, the whole molecule was prone to be obtained by the 
total cleavage in a strong acid, performed by long time reaction that allowed the complete 
removal of the permanent protections from the compound and the separation of the final 
product from the resin. 
The presence of the TIS in solution ensured that the cleaved protecting groups should 
not be reactive again toward the molecule, the TIS acting as a scavenger for these ionic 
compounds. 
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Scheme 2.8 
 
2.8.2 Synthesis of BisBiotinMonoDOTA-(pAB)-C6 
The synthesis of the derivative BisBiotinaMonoDOTA-(pAB)-C6 was carried out 
following the same synthetic route used for the previous compound, starting from Wang 
resin, 2. The first step was the Fmoc deprotection, followed by the binding to the 
bifunctional spacer (Scheme 2.9). 
In this second synthesis the compound N,N-Bis[6-(Fmoc-amino)hexyl]glycine, or 
Spacer C6, 27, was used as spacer; this is an higher homologue of C3, being in fact an N-
substituted Gly, carrying as substituents hydrocarbons with six carbon atoms. 
The use of this spacer is useful in order to further extend the arms that hold biotin, 
with the aim to increase the chance that biotins will penetrate simultaneously in two 
different pockets of avidin. The spacer C6 is not commercially available, and we were 
forced to prepare it as shown in Scheme 2.10.107 
 
                                                
107 Hujakka, H.; Ratilainen, J.; Korjamo, T.; Lankinen, H.; Kuusela, P.; Santa, H.; Laatikainen, R.; Narvanen, 
A. Bioorg. Med. Chem. 2001, 9, 1601-1607. 
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 Scheme 2.9 
 
 
Scheme 2.10 
 
The intermediate 28 after deprotection from Fmoc, has two free amino groups, ready 
to react with the carboxyl group of the compound 8, Fmoc-p-aminobenzoic acid (Fmoc-
PABA), properly activated (Scheme 2.11). 
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The introduction of this compound is not only important for the chain elongation, but 
also can provide a certain degree of rigidity to the two arms, so that they are sufficiently 
outstretched in physiological environment. The phenyl ring of PABA has precisely this 
purpose. 
 
Scheme 2.11 
 
The compound 30, after removing of Fmoc groups, showed two free amino 
functions, that, as above reported, could react with the succinic anhydride, 14: in this way 
we could obtain the two arms ending with two carboxyl groups, available at subsequent 
attack of Lys. 
This step was been achieved, once again, (Scheme 2.12) with the aid of microwave: 
in this case the amino functions were in para position respect to the aromatic ring and thus 
were not prone to react rapidly because the EW effect of the p-CO group. 
The MW radiations were useful, therefore, not only for the reduction of the reaction 
time, but also to lower the activation energy, which in these conditions did not require an 
activating group. 
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Scheme 2.12 
 
During the process, because of the low reactivity of the two amino groups, we 
checked the reaction by a microcleavage in order to verify the formation of the amide 
bonds. 
This was made on a small amount of resin and the crude compound was separated 
and analyzed by UPLC-MS in order to verify the presence of the intermediate 31. The 
control provided an unexpected result: in addition to confirming the presence of compound 
31, we detected peaks corresponding to the cyclized compounds or on a single residue, or 
on both succinic residues were observed. (Figure 2.30 and Figure 2.31). 
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Figure 2.30 Cyclized form of 31 
 
Figure 2.31 MS spectrum of the product 31 
 
The mass spectrum of the intermediate 31 showed a peak at m/z 840.64, 
corresponding to [M+H]+ and a second peak at m/z 420.79, relating to [M+2H]2+, it clearly 
denoted the presence of one mono succinimidic residue with mass of 18 units less: the 
peak at m/z 822.62, corresponding to [M+H]+ and its double charged peak at m/z 411.82, 
relating to [M+2H]2+ species. 
The existence of an equilibrium (Scheme 2.13) between the acidic open form and the 
cyclic imide was confirmed by the study of Stieber and Waldmann.108 The verification of 
the presence of succinimmides was made by addition of 1M NaOH in solution until 
alkaline pH values; the mass spectrum obtained (Figure 2.32) showed the instantaneous 
disappearance of peaks related to the cyclic derivatives. 
  
                                                
108 Stieber, F.; Waldmann, H. Chem. Comm., 2002, 16, 1748-1749. 
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Scheme 2.13 
 
Figure 2.32 MS spectrum of 32 after alcalinization. 
 
The presence of these analogues implied that part of the compound 31 was not really 
available for coupling with building-block 17, thus causing a reduction in yield: in fact the 
reaction, despite the presence of NMM, did not occur in strong basic conditions, but 
between pH 7 and pH 8. 
In order to maximize the yield of the synthetic process, the resin was treated with a 
strongly alkaline solution obtaining the shift of the equilibrium toward the product 
bounded with two succinic acid residues without the presence of terminal succinimmido 
residues. 
Following this step, we proceeded with the coupling between the compound 31 and 
Fmoc-Lys(H)-OtBu, 17, in the presence of appropriate activator (Scheme 2.14). 
The building-block was the same as in the previous synthesis, because we decided to 
maintain the same mechanism of resistance to degradative enzymes used in 
BisBiotinMonoDOTA-C3, also for this molecule. 
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Scheme 2.14 
 
The compound 32 was deprotected in alkaline medium to remove the Fmoc groups, 
so the molecule was then ready to react with biotin, 3 (Scheme 2.15). Once the coupling 
with biotin was performed, it was necessary to remove the MTT protecting group from the 
Lys anchored to the resin, and restore the reactivity of its %-amino group in order to prepare 
the DOTA conjugation. 
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The compound 33 in fact, once deprotected by MTT, contained the free NH2 groups 
and was subjected to the last coupling (Scheme 2.16) with the DOTAtris-tBu, 20, suitably 
activated. 
After the reaction with the chelating agent, we proceeded with the total cleavage: in 
this step was achieved the removal of all protections still bound to the molecule and the 
detachment of the crude compound from the insoluble matrix. 
The resulting product, 34, compared with 21, has arms more rigid and longer, but 
essentially they have in common many elements of the structure. This molecule, in fact, 
was designed to be able to compare their biological characteristics with those of the 
derivative 21, and understand the contribution determined by those modifications. 
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2.8.3 Synthesis of BisBiotinBisDOTA-(PEG6)-C3 
The compound BisBiotinBisDOTA-(PEG6)-C3 was synthesized, as in previous cases, 
from Fmoc-Lys(MTT)-Wang resin, 2. The design of this derivative, however, provides 
some significant differences from the two previous products. 
The first step of the synthesis was the Fmoc removal from the resin followed by 
coupling with the Spacer C3 (Scheme 2.5), similarly to the synthesis of 
BisBiotinMonoDOTA-C3, resulting in the intermediate 12. 
Subsequently, the compound 12 was, once again, deprotected from Fmoc groups 
coupled with 1-Fmoc-amino-3,6,9,12,15,18-esaossaenicosan-21-oic acid or Fmoc-NH-
PEG6-COOH, 35, suitably activated (Scheme 2.17). 
The latter reagent had the function to significantly stretch (and with a single 
synthetic step) the arms that hold the biotin and, most importantly, to keep unfolded the 
aliphatic chains in a very hydrophilic medium, as the physiological one. 
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The intermediate 36 was deprotected from Fmoc groups, with recovery of amine 
functions, and then reacted with Fmoc-#-aminobutyric acid, or Fmoc-L-Abu-OH, 37, a 
non-natural amino acid (Scheme 2.18). 
The choice of this reagent was not casual: in fact, previously experimental data 
confirmed that the amino acid side chain was able to protect the amide bond with biotin, 
making the molecule resistant to biotinidases.109 
For the purpose of our thesis project, the introduction of this amino acid was used to 
assess whether its presence could change the avidin-biotin binding affinity in comparison 
when Lys used in compounds above described. In fact, while the carboxyl group of Lys 
was hydrophilic, Abu protected the amide bond with its side chain, which is an ethyl 
residue with hydrophobic properties. So we wanted to ascertain how this difference of 
hydrophilicity could affect the affinity of this molecule for the avidin. 
 
Scheme 2.18 
 
The compound 38 was deprotected from Fmoc, with restoration of the reactivity of 
Abu amino groups. The chain formation was than completed through the coupling with 
biotin, 3 (Scheme 2.19). 
                                                
109 Wilbur S.D.; Hamlin D.K.; Chyan M.K. Bioconjugate Chem., 2006, 17, 1514-1522. 
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Scheme 2.19 
 
The compound 39 thus obtained, was deprotected by MTT group: the %-amino 
function of Lys, anchored to the Wang resin, was free and thus available for subsequent 
coupling with the bis-Fmoc-(3,5-diamino) benzoic acid, 40 (Scheme 2.20). 
The aromatic compound was used to give rigidity to the structure of the molecule 
and, also, had the role of bi-functional spacer; after the Fmoc removal, in fact, there were 
two free amino functions on which we could build two symmetrical arms that retain two 
chelating groups. The design of this compound required, as its name suggests, the presence 
of two biotin residues, introduced with the aim to increase the affinity towards avidin, but 
also two DOTA groups in order to redouble the radiation dose delivered by each molecule 
of radiopharmaceutical. 
The intermediate 41, once deprotected from Fmoc, underwent the coupling with a 
non-natural aminoacid, the Fmoc-!Ala-OH, 42, who, in the presence of the appropriate 
activator, gave the amide bond with the two amino groups on the aromatic ring (Scheme 
2.21). 
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Scheme 2.20 
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The compound 43, once deprotected from Fmoc groups, was ready to be coupled 
with activated DOTAtris-tBu, 20 (Scheme 2.22). 
The introduction of the aminoacid residue in the molecule has been principally 
designed to increase the distance between the DOTA and the diaminobenzoic acid, 40: the 
intention was to avoid direct reaction of the chelating agents on the aromatic compound, in 
order to eliminate the possibility that the steric hindrance of DOTA could be of 
impediment for the coupling. 
Scheme 2.22 
 
This reaction completed the synthesis of the compound BisBiotinBisDOTA-(PEG)-
C3, 44, who was so detached from the resin with the total cleavage. 
In vitro studies on compounds 21, 34 and 44 for having a preliminary idea of their 
future applicability, beyond the individual data, however, are extremely important to assess 
whether the changes has positively or negatively affected the pharmacokinetics of the 
derivative, in order to understand which way should be followed in the future. To make 
this type of assessment, a careful comparison of the results of in vitro tests of all BisBiotin 
compounds with those MonoDOTA and BisDOTA was therefore necessary. 
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2.8.4 BisBiotin-derivatives carrying the SCN group for tissues and cells 
biotinilation 
Covalent attachment of Biotin-derivatives to cells and tissues could be used to solve 
several problems associated with cellular therapies. The surface of the cells or tissues 
could be modified with biotin-derivative-isothiocyanate (SCN), and the biotin could act as 
an antenna in order to carry the biomolecule selectively on a tissue previously avidinated. 
 These experiments, performed by our co-workers (unpublished data), were designed 
to define the feasibility of Biotin conjugation on the surface of live cells of different 
derivation as well as on islets of Langerhans. In preliminary experiments were utilized 
beta-TC3 and K562 cell lines as well as primary cell culture of bone marrow cells from 
GFP harvested transgenic mice (mice that ubiquitously express the Green Fluorescent 
Protein – GFP) and lather moved to dispersed human islets. The cells were incubated with 
biotin and co-incubated with native Avidin and Oxavidin-treated (an oxidized Avidin 
derivative) human islets. Cultures were monitored by fluorescence microscopy to assess 
the presence of cell-cell interactions, they appeared as bright green luminescence that, in 
case of Oxavidin,110 were more intense than that of the native avidin (Figure 2.33). 
   
Figure 2.33 Fluorescence microscopy of biotinylated cells. 
 
These interesting results led us to design and synthetize the BisBiotin-SCN 
compounds with the aim to improve the binding interactions through the presence of two 
arms containing two biotin residues. On the other hand, the presence of the isothiocyanate 
group could facilitate the docking of the modified biotin on the cell surface. In fact, the 
                                                
110 De Santis, R.; Leoni, B.; Rosi, A.; Albertoni, C.; Forni, G.; Cojoca, R.; Iezzi, M.; Musiani, P.; Paganelli, 
G.; Chinol, M.; Carminati, P. Cancer Biother. Radiopharm. 2010, 25, 143-148. 
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SCN group could react rapidly and in easier manner in physiological conditions than the 
carboxylic group of native biotin. 
 
2.8.5 Synthesis of BisBiotin-(PEG6)-Abu-SCN 
The synthetic steps used for the obtainment of this compound were substantially the 
same for the last synthesis described. For this reason and for brevity are reported here only 
the general scheme but are adequately discussed the elements of novelty. 
The synthetic route followed exactly what already reported in the Scheme 2.17, 
Scheme 2.18 and Scheme 2.19 until the product 39, that was the new starting point, 
deprotected from MTT group, affording compound 39a (Scheme 2.23). 
 
Scheme 2.23 
 
In this way the original &-amino group of Lys was restored and, using the procedure 
reported by Munch et al.,111 easily and rapidly transformed in isothiocyanates using di-tert-
butyl dicarbonate (Scheme 2.25). Although the traditional methods were efficient, we 
                                                
111 Munch, H.; Hansen, J.S.; Pittelkow, M.; Christensen, J.B.; Boas U. Tetrahedron Letters 2008, 49, 3117-
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preferred this synthesis of isothiocyanates which preceded cleanly without intermediate 
work-up, such as extraction or column chromatography, and which did not leave traces of 
by-products. These mild conditions were very useful in solid phase synthesis and the 
excess of reagents and by-products could be completely removed simply by filtrations and 
washes. For this kind of reaction, a desulfurylation reagent leaving only gases and volatile 
byproducts should fit this purpose. Di-tert-butyl dicarbonate (Boc2O) seemed a good 
candidate for the desulfurylation of the corresponding dithiocarbamate as this reagent may 
evolve CO2 and COS during the reaction, and residual carbon disulfide and tert-butanol 
together with the solvent should be removed easily by filtration. As the formation of 
dithiocarbamate in the case of most amines proceeds rapidly, the isothiocyanate can be 
synthesised directly from the amine in the presence of excess carbon disulfide. 
In addition to Boc2O, the authors suggest that a catalytic amount of DMAP (1–3 mol 
%) increased the reaction rate significantly, with visible evolution of gas from the reaction 
mixture. In the reaction pathway, the electrophilic Boc2O reacts with the dithiocarbamate 
with evolution of CO2 to form an unstable ‘mixed dithiocarbamate/carbonate’ adduct that 
rapidly decomposes to the isothiocyanate, COS and tert-butanol (Scheme 2.24). 
Triethylamine is necessary for the stabilisation and complete formation of the 
dithiocarbamate The reaction was carried out on the resin, stirring gently in THF at room 
temperature. The crude compound 45, was recovered by cleavage from the solid support. 
 
Scheme 2.24 
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Scheme 2.25 
 
2.8.6 Synthesis of BisBiotin-(PEG6)-Asp-SCN 
In order to assess the ability of different aminoacids to protect the molecule from the 
enzimatical action, we decided to insert one residue of Asp instead of Abu. The reaction 
was performed in the same way of the product 38 described in Scheme 2.18 but with the 
insertion of Fmoc-Asp-OtBu, 46 instead of Fmoc-Abu-OH (Scheme 2.26). 
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Starting from this point the synthesis proceeded in accordance with the route 
previously described and, with the final cleavage, the crude compound 48 was released as 
showed in Scheme 2.27. 
 
Scheme 2.27 
 
2.8.7 Synthesis of BisBiotin-(PEG2)-pAB-Abu-SCN 
The last compound of this series was designed with the aim of merging the 
characteristics of hydrofilicity and flexibility of PEG with the structural rigidity carried by 
the p-amino benzoic acid. Moreover we decided to use the protection against biotinidases 
provided by the residue of Abu. This one is more hydrophobic than Asp, but the use of this 
molecule during the synthesis simplifies the final deprotection and avoids eventual 
unwanted hydrogen interactions between the carboxylic group of Asp side-chain and the 
oxygen atoms present in PEG. The first step of the synthesis was the deprotection of the 
Lys linked on resin, followed by coupling with the Spacer C3 (Scheme 2.5), similarly to 
the synthesis of BisBiotinaMonoDOTA-C3, resulting in the intermediate 12. Subsequently, 
the compound 12 was deprotected from Fmoc groups and thus ready for coupling with 
Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG-COOH), 49, suitably activated 
(Scheme 2.28). 
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Scheme 2.28 
 
The reaction started from the Fmoc removal of compound 50 and the subsequent 
coupling with Fmoc-pAB-OH, 8 (Scheme 2.29). 
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The coupling with PEG, 49 was repeated once again, in order to obtain the desired 
length of the arms (Scheme 2.30). 
 
Scheme 2.30 
 
The reaction was carried out as already described, by adding biotin on the growing 
structure 53, the removal of the MTT group was achieved by TFA 1% in DCM with 2.5% 
TIS and the released amino group was coupled with Fmoc-!Ala-OH. After the Fmoc 
removal in piperidine, the amino group was transformed in isothiocyanate by reacting with 
CS2, as showed in Scheme 2.31. The final crude product 55, was recovered after cleavage 
from the resin in strongly acidic conditions. 
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Scheme 2.31 
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2.9 Results and discussion 
The in vitro experiments were essential to evaluate the potential role of these new 
biotin derivatives in the clinical settings. They are performed at European Institute of 
Oncology (Milan). Primarily, we estimated the radiochemical purity (RCP) of new 
molecules; then we checked the resistance of the molecule to the action of biotinidases and 
we attempted to verify whether the conjugation steps and the radiolabeling procedure 
altered the natural affinity of biotin for avidin. 
 
2.9.1 Radiolabelling tests 
Radiolabeling studies was carried adding to a solution of biotin derivative in H2O 
MilliQ (2 mg/mL), sodium acetate buffer 1M (pH = 5) and then a solution of the 
radioisotope in the form of chloride (MCl3, with M = 111In, 90Y, 177Lu). The studies was 
carried out at a specific activity of 5.3 and 10.6 MBq/nmole, respectively double and 
quadruple compared with this used to label the MonoDOTA (1) derivative. For this latter 
compound a specific activity of 2.6 and 5.3 MBq/nmol were used. The mixture was 
incubated at 95 °C for 30 min. 
The labelling yield, i.e. the percentage of the total radioactivity in the liked chemical 
form, was determined by Instant Thin Layer Chromatography (ITLC-SG). A molar excess 
of Av and DTPA in saline was added to an aliquot of the radiolabeled mixture. In this 
system, Av/biotin derivative complex remains at the starting point while free metal 
(bounded to DTPA) migrates with the solvent front. The strip was cut in two halves and 
counted in a !-counter (Figure 2.34). 
Figure 2.34 Radio-TLC profile for MonoDOTA (1). 
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RCP is then calculated according to the autoradiographic measures; for both 
radiometals used it was almost 99% or higher (Table 2.4) and the result is the same for 
tests where a specific activity of 5.3 MBq/nmol is used.112 
For radiolabelling of BisDOTA compounds 7 and 11, specific activities were used of 
5.3 and 10.6 MBq/nmol of the compound under experimental conditions similar to those of 
MonoDOTA. Measured RCP was always above 99%.93 
A further increase in specific activity (51.2, 212, 530 MBq/nmol) showed a decrease 
in RCP but still higher than 95%. The possibility of increasing considerably the specific 
activity maintaining high RCPs may represent a great advantage in the clinical application 
of the avidin-biotin system. A new-targeted locoregional therapy, based on avidin and 90Y 
labeled MonoDOTA, has shown great potential in the treatment of breast cancer reducing 
the duration of radiotherapy.22 In this approach, MonoDOTA has been labelled at a 
specific activity of 2.6 MBq/nmol. Using the herein described BisDOTA derivatives 
radiolabeled at high specific activity may lead to a higher uptake by the targeted tumor 
area administering lower 90Y activity, thus reducing the radiation burden to nontarget 
organs. 
 
Table 2.4 RCP of BisDOTA compounds related to MonoDOTA. 
Modified Biotin 90Y 177Lu 
MonoDOTA 
(2.6 MBq/nmol) 99.6% 99.6% 
MonoDOTA 
(5.3 MBq/nmol) 99.5% 99.5% 
BisDOTA-Lys-C3 
(5.3 MBq/nmol) 99.9% 99.7% 
BisDOTA-Lys-C3 
(10.6 MBq/nmol) 99.1% 99.4% 
BisDOTA-Lys-(pAB)-C3 
(5.3 MBq/nmol) 99.9% 99.6% 
BisDOTA-Lys-(pAB)-C3 
(10.6 MBq/nmol) 99.3% 99.2% 
  
                                                
112 Urbano, N.; Papi, S.; Ginanneschi, M.; De Santis, R.; Pace, S.; Lindstedt, R.; Ferrari, L.; Choi, S.J.; 
Paganelli, G.; Chinol, M. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 68-76. 
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For BisBiotin compounds 21, 34 and 44, only preliminary data are available, the 
RCP was calculated on compounds radiolabelled with 111In, always using the combined 
approach ITLC-SG and radio-TLC. 
The behaviour of these compounds to radiolabeling test were different from the 
others, as showed in Table 2.5, BisBiotinMonoDOTA-C3 (21) and BisBiotinBisDOTA-
(PEG6)-C3 (44), showed high RCP at specific activity of 2.6 MBq/nmol, but it decreases at 
higher values of SA. 
Somewhat unexpectedly, the BisBiotinaMonoDOTA-(pAB)-C6 (34) reported a very 
low RCP; in practice the molecule seemed not to be able to chelate the radiometal. 
The data in our possess are still too small to find a plausible reason for this radiolabel 
failure and the product tested was, anyway, of high chemical purity, so is reasonable to 
assume that the problem could be related to some variables of experimental nature. 
 
Table 2.5 RCP of BisBiotin compounds. 
BisBiotin Compounds 111I 
BisBiotinMonoDOTA-C3 
(2.6 MBq/nmol) 
98.3% 
BisBiotinMonoDOTA-C3 
(26 MBq/nmol) 
84.2% 
BisBiotinBisDOTA-(PEG6)-C3 
(5.2 MBq/nmol) 
99.6% 
BisBiotinBisDOTA-(PEG6)-C3 
(52 MBq/nmol) 
60% 
BisBiotinMonoDOTA-(pAB)-C6 
(2.6 MBq/nmol) 
4% 
BisBiotinMonoDOTA-(pAB)-C6 
(26 MBq/nmol) 0.5% 
 
2.9.2 Stability studies 
Stability studies in vitro were performed to verify the BisDOTA derivatives stability 
in human serum to esterases attack (in particular biotinidases). These results were obtained 
taking like benchmark their behaviour in saline. Testes stability were performed on the 
radiolabeled mixture in saline solution then adding an ascorbic acid solution (4 mg/mL in 
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sodium acetate buffer, pH = 5) as radical scavenger diluted 1:3 and finally in human 
serum. 
In each case, the mixture was incubated at 37 °C for 24 and 48 h; the radiochemical 
purity was calculated using ITLC-SG as previously described. 
The results showed that in both ascorbic acid (AA) and human serum (HS), the 
activity was almost completely associated to the labelled biotin derivatives up to 48 h, 
while they were degraded in saline solution. 
These results are compared with those obtained for MonoDOTA compound (1). This 
one was threated in two different ways: aliquots from the labelling mixture were diluted 
with saline or human serum/saline 1:1 solution alternatively. After 2, 6, 12, 24, 36, and 48 
h of incubation at 37 °C, two aliquots (10 µL) of both the mixtures were drawn: one was 
added to Av molar excess and the other was added to saline. 
Figure 2.35 Stability of 90Y-labeled MonoDOTA in saline and diluted human serum. 
 
Stability studies showed that in both saline and diluted human serum the activity was 
almost completely associated to the labeled MonoDOTA molecule up to 48 h (Figure 
2.35). Moreover, the activity dissociated from the 90Y-labeled MonoDOTA conjugate was 
not attributable to the cleavage of the side chain by biotinidase. In fact, the amount of 
cleaved 90Y-DOTA, was very low (about 3%) and did not increase from 2 to 48 h (in the 
serum free 90Y was totally bound to serum protein, personal observation). The release of 
90Y in diluted human serum, observed after 48 h of incubation at 37 °C, is also very low 
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and in any case does not represent a major drawback toward the application of this 
compound in therapy trials. We can affirm that biotinidase was not able to break the 
MonoDOTA conjugate in a significant extent. For the BisDOTA compounds 7 and 11 we 
decided to perform the stability test in NMS, compared with results obtained for biocytin. 
Biocytin is the natural substrate of the biotinidases, an hydrolytic enzyme family 
normally present in human and mouse sera, involved in the assimilation process of (+)-
biotin from diet. Activity of biotinidases in freshly collected NMS was assessed by 
incubating commercial biocytin with NMS, at 37 °C, and verifying the presence of (+)-
biotin as product of the reaction. As shown in Figure 2.36 (panels A and B, profiles 2 and 
3), after 2 h of incubation, biocytin (retention time 12 min; [M+H]+ = 373.5 Da) was 
effectively hydrolysed to produce a new species, at about tR = 12.5 min, with a molecular 
weight [M+H]+ = 245.1 Da, corresponding to (+)-biotin molecular weight (profile 3). 
Analysis of BisDOTA-Lys-(pAB)-C3 (11) incubated with NMS for 2 h at 37 °C (profile 4) 
showed that no peak, with a retention time of about 12.5 min and corresponding to (+)-
biotin, appeared, thus underlining the resistance of 11 to biotinidases activity. In strict 
agreement with these results, the peak of BisDOTA-Lys-(pAB)-C3 was fully recovered 
after the incubation step. Similar results were obtained with BisDOTA-Lys-C3 derivative 
(7) (data not shown). 
Figure 2.36 LC-MS analyses of BisDOTA derivatives resistance to biotinidase activity 
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2.9.3 Studies of binding to avidin 
In vitro tests were realized in order to check whether the new biotin derivatives 
preserve the good affinity towards the Av or Sav. 
The binding studies of the 90Y-labeled MonoDOTA derivative (1), in the presence of 
a 1:2 Av/1 molar ratio (which is two times the natural 1:4 molar ratio), showed that about 
85% of 90Y-labeled compound 1 was bound to Av, whereas at the natural 1:4 molar ratio 
only about 50% was bound (Figure 2.37). The average percentage of activity not 
specifically retained by the concentrator (about 4%) was subtracted from the counts found 
in the top part of the concentrator. Data at 2 and 24 h at 37 °C were similar, indicating that 
the binding occurs rapidly and is almost irreversible despite the linkage with the bulky 
DOTA molecule. 
 
Figure 2.37 Percentage of activity due to 90Y-labeled (1) bound to Av. 
 
HABA (4’-hydroxyazobenzene-2-carboxylic acid) is a reagent that enables a quick 
estimation of the mole-to-mole ratio of biotin to protein. To quantify biotin label 
incorporation, a solution containing the biotin derivative is added to a mixture of HABA 
and avidin. Because of its higher affinity for avidin, biotin displaces the HABA from its 
interaction with avidin and the absorption at 500 nm decreases proportionately. By this 
method, an unknown amount of biotin in a solution can be evaluated in a single cuvette by 
measuring the absorbance of the HABA-avidin solution before and after addition of the 
biotin-containing sample. The change in absorbance relates to the amount of biotin in the 
sample. The typical protocol is the following: 900 µL of the avidin-HABA reagent in a 1 
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mL cuvette; measure the absorbance at 500 nm (A500 HABA/avidin); add 100 µL of 
biotinylated sample and mix. Measure of the absorbance at 500 nm (A500 
HABA/avidin/biotin), the A500 should be stable. 
 
&A500 = (0.9 'A500 H/A) - (A500 H/A/B) 
 
For each biotin-derivative synthesized, a distribution curve showing biotin-avidin 
molar ratio vs &A500 was built (Figure 2.38). 
 
Figure 2.38 Inhibition of avidin/HABA complex by (+)-biotin (blue), BisDOTA-C6 (yellow), BisDOTA-
Lys-C3 (cyan), BisDOTA-Lys-(pAB)-C3 (red) and MonoDOTA (pink). 
 
The avidin binding activity of BisDOTA derivatives was also determined by HABA 
assay in comparison with (+)-biotin.  The assay utilizes the observation that HABA shows 
dramatic spectral changes when it binds to avidin. Free HABA has an absorption peak at 
348 nm, while the HABA/avidin complex has strong absorption at 500 nm. Since the 
affinity between HABA and avidin is relatively weak (Kd = 5.8 ' 10-6 M) compared to the 
affinity between (+)-biotin and avidin (Kd = 1 ' 10-15 M), (+)-biotin can easily replace 
HABA from the HABA/avidin complex, resulting in a decrease of absorption at 500 nm. 
To estimate the apparent avidin binding affinity of biotin and biotin-derivatives, several 
competitive binding studies have been performed adding (+)-biotin and corresponding 
biotin-derivatives to the HABA/avidin sample and measuring any change in absorbance. 
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As shown in Figure 2.39, all BisDOTA compounds were able to inhibit the HABA/avidin 
complex in a dose dependent manner. 
 
Figure 2.39 Inhibition of the HABA/avidin complex by (+)-biotin (!, black line), BisDOTA-Lys-C3 ((, red 
line), BisDOTA-Lys-(pAB)-C3 (), green line) and BisDOTA-C3 (*, blue line). 
 
Nevertheless, due to the differences in their spacer arms, BisDOTA-Lys-C3 (7) and 
BisDOTA-Lys-(pAB)-C3 (11) are very similar to the native (+)-biotin. For sake of clarity, 
the relevant HABA displacement abilities are also compared in Table 2.6. 
 
Table 2.6 Displacement of HABA from Avidin Complex. 
Biotin derivatives HABA/Av inhibition % 
D-(+)-biotin 100% 
MonoDOTA 87% 
BisDOTA-C3  66% 
BisDOTA-C6 64% 
BisDOTA-Lys-C3 95% 
BisDOTA-Lys-(pAB)-C3 97% 
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The melting curve of avidin/BisDOTA complex shows an inflection point at about 
90 °C, which is higher than that of the avidin alone (about 80 °C) (Figure 2.40). Indeed, 
the melting curves of avidin/BisDOTA-Lys-C3 and avidin/BisDOTA-Lys-(pAB)-C3 
complexes showed no valuable inflection point in the temperature range 25-95 °C, 
similarly to avidin/(+)-biotin complex. 
 
Figure 2.40 Melting curves of avidin (brown line); avidin/BisDOTA-C3 complex (blue line); 
avidin/BisDOTA-Lys-C3 complex (red line); Avidin/BisDOTA-Lys-(pAB)-C3 complex (green line); 
avidin/(+)-biotin complex (black line). 
 
The introduction of a spacer containing a carboxylate function in # to the 
biotinamide (BisDOTA-Lys-C3, 7), increased avidin affinity obtaining comparable values 
with MonoDOTA derivative. 
The BisDOTA-Lys-C3 modification with a more rigid and planar spacer (BisDOTA-
Lys-(pAB)-C3) carried an high increment in the binding affinity, indeed comparable with 
biotin. 
The HABA affinity test was also useful for BisBiotin compounds 34 and 44, 
providing data that can be compared with the previous results in order to assess the 
applicability of the products (Figure 2.41). 
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Figure 2.41 Inhibition of the avidin/HABA complex from biotina (blue), BisBiotinBisDOTA-(PEG6)-C3 
(yellow) and BisBiotinMonoDOTA-(pAB)-C6 (pink). 
 
For BisBiotinMonoDOTA-C3 (21) and BisBiotinBisDOTA-(PEG6)-C3 (44) data 
were similar: both compounds showed good affinity for avidin, but not so excellent as the 
BisDOTA compounds synthesized on solid phase. 
In fact they showed an affinity slightly lower than MonoDOTA, but the affinity was, 
however, still of interesting level. 
The BisBiotinMonoDOTA-(pAB)-C6, in perfect harmony with the radiolabelling 
results, showed very little affinity for avidin. The data, once again, were not sufficient to 
make a weighted assessment regarding the poor performances of 34, the low affinity of the 
similar BisDOTA could suggest a parallelism and indicate that the spacer C6 is not suitable 
for these derivatives, but there aren’t yet sufficient data to support this thesis. 
In addition, the two compounds, presented differences in affinity for avidin, in fact 
the derivative 34 highlighted a very little affinity. 
All of these results, positive or negative, are still essential to evaluate not only the 
products in question, but also the direction of research to be undertaken in future.
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Chapter 3 
CYCLOPEPTIDES AS CHELATING AGENTS 
 
3.1 Introduction 
Peptides are very efficient ligands for many metal ions. Their coordination capacity 
originates from presence of electron-donor functional groups in their side chains. Peptide 
complexes with first transition metals are under investigation because they mimic the 
metalloprotein binding sites.113 Many natural peptides may contain a competitive donor 
atom in the side chain. The most important among them are the pyridine-like imidazole 
nitrogen of His (N3) and the oxygen #-carboxylate of Asp. His or Asp residues are often 
critical for the biological activity of natural peptides and involving it in metal ion 
coordination may drastically change the biological activity of peptides. 
The imidazole ring of His residues plays an important role in the biological function 
of the active sites in many enzyme systems and in the metal ion coordination points of 
several transport proteins. Furthermore, this residue is present in low molecular weight 
complexes that serve as delivery system of copper to tissue or that alters the growth rate or 
the state of differentiation of cultured cells and organism. This amino acid links metals 
ions, in particular Cu(II), in a strong way, by his imidazolic N3 (N+) which originates a 
high stably six-membered ring with the terminal amino group at pH > 4.114,115 It is well 
known that three His residues constitute the ligands of zinc in carbonic anhydrase and that 
four His residues coordinate the copper in bovine superoxide dismutase.116 On the other 
hand, the N-terminal region of the protein bovine serum albumin (BSA) containing the 
sequence Asp-Thr-His-Lys is known to provide a specific binding site for Cu(II) ions.117 In 
                                                
113 Kozlowski, H.; Bal, W.; Dyba, M.; Kowalik-Jankowska, T. Coord. Chem. Rev. 1999, 184, 319-346. 
114 Casolaro, M.; Chelli, M.; Ginanneschi, M.; Laschi, F.; Muniz-Miranda, M.; Papini, A.M.; Sbrana, G.; 
Spectrochim. Acta. Part A, 1999, 55A(7-8), 1675-1689. 
115 Daniele, P.G.; Zerbinati, O.; Aruga, R.; Ostacoli, G. J. Chem. Soc. Dalton Trans. 1988, 1115-1120. 
116 Tainer, J.A.; Getzoff, E.D.; Richardson, J.S.; Richardson, D.S. Nature 1983, 306, 284. 
117 Peters, T.Jr.; Blumenstock, F.A. J. Biol. Chem. 1967, 242, 1574. 
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1974 it was first reported that the tripeptide H-Gly-Gly-His-OH could mimic Cu(II) 
binding characteristic of serum albumin.118 Recently, other linear peptides His-containing 
and mimicking the N-terminal Cu(II)-binding site of BSA have been synthesised and 
studied.119 Subsequently, a study reported the interactions between divalent metal ions, 
such as Cu(II) and Zn(II) and short linear peptides containing His–Xaa–His. This motif in 
the peptide sequence is commonly used as a model for the copper(II) binding site of 
superoxide dismutase.120 The multi-His sequences are also basic for the copper(II) binding 
motifs in other proteins like APP (amyloid precursor protein121 or SPARC - secreted 
protein, acidic and rich in cysteine).122 In the last decade, the neurodegenerative disorder 
called Creutzefeldt-Jacob disease, appeared onto the scene. The illness was due to the 
conversion of the normal cellular prion protein (PrPc) into the pathological isoform PrPSc. 
Recently studies have shown PrPC is a copper(II) protein involved in copper metabolism 
in the brain. Studies with recombinant protein and peptides related to its sequence have 
shown that prion protein binds copper ions in its N-terminal region which contains a series 
of octapeptide repeats with the consensus sequence PHGGGWGQ.123 These finds 
prompted the synthesis of numerous linear oligopeptides containing histidine in the effort 
to understand the behaviour of the normal and pathological octarepeat sequence. 
There is great interest in the chemical characterisation of copper(II) complexes with 
oligopeptides. Indeed, a small but significant fraction of copper(II) in biological fluids 
appears to be associated with low molecular weight species; it is believed that this fraction 
is primarily responsible for the homeostasis of copper(II) and for its transfer among 
various storage and utilisation sites. Of particular significance is a recent study by 
Armstrong et al. where a detailed speciation of the various copper(II) species that are 
present in biological fluids is reported. Notably, in the blood stream, the low molecular 
weight copper(II) fraction is in equilibrium with macromolecular ligands such as serum 
albumin and serum transferrin. 
                                                
118 Lau, S.; Kruck, T.P.A.; Sarkar, B. J. Biol. Chem. 1974, 249, 5878-5884. 
119 Quagraine, E.K.; Kraatz, H.B.; Reid, R.S. J. Inorg. Biochem. 2001, 85, 23-32. 
120 Pogni, R.; Baratto, M.C.; Busi, E.; Basosi, R. J. Inorg. Biochem. 1999, 73, 157. 
121 ,uczkowski, M.; Wisniewska, K.; ,ankiewicz, L.; Koz-owski, H. J. Chem. Soc. Dalton Trans. 2002, 
2266. Multhaup, G. et al. Science 1996, 271, 1406. 
122 Remelli, M.; ,uczkowski, M.; Bonna, A.M.; Mackiewicz, Z.; Conato, C.; Koz-owski, H. New J. Chem. 
2003, 27, 245–250. 
123 Kramer, M.L.; Kratzin, H.D.; Schmidt, B.; Romer, A.; Windl, O.; Liemann, S.; Hornemann, S.; 
Kretzschmar, H. J. Biol. Chem. 2001, 276, 16711. 
Chapter 3. Cyclopeptides as chelating agents 
 90 
Starting from the study of a series of linear tetrapeptides124 and cyclotetrapeptides125 
containing the histidine residue, synthesized in the “Laboratory of Peptides & Proteins 
Chemistry & Biology” of the University of Florence, the role of His and Gly residues 
coordination abilities towards copper(II) ions was been addressed. Particular emphasis is 
given to the consequences of the specific position of a unique histidine residue within a 
model, N-terminal protected, tetrapeptide sequence. For this aim we have synthesized the 
N-acetylated linear tetrapeptides with a single His, N and COOH protected oligopeptides 
with two His, but in primis we have investigated a series of cyclotetrapeptides containing 
two His. 
Cyclotetrapeptides are constrained cyclic peptides whose synthesis is considered a 
difficult task. A methodology based on head-to-tail on-resin cyclization by anchoring the 
His side-chain was used. The combination of this strategy with an orthogonal three-
dimensional protection scheme such as the Fmoc/tBu/OAl results in a powerful head-to-
tail cyclization methodology. The use of a three-dimensional protection scheme allows the 
orthogonal deprotection of the C- and N-termini for the subsequent head-to-tail on-resin 
cyclization. The solid-phase cyclization, compared to the solution one, takes advantage 
from the pseudodilution phenomenon to avoid cyclooligomerization that is critical in the 
synthesis of cyclotetrapeptides, where the ring closure is not favoured over the 
intermolecular cyclization, due to the intrinsic rigidity induced by the +-character of the 
peptide bond. The proposed synthetic approach presents the great advantage of obtaining 
cyclic scaffolds still bound to the resin, with functionalities ready for further modifications. 
The optimization of all the parameters and the comprehension of their role can be 
considered a starting point for the synthesis of libraries of constrained cyclopeptides. 
This work has the aim to find a suitable alternative to the traditional chelating agents 
(DOTA and TETA) for use in radioimmunoterapies, and more specifically for the 
obtainment of a chelating agent designed ad hoc for each radiometal used and moreover 
for an efficient chelation of 64Cu/67Cu used in PET and SPECT. 
                                                
124 Matera-Witkiewicza, A.; Brasun, J.; Swiatek-Koz-owska, J.; Pratesi, A.; Ginanneschi, M.; Messori L. J. 
Inorg. Biochem. 2009, 103, 678–688. 
125 Brasun, J.; Matera-Witkiewicz, A.; O-dziej, S.; Pratesi, A.; Ginanneschi, M.; Messori, L. J. Inorg. 
Biochem. 2009, 103, 813–817. 
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3.1.1 Radiometals for imaging of disease 
Single-photon emission computed tomography (SPECT) and positron emission 
tomography (PET) were the first molecular imaging modalities used clinically. SPECT 
requires the use of a contrast agent labeled with a "-emitting radionuclide, which should 
have an ideal " energy of 100-250 keV. These " rays are recorded by the detectors of a 
dedicated " camera or SPECT instrument and after signal processing can be converted into 
an image identifying the localization of the radiotracer. PET requires the injected 
radiopharmaceutical to be labelled with a positron-emitting radionuclide. As the 
radionuclide decays, it ejects a positron from its nucleus, which travels a short distance 
before being annihilated with an electron to release two 511 keV " rays 180° apart that are 
detected by the PET scanner. After sufficient acquisition time, the data are reconstructed 
using computer-based algorithms to yield images of the radiotracer’s location within the 
organism. Compared with SPECT, PET has greater advantages with respect to sensitivity 
and resolution and has been gaining in clinical popularity, with the number of PET-based 
studies expected to reach 3.2 million by 2010.126 While SPECT and PET technologies have 
been around for decades, their use remained limited because of the limited availability of 
relevant isotopes, which had to be produced in nuclear reactors or particle accelerators. 
However, the introduction of the small biomedical cyclotron, the self-contained 
radionuclide generator, and the dedicated small animal or clinical SPECT and PET 
scanners to hospitals and research facilities has increased the demand for SPECT and PET 
isotopes. 
Traditional PET isotopes such as 18F, 15O, 13N, and 11C have been developed for 
incorporation into small molecules, but due to their often lengthy radiosyntheses, short 
half-lives, and rapid clearance, only early time points were available for imaging, leaving 
the investigation of biological processes, which occur over the duration of hours or days, 
difficult to explore. With the continuing development of biological targeting agents such as 
proteins, peptides, antibodies and nanoparticles, which demonstrate a range of biological 
half-lives, a need arose to produce new radionuclides with half-lives complementary to 
their biological properties. As a result, the production and radiochemistry of radiometals 
such as Zr, Y, In, Ga, and Cu have been investigated as radionuclide labels for 
                                                
126 Society of Nuclear Medicine. http://interactive.snm.org/index.cfm?, 2009. 
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biomolecules since they have the potential to combine their favorable decay characteristics 
with the biological characteristics of the targeting molecule to become a useful 
radiopharmaceutical (Table 3.1 and Table 3.2).127 
In case that copper is used with a chelating agent, is important to investigate its 
coordination chemistry. While +1 and +3 oxidation states are both accessible for copper in 
the presence of suitable donors, 3d9 Cu(II) remains the predominant state for radiocopper 
chemistry in protic media. 
 
Table 3.1 "- and !-Emitting radiometals. 
 
Table 3.2 Positron-emitting radiometals. 
 
The aqueous cupric ion was long believed to have a tetragonally distorted hexa-aqua 
structure until a 2001 report suggested only five-coordination.128 Its water-exchange rate 
has been found to be very rapid compared with most common first-row transition metal 
cations and as a result it has relatively facile substitution chemistry despite having some 
crystal-field stabilization. This is usually ascribed to the Jahn-Teller distortion that 
elongates one or more of its coordinated ligands. Classified as a cation of borderline 
                                                
127 Welch, M.J.; Redvanly, C.S., Eds.; Handbook of Radiopharma-ceuticals: Radiochemistry and 
Applications; John Wiley & Sons Inc.: Hoboken, NJ, 2003. 
128 Pasquarello, A.; Petri, I.; Salmon, P.S.; Parisel, O.; Car, R.; Toth, E.; Powell, D.H.; Fischer, H.E.; Helm, 
L.; Merbach, A.E. Science 2001, 291, 856. 
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hardness, the high affinity of Cu(II) for borderline nitrogen donors is well established. 
With a relatively small ionic radius of between 57 and 73 pm for coordination numbers 4-
6, it is particularly suitable for the formation of five membered chelate rings; indeed the 
chelate effect is epitomized in its ethylenediamine family of complexes.129 The popular use 
of polyazamacrocycles, especially cyclen and cyclam, for strong binding of Cu(II) is a 
consequence of the added advantage of the macrocyclic effect,130 as borne out by their 
extensive coordination literature.131,132 The importance of in vivo redox activation of 
metallodrugs incorporating Pt(IV), Ru(III), and Co(III) has received increasing attention. 
The role of bioreduction in copper radiopharmaceutical efficacy has been intensively 
studied in their thiosemicarbazone complexes.133 Convincing evidence for the formation 
and selective retention/decomplexation of Cu(I)-intermediates from Cu(II) precursors in 
hypoxic tissues has been presented.134 Whether Cu(II)/Cu(I) bioreduction is also a viable 
pathway for irreversible in vivo radiocopper loss from other chelator complexes and their 
bioconjugates is an intriguing possibility. There is some compelling evidence for the 
deteriorated in vivo performance of related Cu(II) complexes differing only in their 
reduction propensities. Specifically, the “long arm” dicarboxyethyl pendant-armed Cu(II) 
complex of cross- bridged cyclam has an Ered almost 400 mV higher (or more positive) 
than that its carboxymethyl-armed analogue.135 The former has been found to exhibit 
significantly inferior bioclearance behavior despite very similar coordination geometry and 
acid-inertness. The plasticity of the Cu(II) coordination geometry can be gleaned from a 
literature survey of 89 of its complexes with cyclen and cyclam derivatives. Coordination 
numbers (CN) ranging from 4 to 6 were found with geometries approximating square 
planar, square pyramidal, trigonal bipyramidal, and octahedral. Tetradentate chelators are 
usually designed to cater to Cu(II)’s strong affinity for ligands favouring a square-planar 
geometry. Common donor sets include two amino or imino nitrogens combined with two 
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charge neutralizing anionic amido, oxo, or thiolato sites. These include numerous Schiff 
base or amino acid derived chelators. As a result, hexadentate chelators have become the 
most investigated in radiocopper chemistry (Figure 3.1). Popular scaffolds include 
tetraazamacrocycles, derived from cyclic tetrapeptides. 
Figure 3.1 Cu(II)/DOTA. 
 
3.2 Synthesis of cyclen scaffolds from cyclotetrapeptides 
The development of new coordinating ligands is of straightforward actuality for the 
study and the synthesis of diagnostic and therapeutic drugs, which can mimic the binding 
site of metalloproteins. Tetraazamacrocyclic compounds, as 1,4,8,11-
tetraazacyclotetradecane (cyclam) and 1,4,7,10-tetraazacyclododecane (cyclen) derivatives 
(Figure 3.2) have found wide application in medicinal chemistry.136 In particular, cyclen 
derivatives have recovered considerable interest in the development of MRI contrast 
agents137 and as radionuclides vehicles.138 
 
NH
NH
HN
HN NH HN
NH HN
cyclam cyclen  
Figure 3.2 Cyclam and Cyclen. 
                                                
136 Bradshaw, J.S.; Krakowiak, K.E.; Izatt, R.M. In “Aza-Crown Macrocycles: The Chemistry of Hetericyclic 
Compounds”, Wiley&Sons, New York, 1993, pp. 16-21, 83-85, 157-165. 
137 Caravan, P.; Ellison, J.J.; McMurray, T.J.; Lauffer, R.B. Chem. Rev. 1999, 99, 2293-2352. 
138 Burgess J. Chem. Soc. Rev. 1996, 85-92. 
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Cyclen is the key intermediate for the preparation of more complex compounds,139 
such as bis-tetraazamacrocycles, polyazamacrocycles and N-alkylated cyclens. Different 
condensation strategies for the synthesis of cyclens have been described, but the traditional 
approach reported by Richman and Atkins,140 with its variants, where the condensation 
reaction involves a tris-N-tosyl diethylenetriamine and an N-tosyl diethanolamine 
ditosylate, remains the most convenient. In order to avoid tosylate chemistry, different 
protections of the aza-compounds were considered either envisaging condensation of 
tricyclic intermediates,141 or tetracyclic precursors.142 
A convenient retro-synthetic pathway to tetraazamacrocycles can be envisaged 
considering cyclen and cyclam derivatives as pseudopeptides. In fact, reduction of the 
amide bond of head-to-tail cyclotetrapeptides, containing four #-amino acids, can lead to 
cyclen derivatives, while cyclams can be obtained by cyclotetrapeptides containing % and 
#-amino acids in alternate positions.143 Moreover, the cyclen core derived from 
cyclotetrapeptides is a possible scaffold for metal complexation with increased chelating 
properties, thanks to the side-chains of suitable amino acids to be introduced in the 
precursor peptide sequence. 
Syntheses leading to cyclen derivatives mono-substituted at position 2 were 
described;144 only one compound, tetraethyl substituted at positions 2, 5, 8, and 10, was 
reported.145 
In PeptLab was investigated the synthesis of an enantiomerically pure cyclen 
derivative disubstituted at positions 2 and 8 obtained by reduction of cyclo(His-Gly-His-
Gly), using a solid-phase strategy. 
  
                                                
139 Bender, J.A.; Meanwell, N.A.; Wang, T. Tetrahedron 2002, 58, 3111-3128. 
140 Richman, J.E.; Atkins, T.J. J. Am. Chem. Soc. 1974, 96, 2268-2270; Atkins, T.J.; Richman, J.E.; Oettle, 
W.F. Org. Synth. 1978, 58, 86-98. 
141 Jazwinski, J.; Kolinski, R. Tetrahedron Lett. 1981, 22, 1711-1714. 
142 Weisman, G.R.; Reed, D.P. J. Org. Chem. 1996, 61, 5186-5187; Hervé, G.; Bernard, H.; Toupet, L.; 
Handel, H. Eur. J. Org. Chem. 2000, 33-35; Athey, P.S.; Kiefer, G.E. J. Org. Chem. 2002, 67, 4081-
4085. 
143 Achmatowicz, M.; Jurczak, J. Tetrahedron: Asymmetry 2001, 12, 111-119. 
144 Garrity, M.L.; Brown, G.M.; Elbert, J.E.; Sachleben, R.A. Tetrahedron Lett. 1993, 34, 5531-5534. 
145 Tsuboyama, K.; Higashi, I.; Yanagita, M. Tetrahedron Lett. 1970, 11, 1367-1370. 
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Figure 3.3 2,8-bis-(1H-imidazol-4-ylmethyl)-1,4,7,10-tetraazacyclododecane 
 
Reduction of the amide bonds of cyclo[His-Gly-His(trityl-resin)-Gly] was 
undertaken by an on-resin procedure, by treatment with a solution of BH3$THF.146 
The new scaffold cyclen analogue 2,8-bis-(1H-imidazol-4-ylmethyl)-1,4,7,10-
tetraazacyclododecane (Figure 3.3), containing two imidazole groups (coming from the 
His residues present in the skeleton of the starting material), possesses increased chelating 
properties, respect to the usual tetraazamacrocycles, which can be used as coordinating 
systems in metalloproteins characterization. 
Anyway the method applied showed very low yields of completely reduced 
compounds, with formation of by-products containing only one, two or three reduced 
peptide bonds. Tentative reduction with LiAlH4 in THF gave same results. 
Because of this problem we decided to study the coordination properties of the 
various cyclic peptides without reduction of the amidic bonds. 
 
3.3 14-membered tetraza cyclic tetrapeptide 
A small but still significant fraction of copper(II) ions in biological fluids appears to 
be associated with low molecular weight species; it is believed that this fraction is 
primarily responsible for the homeostasis of copper(II) and for its transfer among various 
storage and utilization sites. 
                                                
146 Alcaro, M.C.; Orfei, M.; Chelli, M.; Ginanneschi, M.; Papini, A.M. Tetrahedron Lett. 2003, 44, 5217-
5219. 
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Peptides form a special group of substances capable of effective copper(II) binding; 
among them, cyclopeptides deserve a special attention. Cyclopeptides play a variety of 
roles in living organisms; indeed they may act as hormones, toxins, antibiotics, molecules 
with enzymatic functions or as carrier molecules.147,148,149 The most known is valinomicin, 
cyclopeptide is able of binding the alkali metal ions and transporting them through the 
biological membranes. 
The previous studies on the binding abilities of cyclopeptides towards Cu(II) 
ions150,151,152,153 showed that His-containing cyclopeptides are able to bind copper(II) 
tightly through imidazole as well as amide nitrogens. The pH and the peptide ring size 
have a great impact on the kind of the coordinated nitrogens. The acidic pH favors the 
formation of complexes with imidazole nitrogens coordinated to the metal ion while in the 
basic conditions the binding of the amide nitrogens is highly preferred. The ring size is 
significant for the coordination mode. The study on the cyclopeptides with twelve 
membered rings have shown that the ring is too small for the formation of the complex 
with the [4 ' N-] binding mode. Insertion of one more carbon atom into the peptide cycle 
causes that the oxidation of the copper is observed.152 For the peptides with greater than 
13-membered rings the formation of the complex with the [4 ' N-] binding mode is 
preferred. 
The cyclopeptides with four amide nitrogens may be somehow related to the 
corresponding tetraazamacrocycles,154,155 commonly endowed with very high binding 
constants for Cu(II), of potential use in 64Cu-based radiotherapeutic strategies.156 
                                                
147 Ovchinnikov, Y.A.; Ivanov, V.T. Tetrahedron 1975, 31, 2177–2209. 
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149 Odier, F.; Vey, A.; Bureau, J.P. Biol. Cell 1992, 74, 267–271. 
150 Brasun, J.; Gabbiani, C.; Ginanneschi, M.; Messori, L.; Orfei, M.; Swiatek-Kozlowska, J. J. Inorg. 
Biochem. 2004, 98, 2016–2021. 
151 Brasun, J.; Matera, A.; O-dziej, S.; Swiatek-Koz-owska, J.; Messori, L.; Gabbiani, C.; Orfei, M.; 
Ginanneschi, M. J. Inorg. Biochem. 2007, 101, 452–460. 
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154 Motekaitis, R.J.; Rogers, B.E.; Reichert, D.E.; Martell, A.E.; Welch, M.J. Inorg. Chem. 1996, 35, 3821–
3827. 
155 Martell, A.E.; Smith, R.M. Critical Stability Constants, vol. 62, Plenum Press, New York, 1989 (Suppl.). 
156 Ferreira, C.L.; Yapp, D.T.; Lamsa, E.; Gleave, M.; Bensimon, C.; Jurek, P.; Kiefer, G.E. Nucl. Med. Biol. 
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The cyclic peptide that is investigated here, c(#3homoLys-DHis-!Ala-His) (DK14 
hereafter), is a structural analog of c(Lys-DHis-Gly-His), but bears two additional carbons 
thus consisting of 14 members peptide cycle (Figure 3.4). In principle, the greater ring size 
might confer a higher flexibility to this ligand than shown by 12-member cyclopeptides. 
Also, we thought that a the detailed comparison of the behaviour of the here reported 
copper(II) complexes with those formed by c(Lys-DHis-Gly-His) might provide further 
insight into the structural and thermodynamic properties of copper(II) cyclopeptide 
systems. 
 
Figure 3.4 c(#3homoLys-DHis-!Ala-His) (DK14) 
 
The protonation constants for the studied peptide are given in Table 3.3. The 
c(#3homoLys-DHis-!Ala-His) (56) (DK14) is characterized by three protonation constants 
which can be assigned to the two histidine and one lysine residues. The protonation 
constants for the ligand with the 14-atoms cycle are slightly higher than those earlier 
obtained for its analog with the twelve-member ring (DK12) (Table 3.3). 
The coordination of copper(II) starts around pH 4.5 through the formation of the 
CuH2L species (Figure 3.5). The presence of the maximum absorption at 703nm (Table 
3.4) suggests copper(II) coordination of 1N type. The value of log K* = -2.47 (log K* = 
log #CuH2L - log#H3L)157 supports binding of the nitrogen from a first imidazole ring. 
                                                
157 Koz-owski, H.; Kowalik-Jankowska, T.; Jezowska-Bojczuk, M.; Coord. Chem. Rev. 2005, 249, 2323–
2334. 
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When pH increases, dissociation of the next proton takes place from the second 
imidazole ring leading to formation of the CuHL species. However, the concentration of 
this species is too low for any satisfactory spectroscopic characterization. Nevertheless, the 
value of log K = 6.45 (Table 3.3) for proton dissociation from the 2-nd His is almost the 
same as for free ligand (logKIm2 = 6.63). 
 
Table 3.3 Potentiometric data for Cu(II) complexes with 56 and 58. 
 c(!3homoLysDHis!AlaHis) c(LysDHisGlyHis)  
HL 9.99±0.01 9.51 
H2L 16.62±0.02 16.05 
H3L 
 
22.38±0.01 21.45 
logK(NH2) 9.99 9.51 
logK(Im) 6.63 6.54 
logK(Im) 5.76 5.40 
 log! 
CuH2L 19.91±0.06 - 
CuHL 13.46±0.10 14.76 
CuH-1L 1.22±0.02 3.49 
CuH-2L -6.86±0.03 -5.54 
CuH-3L -15.57±0.03 - 
CuH-4L -26.16±0.03 -26.22 
log!CuH2L-log!CuHL 6.45 - 
log!CuHL-log!CuH-1L 12.24 11.27 
log!CuH-1L-log!CuH-2L 8.08 9.03 
log!CuH-2L-log!CuH-3L 8.71 - 
log!CuH-3L- log!CuH-4L 10.59 - 
log!CuH-2L-log! CuH-4L - 20.68 
 
 
This finding suggests that the presence of the copper(II) ion in the complex has no 
impact on dissociation of the proton from 2nd His residue and that binding of a second 
nitrogen to the metal does not take place. 
With a further pH increase, the cooperative dissociation of two protons is observed 
and the CuH-1L species is formed. The spectroscopic data (Table 3.4) are suggestive of 3N 
type copper(II) coordination. Analysis of CD data (Table 3.4, Figure 3.6) suggests that 
nitrogen from the imidazole ring as well as two amide nitrogens are bound to the metal ion. 
This type of coordination dominates at physiological pH (Figure 3.5). 
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The proposed CuH-1L structure obtained from theoretical calculations is shown in 
Figure 3.7. Thus, DK14 similarly to DK12 predominantly forms a complex with a 
characteristic [NIm, 2 ' N-] binding mode at physiological pH (Figure 3.5). 
 
Table 3.4 Spectroscopic data for Cu(II) complexes with 56 and 58. 
 c(!3homoLysDHis!AlaHis) c(LysDHisGlyHis) 
 
Comp. 
UV-Vis CD EPR UV-Vis CD EPR 
"  &  "  "&  AII g "  &  "  "&  AII g 
 
CuH2L 
 
703 
 
34 
- -  
136 
 
2.359 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
CuHL - - - -   681.5 46 665 337b) 
0.04 
-0.05 
- - 
CuH-1L 
 
 
 
 
 
 
681 
495 
341 
 
 
 
 
71 
90 
sh 
 
 
 
 
520 
467,50 
414,5 sh 
363,5 sh 
317,50 
291,5 sh 
257,50 
0,27 
-0,26 
0,12 sh 
0,30 sh 
0,09 
0,24 sh 
0,78 
191 2.244 596 
325 
124 
sh 
645d) 
553d) 
488d) 
355b) 
 
 
 
0.12 
-0.06 
0.07 
-0.35 
 
 
 
171 2.210 
CuH-2L 
 
 
 
495 
440 
 
119 
Sh 
 
- - - - 587.5 
326 
211 
722 
647d) 
562d) 
489d) 
355b) 
0.07 
-0.05 
0.12 
-0.34 
174 2.215 
CuH-3L 
 
 
 
 
 
 
 
495 
443 
 
 
 
 
 
 
86 
91 
 
 
 
 
 
 
517,20 
463,60 
414,20 
sh 
327 
291,60 
280,80 
261,20 
240 
0,88 
-0,58 
0,08 sh 
-0,05 
0,35 
0,26 
0,95 
-1,19 
216 2.151 - - - - - - 
CuH-4L 
 
 
 
 
 
495 
446 
 
 
 
 
100 
105 
 
 
 
 
517,20 
463,60 
414,4 sh 
325 sh 
291 
261,20 
1,04 
-0,73 
 0,07 sh 
-0,14 sh 
0,44 
1,23 
216 2.151 580 
326 
205 
730 
587d) 
492d) 
348 
 
 
 
-0.05 
0.2 
-0.21 
 
 
 
174 2.220 
I = 0.1 M KNO3, 25 °C. The ligand concentration was 1 ' 10-3 M. Ligand to metal ratio 1.5:1. 
 
In Figure 3.7 the structure of the CuH-1L species obtained from theoretical 
calculations is shown. Central metal ion is coordinated by two deprotonated amide 
nitrogen atoms and nitrogen from imidazole moiety. Three calculated Cu–N distances are 
almost equal (1.96 Å). All of these four atoms (central ion and three nitrogen atoms) are 
located in one plane. The deviation from the planarity, calculated as deviation of sum of 
three N–Cu–N angles minus 360 degrees is only about 7 degrees. Planar geometry of the 
coordination sphere is suggested by spectroscopic measurements (Table 3.4, Figure 3.5). 
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Figure 3.5 Species distribution curves for DK14-Cu2+ (solid line) and DK12-Cu2+ (dashed line) complexes at 
25 °C and I = 0.1 M KNO3. The ligand concentration was 1 ' 10-3 M. Ligand to metal ratio 1.5:1. 
 
The fourth coordination position is completely exposed to solvent and is probably 
occupied by water molecule. Additionally, we can observe that one of the carbonyl oxygen 
atoms from the peptide is located perpendicular to the coordination plane defined by the 
central copper(II) ion and the three nitrogen atoms and forms an additional coordination 
bond with metal ion (the Cu–O distance is 2.1 Å). 
 
Figure 3.6 The CD spectra for the Cu(II)-DK14 system. 
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Above pH 8 two additional protons are dissociate and the CuH-2L and CuH-3L 
species are formed. The log K = 8.08 for the first complex and log K = 8.71 for second one 
suggest proton dissociation from the two remaining amide nitrogens and subsequent 
formation of the 4 N complex with four amide nitrogens bounded to the metal ion. The 
spectroscopic parameters show the square planar symmetry of the formed species. The 
strong blue shift in the absorption spectra of the species mentioned above (Table 3.4) 
suggests the very strong influence of four nitrogens in the equatorial plane on the copper 
ion. This result and the major EPR parameters confirm copper(II) coordination by four 
nitrogen atoms (N4 equatorial donor set) at the highest pH values.  
In the CD spectrum (Figure 3.6) the charge transfer contribution around the 290 nm 
seems also to support an increasing contribution from the Cu–N transitions starting from 
CuH-1L species. Notably, large CD perturbation is observed in concomitance with the 
transition from CuH-1L (Figure 3.7) to the CuH-2L species, while this latter show similar 
CD behaviour to the CuH-3L and CuH-4L species. 
 
Figure 3.7 The proposed structure of the CuH-1L species. The copper(II) ion is shown in cyan, oxygen, 
carbon and nitrogen atoms are shown in red, black and blue respectively. 
 
In Figure 3.8 the proposed structure of the CuH-3L complex obtained from 
theoretical calculations is shown. The central metal ion is completely separated from 
solvent by six nitrogens. Two of these come from the two histidine side-chains, while the 
other four are deprotonated amide nitrogens forming an octahedral arrangement. The 
whole coordination sphere of the central copper(II) ion is thus very symmetrical. Four 
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deprotonated amides form a very regular square planar system. All Cu–N distances are 
equal to 1.98 Å and the N–Cu–N angles are equal to 85 or 95 degrees, which suggests very 
small deviation from ideal coplanar location of the ligands and the central ion. This type of 
coordination is confirmed by spectroscopic studies (Table 3.4). Both imidazole rings are 
located perpendicular to the plane defined by the central ion and the four deprotonated 
amide nitrogens; both Cu–Nim distances are in this case equal to 2.35 Å. Stereochemistry 
of the ligand clearly shows that the complex presented here is the only case where two 
imidazole rings are bound to the same metal ion. At low pH, only complexes with one 
imidazole ring bound to the copper(II) center are observed, because imidazole rings of two 
histidine residues are located from the opposite sides of the cyclopeptide ring. 
 
Figure 3.8 The proposed structure of CuH-3L complex obtained from theoretical calculations. The copper(II) 
ion is shown in cyan, oxygen, carbon and nitrogen atoms are shown in red, black and blue respectively. 
 
The theoretical calculations thus point out that the CuH-3L species is characterized by 
a [2 ' NIm, 4 ' N-] binding mode (Figure 3.8). The some support for the proposed CuH-3L 
structure can be find in the CD data. 
The CD features that are observed around 290 nm should be assigned to amide to 
copper(II) charge transfers.158,159 In turn, features assignable to His to Cu(II) CT should fall 
in the 330–350 nm range. Notably we can see a well-shaped positive band in that range at 
low pH; then this band changes its sign (becomes negative) and then shows a clear increase 
at high pH values. Possibly this band is indicative of apical coordination of at least one 
                                                
158 Kowalik-Jankowska, T.; Biega, ,.; Kuczer, M.; Konopinska, D. J. Inorg. Biochem. 2009, 103, 135–142. 
159 Gralka, E.; Valensin, D.; Porciatti, E.; Gajda, C.; Geggelli, E.; Valensin, G.; Kamysz, W.; Nadolny, R.; 
Guerrini, R.; Bacco, D.; Remelli, M.; Koz-owski, H. Dalton Trans. 2008, 5207–5219. 
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imidazole. The presence of such band in the CD spectra might be stressed as indicative of 
imidazole coordination but we have to avoid excessive speculation. 
The last formed species is the CuH-4L complex. LogK = 10.56 for CuH-4L formation 
and the same spectroscopic characteristics (Table 3.4) suggest proton dissociation from the 
Lys residue. 
The comparison of the copper(II) coordinating abilities of c(#3homoLys-DHis-!Ala-
His) with those of its 12 member cyclic analog, c(Lys-DHis-Gly-His) (Figure 3.5), shows 
that DK12 coordinates Cu(II) more effectively than its #-analog. The smaller ring size 
makes formation of the complex with [NIm, 2 ' N-] binding mode easier and the formed 
complex is thus more stable (Figure 3.5). However, the insertion of two additional atoms in 
the peptide ring allows copper(II) coordination by four amide nitrogens from the 
cyclopeptide starting from pH 8. 
 
3.4 13-membered tetraza cyclic tetrapeptide 
3.4.1 Introduction to copper complexation in biological systems 
Among the metallic oligoelements necessary to the human organism, the copper, 
even if it is not the most abundant one, is still among the most active in the biochemical 
pattern, especially for the correct working of the high number of the cellular redox 
reactions. Cu(II) ion is the most tightly bound metal ion in the chelating centers, which 
accounts for the fact that the copper present in living cells is almost entirely complexed 
with proteins or peptides. Copper ions lies at the active center of a versatile group of redox 
catalysts like cytochrome-c oxidase, galactose oxidase or superoxide dismutase (SOD). 
Copper(II) is stored in the brain cells in the human prion protein (PrP) where is bonded to 
four repeats of eight-residue sequence PHGGGWGQ where the Cu(II), at neutral pH 
values, is bonded to one imidazole and two amide nitrogens. The necessary amount of 
copper(II) ion assumed by the diet is in the range of 1.5-3.0 mg pro die. A correct 
homeostasis of copper and of the other transition metals, so called oligo-elements, is 
fundamental for the correct physico-chemical equilibrium of the organism. The control of 
toxicity of copper is based on mechanisms like redox enzymes function, extra- and intra-
cellular chelation and a fine tuning of transmembrane transport. Hence the correct plasma 
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transport of copper is fundamental for the homeostasis of this metal and is ensured by 
various proteins among them ceruloplasmin and serum albumin play an important role. 
Noteworthy, a significant fraction of Cu(II) is bonded to low molecular peptide species 
which act as carriers in the biological fluids.160 It is know that at the physiological pH 
values Cu(II) is tightly bonded to the imidazole side chain of the histidine residues, that is 
able to coordinate copper ions since acidic pH. Peptide bonds also are also deprotonated at 
pH 7 in Cu(II) coordination, often  in collaboration with the Nim atom. Notably, 
cyclopeptides of suitable size, containing histidine residues, are generally able to 
coordinate Cu(II) stronger than the corresponding  linear oligopeptides. That is true when 
cyclotetrapeptides with the -His-Xaa-His- motif are involved in the coordination.151 
Cyclopeptides are growing in importance as their action like hormones, antibiotics, 
enzymes or carrier molecules is lightened. Moreover, the metals complexation of these 
molecules shows great interest as mimics of the sites of coordination in the 
macromolecular ligands like proteins. This prompted us some time ago to undertake the 
study of the speciation of the complexes of Cu(II) ion with several oligopeptides, linear but 
especially cyclopeptides, containing histidine residues.114,124,161,162,163,164,165 
The coordination with Cu(II) ion was studied by the best useful spectroscopic 
methods, in a large range of pH values, detecting the principal donor sets and determining, 
with the aid of the potentiometric slopes, the structure of the most abundant species. 
Recently, a new 13 membered cyclotetrapeptide was prepared (Scheme 3.1), containing L- 
and D-His residues c(Lys-DHis-!Ala-His) (DK13) (58) and Cu(II) was added. Surprisingly, 
the investigation methods used (optical spectroscopy, NMR, MS and electrochemistry) all 
strongly suggested that at alkaline pH only a stable species of Cu(III) was present, being 
formed through the action of dioxygen on the original reduced Cu(II).152 
 
                                                
160 Jones, P.W.; Taylor, D.M.; Williams, D.R. J. Inorg. Biochem. 2000, 81, 1-10. 
161 Chelli, M.; Ginanneschi, M.; Laschi, F.; Muniz-Miranda, M.; Papini, A.M.; Sbrana, G. Spectrochim. Acta, 
Part A, 1999, 55A, 1675-1689. 
162 Sabatino, G.; Chelli, M.; Mazzucco, S.; Ginanneschi, M.; Papini, A.M. Tetrahedron Lett. 1999, 40, 809-
812. 
163 Orfei, M.; Alcaro, M.C.; Marcon, G.; Chelli, M.; Ginanneschi, M.; Kozlowski, H.; Brasun, J.; Messori, L. 
J. Inorg. Biochem. 2003, 97, 299-307. 
164 Alcaro, M. C.; Sabatino, G.; Uziel, J.; Chelli, M.; Ginanneschi, M.; Rovero, P.; Papini, A.M. J. Pept. 
Science, 2004, 10, 218-228. 
165 Brasun, J.; Gabbiani, C.; Ginanneschi, M.; Messori, L.; Orfei, M.; Swiatek-Kozlowka, J. J. Inorg. 
Biochem. 2004, 98, 2016-2021. 
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Scheme 3.1 The three cyclopeptides studied. 
 
3.4.2 Preliminary study on Cu(III)/DK13 complex 
The ligand c(Lys-DHis-!Ala-His) (DK13, 58) (Scheme 3.1) manifested a very 
peculiar and unexpected reactivity towards copper(II) ions. Indeed, addition of a 
stoichiometric amount of copper(II) sulphate to a DK13 solution, adjusted at pH 8 by 
NaOH, resulted into the progressive development of a very intense and unexpected orange 
colour. The colour intensity was even higher at pH 12. The process was thus investigated 
by UV-Vis spectroscopy. Typical spectrophotometric profiles for DK13/copper(II) 
samples at various pH values are shown in Figure 3.9. 
At pH 12.2 two main bands are detected at about 250 and 330 nm (& ( 9840 and & ( 
5580, respectively) while a very weak absorption around 500 nm indicates the persistence 
of a residual amount of the copper(II) species. We quickly realised that the development of 
the above characteristic spectral pattern is critically dependent on the presence of 
atmospheric oxygen: as a matter of fact, the bands at 250 and 330 nm did not appear when 
working under strict anaerobic conditions. We also observed that this process is pH 
dependent, being stressed by the highest pH values. When recording the spectrum of the 
same sample after 24 h (r.t., pH = 12.2) the two main absorption maxima looked 
substantially conserved, with a small decrease in intensity, implying a substantial stability 
for the obtained species. 
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Figure 3.9 UV-vis spectrum of the system DK13/copper(II) at increasing pH values. The UV maxima 
corresponding to the copper(III) formation are shown (DK13, 0.15 ' 10-3 M; CuSO4, 0.1 ' 10-3 M). pH 
values are specified on the profiles. 
 
On the basis of previous literature we hypothesized that the above 
spectrophotometric behaviour might be ascribed to the progressive oxidation of copper(II) 
to copper(III), induced by atmospheric oxygen and favoured by copper coordination to 
four deprotonated amide nitrogen donors, within a roughly square planar chromophore.166 
Indeed, square planar d8 copper(III) centers are known to exhibit very intense LMCT bands 
in the UV region,167 as it is the case here. 1H-NMR spectra, recorded on the orange 
solution, showed four relatively narrow signals of the imidazole protons. Also, the entire 
protons pattern suffered of a very modest line broadening at variance with previously 
reported cases. This behaviour is indicative of a possible extensive copper(II)-to-
copper(III) oxidation. The spectrum of the same sample recorded after 1 h did not reveal 
any new signals again implying a substantial stability of the existing copper(III) species. 
The orange solution was further analysed by electrospray (ESI) mass spectrometry (MS). 
The ESI-MS measurements were carried out in methanolic equimolar (5'10-4 M) DK13-
copper solutions at different pH values (Figure 3.10). It is noteworthy that, independently 
from the pH of the solution, only monoprotonated species are detected, while highly 
charged ions are not formed. 
                                                
166 Burke, S.K.; Xu, Y.; and Margerum, D.W. Inorg. Chem. 2003, 42, 5807-5817 and references therein. 
167 McDonald, M.R.; Fredericks, F.C.; Margerum, D.W. Inorg. Chem. 1997, 36, 3119-3125. 
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Figure 3.10 ESI-MS spectra of a 1:1 DK13-Cu(II) solution at pH 8. 
 
Under basic conditions, the most abundant ions in the 530-540 m/z region are at m/z 
534 (Figure 3.10). These species differ 1 u from the expected ions at m/z 535 due to the [L-
Cu(II)–H]+ species. This shift suggests that the measured positive species has a proton less 
than expected, thus clearly indicating an almost quantitative oxidation of Cu(II) to Cu(III). 
Tandem mass spectrometry has been used to obtain information about copper coordination 
in the complexes. The most abundant decomposition produced by the species [L-Cu(III)-
2H]+ is due to the elimination of an ammonia molecule (Figure 3.11). Ions at m/z 309 are 
attributable to consecutive eliminations of Ala and His from [L-Cu(III)-NH3-2H]+. 
Abundant ions attributable to elimination of one or more aminoacidic residues are not 
detectable. This suggests strong interactions of the metal with DK13. 
 
Figure 3.11 ESI-MS/MS spectra of the species [L-Cu(III)-2H]+ (m/z 534). 
 
The physicochemical results reported so far point out quite unambiguously that the 
formed orange product is truly a copper(III) species resulting from progressive aerobic 
oxidation of copper(II) to copper(III). The process is spontaneous under normal aerobic 
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conditions suggesting that the DK13 ligand strongly stabilizes the oxidation state +3 of 
copper. Since the oxidation process is highly favoured by strong alkaline conditions, it is 
well conceivable that the observed stabilisation arises from coordination of four 
deprotonated amide groups to copper, generating a [Cu(III)(H-4L)] species. 
 
 
Figure 3.12 1H-NMR spectrum (D2O, pH 12.5): (a) DK13 ligand; (b) DK13/CuSO4 3:1  
(DK13, 6.0 ' 10-3 M). Spectra were recorded on a Varian 400 MHz Mercury Plus at room temperature. 
 
Notably, 1H-NMR spectra, recorded on the orange solution, showed four narrow 
signals of the imidazole protons. The entire proton pattern, collected at low ligand-to-
copper(II) ratio, did not suffer from significant line broadening at variance with previously 
reported cases (Figure 3.12). This behaviour is suggestive of nearly quantitative oxidation 
of paramagnetic copper(II) to diamagnetic copper(III). 
The 1H-NMR spectrum of the same sample taken after 1 h did not reveal any 
significant change, implying a substantial stability of the copper(III) species. 
To further define such a stabilisation, electrochemical and spectroelectrochemical 
measurements were carried out. A freshly prepared mixture of DK13 and CuSO4 in diluted 
NaOH solution (pH 12) under nitrogen atmosphere affords a substantially colourless 
solution that does not exhibit any response in cyclic voltammetry. This means that the 
strong coordination of the Cu(II) ion to the DK13 ligand shifts the Cu(II) reduction beyond 
the cathodic window of the alkaline solution. In fact, a CuSO4 solution at pH 6.5 
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undergoes the Cu(II)/Cu(I)/Cu(0) sequence at +0.15 V and at +0.01 V, respectively, and 
exhibits in the reverse scan the anodic stripping of electrodeposed copper metal at +0.24 V 
(V, vs. NHE). Upon standing at air, the DK13-CuSO4 solution progressively turns orange 
affording, after 24 hours, the voltammetric profiles shown in Figure 3.13. A poorly 
resolved reduction process in cyclic voltammetry (asterisked peak-system), but sufficiently 
well defined in differential pulse voltammetry appears (E°’ = +0.04 V, vs. NHE) which 
apparently features partial chemical reversibility. Since no anodic stripping is present in 
the reverse scan, it seems reasonable to attribute the actual cathodic process to the 
copper(III)/copper(II) transition. 
 
Figure 3.13 Cyclic (—) and differential pulse (•••) voltammograms recorded at a glassy carbon electrode in 
NaOH solution (pH 12) containing CuSO4 (0.6x10–3 M) and DK13 (0.7x10–3 M). Scan rates: (—) 0.05 Vs–1; 
(•••) 0.02 Vs–1. 
 
A similar, poorly resolved, cyclic voltammetric pattern was earlier found for the c(#-
Ala-Gly-!Ala-Gly)/CuIII complex, which was prepared by anodic oxidation of the related 
copper(II) complex.168 
For a better definition of the extent of chemical reversibility of the CuIII/CuII 
reduction in our system, we recorded the spectroelectrochemical trend of DK13/copper(III) 
at pH 12 upon stepwise reduction (Figure 3.14), followed by stepwise reoxidation. 
Notably, the two main bands (.max 245 and 324 nm, respectively) progressively decrease, 
but upon step-by-step reoxidation (Ew +0.2 V), the original spectrum is restored. This 
characteristic behaviour as well as the presence of a well-defined isosbestic point at 220 
nm testifies to the chemical reversibility of the CuIII/CuII interconversion. 
                                                
168 Rybka, J.S.; Margerum, D.W. Inorg. Chem. 1981, 20, 1453-1458. 
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Figure 3.14 UV-Vis spectral trend recorded in a OTTLE cell upon progressive reduction. 
 
This means that the apparent partial chemical reversibility detected in cyclic 
voltammetry most likely arises from electrode surface phenomena. Previous studies 
reported that the CuII/Gly4 solutions are autoxidized by dioxygen uptake at pH 7-10 
through the formation of an autocatalytic [Cu(III)(H-3Gly4)]- complex.169 In any case, a 
copper(III)-coordinated species could only be obtained by chemical or electrochemical 
oxidation. At variance, the present DK13/copper(II) system is nearly quantitatively 
oxidized to copper(III) by atmospheric oxygen at room temperature. Because this 
oxidation process is highly favoured by strong alkaline conditions, it is well conceivable 
that the stabilization observed arises from copper coordination to four deprotonated amide 
nitrogen atoms, thus generating a [Cu(III)(H-4L)]- species. Margerum et al. stated for their 
peptide ligands that N- ions from the deprotonated peptide backbone are the strongest / 
donors in copper/peptide complexes and can stabilize a copper(III) species. We can assume 
that copper(III) ions may accommodate the ligand’s cavity, thus affording a square-planar 
complex. Notably, the stabilization effects brought about by our ligand are far higher than 
those reported by Margerum et al. for the related 14-membered peptide c(#-Ala-Gly-!Ala-
Gly). As a matter of fact, the formal electrode potential of the DK13/copper(III,II) system 
is lower (by about 0.4 V) than that reported for c(#-Ala-Gly-!Ala-Gly) at alkaline pH, 
probably reflecting the thermodynamic stabilization triggered by the higher planarity 
imposed by the present 13-membered macrocycle. To better understand the role of the His 
side chains in the overall reaction, we prepared the new ligand c(Lys-Gly-!Ala-Gly) 
(GK13, 59), where the two histidines are replaced by two glycines. Upon the addition of an 
                                                
169 Kurtz, J.L.; Burce, G.L.; Margerum, D.W. Inorg. Chem. 1978, 17, 2454-2460. 
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equimolar amount of CuSO4 at pH 12, a light-blue precipitate soon formed. 
Ultraperformance liquid chromatography MS (UPLC-MS) inspection of the remaining 
aqueous solution did not reveal the presence of the GK13 ligand. Thus, in view of the 
highly different behavior shown by GK13 in comparison to DK13, we can say that the 
presence of the histidine ligands is crucial to ensure complete occurrence of the copper(II) 
to copper(III) oxidation reaction and solubilisation of the resulting copper(III) species. 
 
3.5 Study on Cu(III)/DK13 complex using synchrotron 
radiation 
In order to define the three dimensional structure of this unexpected 
Cu(III)/Cyclopeptide complex X-Ray Absorption Spectroscopy (XAS) data have been 
collected at the ID26 beamline of the European Synchrotron Radiation Facility (ESRF) 
storage ring (Grenoble, F) in collaboration with Dr. Gabriele Giuli from the University of 
Camerino. Cu K-edge XANES (X-ray Absorption Near Edge Structure) and EXAFS 
(Extended X-ray Absorption Fine Structure) step scan spectra were acquired in 
fluorescence mode with ring current ranging from 90 to 60 mA. Radiation was 
monochromatised by means of a double-crystal Si (311) monochromator to achieve high-
energy resolution at the Cu K-edge. Beam size at the sample was 250 ' 1000 0m. Cu K-
edge XANES and EXAFS spectra were acquired in fluorescence mode monitoring the 
emitted fluorescence signal with a high-purity multi-element Ge detector. XAS data were 
collected in quick-scan mode by simultaneously scanning the monochromator angle and 
the undulator gap with a typical energy step of 0.2 eV and counting about 160 ms per 
point. In order to reduce radiation induced damage of the peptide samples, spectra have 
been collected at 10 K in a He cryostat, and the intensity of the incident radiation at the 
sample has been adjusted by means of Al filters. Preliminary time scans allowed to 
ascertain that the samples suffered no damage within 1300 seconds exposure to the X-ray 
beam. For each sample 1000 seconds long spectra have been acquired at different sample 
positions in order not to alter the sample. Average of 10 to 60 scans, depending on sample 
Cu concentration, allowed to obtain a good signal to noise ratio for all the samples. 
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Experimental XANES spectra were corrected by background subtraction with a 
linear function and then normalised for atomic absorption on the average absorption 
coefficient of the spectral region from 9030 to 9210 eV. Energy was calibrated against a 
standard of Cu metal (8979 eV). The threshold energy was taken as the first maximum of 
the first derivative of the spectra, whereas peak positions were obtained by calculating the 
second derivative of the spectra. Pre-edge peak analysis was carried out following the 
same procedure found in Wilke et al.170 The pre-edge peak was fitted by a sum of pseudo-
Voigt function, and the integrated intensities along with centroid energies were compared 
with those of the standards analysed here and others from the literature in order to extract 
information on Cu oxidation state and coordination number in the samples studied. 
EXAFS data reduction and analysis was done by means of the GNXAS package 
(Filipponi & Di Cicco, 2000).171 This program extracts )(k) signal from the raw spectrum 
without performing Fourier filtering and thus avoiding possible biases deriving from 
incorrect background subtraction. The theoretical amplitudes and phase shifts are 
calculated ab initio according to the Muffin-Tin approximation. The Hedin-Lundquist 
complex potential172 was used for the exchange-correlation potential of the excited state. 
The amplitude reduction factor (S02) has been fixed to 0.85. 
 
3.5.1 Theoretical XANES calculations 
XAS calculations are carried out starting from the Fermi’s golden rule to obtain the 
photoabsorption cross section within the dipole approximation. One important step is to 
calculate the final state of the photoelectron transition moment, which describes the 
physical process of scattering the electron photoemitted by the central atom by outer 
atoms. This is done in the framework of MS theory173 using a MT approximation for the 
shape of the potential of the cluster of atoms included. The cluster size and the lmax value 
(i.e. the maximum l value of the spherical harmonic expansion of the scattering path 
operators) were chosen on the basis of a convergence criterion; MT radii were chosen on 
                                                
170 Wilke, M.; Farges, F.; Petit, P.E.; Brown, G.E.; Martin, F. American Mineralogist 2001, 86, 714-730. 
171 Filipponi, A.; Di Cicco, A. “GNXAS: a software package for advanced EXAFS multiple-scattering 
calculations and data-analysis”, TASK Quarterly 2000, 4, 575-669. 
172 Hedin, L.; Lundquist, B.I. J. Phys. C 1971, 4, 2064-2083. 
173 Natoli, C.R.; Benfatto, M.; Della Longa, S.; Hatada, K. J. Synchrotron Radiat. 2003, 10, 26-42. 
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the basis of the Norman criterion,174 including an overlap between MT spheres that is 
optimized by fitting the ovlp parameter (only one parameters for the entire set of MT 
radii). The choice of MT radii fixes the constant MT potential V0 and the charge densities 
within each MT sphere. Different values of ovlp, within reasonable values (between 1% 
and 10%), change the goodness of the fit but without relevant effects in the structural 
parameters determination. 
V0imp is the value of the Muffin-Tin potential (V0) when it is refined to best fit the 
XANES spectra of copper compounds. The potential generator of MXAN (program 
VGEN) calculates this parameter automatically, however refining V0imp provides an 
improvement both in c2 and thus in the accuracy of structural results. The value of (10 ± 2) 
eV was found to be optimal for the system under study. 
The real part of the exchange term was calculated using the Hedin-Lundqvist energy-
dependent potential,172 while all of the inelastic losses were taken into account by a 
phenomenological method previously described in detail.175 According to this method, 
inelastic processes are taken into account by a convolution with a broadening function, 
with a width 1 given by 1 = 1c + 1(E). The constant part 1c includes contributions from the 
core-hole lifetime (1.5 eV, lorentzian convolution) and the experimental resolution (0.6-0.8 
eV, gaussian convolution), while the energy dependent term 1(E) (lorentzian convolution) 
represents the inelastic processes. 1(E) is zero below an onset energy Es, and begins to 
increase from a value As following the universal functional form related to the mean free 
path in a solid.176 This method introduces three nonstructural parameters that are derived 
during the fit on the basis of a Monte Carlo search at each step of computation. 
A constant experimental error of 0.012 normalized units (i.e. units for which the 
absorption jump is equal to 1) was chosen. Starting model structure used for the 
calculations has been built according to DFT calculations. Preliminary calculations of 
theoretical spectra have been performed using Hedin-Lundquist real potential, calculating 
Muffin-Tin radii according to the Norman criterion, and allowing 10% sphere overlap. The 
minimization of the c2 function was performed in the space of structural parameters, i.e. 
the first (4 nitrogens) and second (8 carbons) coordination shell. 
                                                
174 Norman, J.G. Mol. Phys. 1974, 81, 1191-1198. 
175 Benfatto, M.; Della Longa, S.; Natoli, C.R. J. Synchrotron Radiat. 2003, 10, 51-57. 
176 Müller, J.E.; Jepsen, O.; Wilkins, J.W. Solid State Commun. 1984, 42, 4331-4343. 
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3.5.2 XANES Pre-edge analysis 
In Figure 3.15 are shown the XANES spectra of representative Cu model compounds 
with known oxidation state and the peptides under study. As the metal K-edge structures 
vary according to number, type and geometric arrangements of ligands, as well as the 
metal oxidation state, comparison of the peptide spectra with those of model compounds 
can allow to get information on the oxidation state and structural surrounding of the 
studied metal (i.e. Cu). It is apparent a general shift to higher energy of the absorption 
threshold of the model compound spectra with increasing Cu oxidation state from Cu(I) to 
Cu(III). Also a peak labeled A in the edge region shifts to higher energy with increasing 
Cu oxidation state. Moreover, a peak in the pre-edge region (peak P) is absent in the Cu(I) 
model compounds whereas is present in Cu(II) and Cu(III) compounds. This peak, often 
referred as pre-edge peak, is related to a 1s to 3d electronic transition in the 
photoabsorbing atom (in this case Cu) and is a direct probe of the unfilled d orbital 
population. 
 
Figure 3.15 XANES spectra of Cu model compounds with known oxidation state (left panel) and the 
peptides under study (right panel). 
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The observed variations of edge positions and pre-edge peak position and intensities have 
been already observed in a number of systems of both organic and inorganic 
nature.177,178,179,180 However, the quantitative interpretation of XANES spectra is 
sometimes rendered difficult because of the high complexity of multiple scattering paths 
invilved and because of the huge number of parameters affecting the shape of the XANES 
region. In this respect, the pre-edge peak can be a useful indication of the metal oxidation 
state.181 
The background subtracted pre-edge peak is shown in the inset of Figure 3.15 for 
both the model compounds (left panel) and peptides (right panel). The energy position of 
this peak can be a precise indication of the Cu oxidation state: while it is absent in Cu(I) 
compounds, it is present at ca. 8978 eV for most Cu(II) model compounds. Its shift to 
higher energy and increase in integrated intensity in the case of Cu(III) compounds. The 
Cu(III) model compound shown here (Na5[Cu{TeO4(OH)2}2]*16H2O - ditelluratocuprate 
DTC - Figure 3.16) display a pre-edge peak centroid at 8979.3 ± 0.3 eV with an integrated 
intensity of 0.044. 
 
Figure 3.16 Ditelluratocuprate(III) 
 
                                                
177 Kau L.S.; Spira-Solomon D.J.; Penner-Hahn J.E.; Hodgson K.O.; Solomon E.I. J. Am. Chem. Soc. 1987, 
109, 6433-6442. 
178 DuBois, J.L.; Mukherjee, P.; Stack, T.D.P.; Hedman, B.E.; Solomon, I.; Hodgson, K.O. J. Am. Chem. Soc. 
2000, 122, 5775-5787. 
179 Farges, F.; Siewert, R.; Ponader, C.W.; Brown, G.E.; Pichavant, M.; Behrens, H. Can. Mineral. 2006, 44, 
755-773. 
180 Chillemi, G.; Barone, V.; D’Angelo, P.; Mancini, G.; Persson, I.; Sanna, N. J. Phys. Chem. B 2005, 109, 
9186-9193. 
181 Brown, G.E.; Farges, F.; Calas, G. Rev. Mineral. Geochem. 1995, 32, 317-410. 
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Comparison of peptide pre-edge peak data with those of model compounds can probe 
Cu oxidation state in the studied peptide samples. Accurate analysis of pre-edge peak data 
of the peptide samples allowed to ascertain the presence of Cu(III) in the DK13 sample and 
Cu(II) in the GK13. In particular, while the pre-edge peak of the GK13 sample is perfectly 
compatible with those of divalent Cu model compounds analysed here and reported in the 
literature, the pre-edge peak of DK13 spectrum display an energy (8979.8 eV) compatible 
to that of the DTC shown here (and with other data from the literature178) but has an higher 
integrated intensity (0.095) than the DTC, possibly due to a less centrosymmetric 
geometrical environment around Cu than in the DTC. The pre-edge peak of LK13 sample 
is compatible with the presence of Cu(II) with minor contribution from Cu(II). 
 
3.5.3 EXAFS analysis 
In Figure 3.17a are shown the experimental (open symbols), theoretical (solid lines) 
and residual EXAFS signals of the Cu(III) (DK13) and Cu(II) (GK13) peptide samples. 
The theoretical signals have been calculated starting from a simplified model structure 
reproducing the 13-element ring and neglecting the imidazole side chains contributions. 
The signals have a low intensity and are almost completely dumped in the high-energy 
region. The Fourier transforms of the EXAFS signals confirm that there are no important 
contributions from distances farther than 4 Å. 
The theoretical contributions to the EXAFS signals from each shell of the model 
structure are shown in Figure 3.17b for two peptides: the most important contributions 
comes from the 4 N atoms bonded to Cu and from the 6 nearest C atoms. The EXAFS 
derived Cu-N distances are sensibly shorter in the DK13 sample relative to GK13 (1.78 ± 
0.02 Å and 1.91 ± 0.02 Å respectively). The shorter distance (1.78 Å for DK13) is 
consistent with other Cu(III)-N distances found in the literature178 and is thus a further 
confirmation of the presence of trivalent copper in this peptide. On the other hand, the Cu-
N distance found for GK13 (1.91 Å) compares well with known values for divalent 
copper.178 
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Figure 3.17 Cu K-edge EXAFS signals (a) and Fourier Transforms (b) of Cu(III) and Cu(II) peptide 
samples. 
 
3.5.4 XANES analysis 
Theoretical XANES spectra of DK13 and GK13 are shown in Figure 3.18. Their 
changes going from GK13 to DK13 are satisfactorily reproduced in the one-electron, 
multiple scattering scheme adopted by the MXAN program. In particular the observed 
blue-shift of the spectrum going from the cuprous to cuprate compound correspond to a 
decrease of the average first shell distance. In this figure the experimental spectra have 
been shifted by ca. 8985 eV to lower energy in order to match the theoretical spectra. The 
fits include the first and second shell average distances. The results of the MXAN fits are 
in quite agreement with the EXAFS analysis. The Cu-N average distance is (1.80 ± 0.04) 
Å for DK13 and (1.91 ± 0.02) Å for GK13, and the average second shell Cu-C distance is 
(2.84 ± 0.08) Å and (2.94 ± 0.02) Å, respectively. 
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Figure 3.18 Experimental XANES curves for DK13 (in red) and GK13 (in blue), compared with those 
obtained after the structural refinements (solid lines). 
 
3.5.5 Conclusions 
Comparison of XANES pre-edge peak features with those of Cu model compounds 
allowed to determine the Cu oxidation state in the three peptides: Cu is purely divalent in 
GK13 purely trivalent in DK13 and present as both Cu(II) and Cu(III) in LK13. Also edge 
energies and the <Cu-N> distances derived independently by GNXAS (1.79 Å and 1.90 Å 
in the EXAFS range) and MXAN (1.80 Å and 1.91 Å in the XANES range) for DK13 and 
GK13 respectively, are consistent with the XANES determined Cu oxidation states. 
Preliminary theoretical XANES spectra (data not shown) calculated using the 
MXAN code in a different way (i.e. by fixing the optimized distances and releasing 
angular parameters) suggest that the CuN4 unit is not perfectly planar but form a distorted 
pyramid. The Cu(III) is bonded to the four peptide nitrogens, giving rise a quasi-planar 
square structure. In fact the deviation from the planar coordination is very small (the angle 
N-Cu-N of two opposite nitrogens is about 170°) and the pyramidal structure is near to be 
flat. 
The lack of a similar structure of Cu(III) in the other compounds studied, although 
having the same size of the peptide cycle, may be explained by the lack of the imidazole 
side chains, that are no present in compound 59 (Figure 3.19) and are of the same chirality 
in compound 57. The mechanism by which the histidine residues act in forming the 
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suitable cradle for Cu(III) forming by dioxygen is not clarified at this stage. A pH 
dependent study in aqueous solution will be necessary for revealing the chaperon 
mechanism of the D- and L-histidine in compound 58 (Figure 3.20). 
 
 
Figure 3.19 Proposed planar three-dimensional structure for Cu(II)/GK13; the angle N-Cu-N with the two 
opposite nitrogens is about 180°. 
 
Figure 3.20 Proposed three-dimensional structure for Cu(III)/DK13; the angle N-Cu-N with the two opposite 
nitrogens is about 170°. 
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Chapter 4 
TrxR AS A TARGET FOR ANTICANCER DRUGS 
 
4.1 Introduction 
4.1.1 Gold compounds, new attractive metallodrugs for cancer treatment 
The serendipitous discovery of the anticancer properties of cisplatin and its 
platinum(II) analogues and their wide clinical success in current cancer treatments 
promoted a great deal of interest in the area of metal-based antitumor agents.182,183 The 
outstanding anticancer effects observed for platinum(II) compounds suggested that other 
metal-based compounds might be similarly useful as antitumor drugs while, hopefully, 
displaying different patterns of anticancer activities and selectivities. Among the several 
classes of metal compounds that have been taken into consideration as potential anticancer 
agents starting from the 80’s (e.g. ruthenium, palladium, titanium, copper, tin, and so on), a 
few investigations have focused on a variety of gold compounds in the oxidation states 
either +3 or +1.184,185 Notably, gold(I) compounds were quickly considered as possible 
antiproliferative agents soon after the discovery of cisplatin, as some of them were already 
in the clinics for the treatment of rheumatoid arthritis; in turn, gold(III) compounds looked 
pairwise very attractive for cancer treatment as the gold(III) centers are known to originate 
square planar complexes that are isoelectronic and isostructural to those of platinum(II) 
and might exhibit similar biological actions. 
A conspicuous number of gold(I) and gold(III) compounds were thus assayed, during 
the 80’s, either in vitro or in vivo, as antitumor agents but the results obtained at that time 
were rather disappointing.184,185 Indeed, gold(I) compounds turned out to be fairly active in 
                                                
182 Bruijnincx, P.C.; Sadler, P.J. Curr. Opin. Chem. Biol. 2008, 12, 197. 
183 Zhang, C.X.; Lippard, S.J. Curr. Opin. Chem. Biol. 2003, 7, 481. 
184 Messori, L.; Marcon, G. in: Sigel, A.; Sigel H. (Eds.), Metal Ions in Biological Systems, vol. 42, Marcel 
Dekker Inc., New York, 2004. 
185 Gabbiani, C.; Casini, A.; Messori, L. Gold Bull. 2007, 40, 73. 
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vitro but practically ineffective in vivo, most likely as a consequence of extensive binding 
to serum proteins and inactivation; conversely, gold(III) compounds, although highly 
cytotoxic in vitro, manifested, on the average, a poor chemical stability and, also, a rather 
pronounced systemic toxicity in animal models that heavily limited their further 
investigation or application. Studies on gold compounds as experimental anticancer agents 
were therefore rapidly stopped and almost completely abandoned for many years. 
 
Scheme 4.1 Schematic drawing of [Au(terpy)Cl]Cl2 (60), [Au(bipyc-H)(OH)][PF6] (61), meso-
tetraarylporphyrins complexes (62), Au(pydmb-H)(AcO)2] (63) (where pydmb = 2-(1,1-dimethylbenzyl)-
pyridine)) and of the gold(III) dithiocarbamate complexes containing N,N-dimethyldithiocarbamate (64) and 
ethylsarcosinedithiocarbamate (65) ligands. 
 
Only around the mid 1990s, new classes of gold(III) compounds were synthesized 
and characterised that showed improved stability profiles and turned out to be more 
appropriate for pharmacological application; most of those novel compounds were assayed 
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on simple in vitro or in vivo biological models of cancer, with quite promising results.186 
The new gold compounds studied, depicted in Scheme 4.1, comprise classical gold(III) 
compounds with polydentate ligands (e.g. AuTerpy) (60),187 a few organogold(III) 
compounds (e.g. DAMP and Aubipyc) (61),188 various gold(III) porphyrins (63), two 
major gold(III) dithiocarbamates (64, 65),189 a series of dinuclear gold(III) compounds 
(e.g. AuOXO6) (62).190 Pairwise, various gold(I) compounds, with innovative chemical 
and biological features, were prepared and characterised, in the same years, by Berners-
Price and coworkers.191 
On the average, all these novel gold compounds turned out to be highly cytotoxic in 
vitro against representative human tumor cell lines, with IC50 values often falling in the 
low micromolar or even nanomolar range. For a few of them an appreciable activity in vivo 
was also established although the reported in vivo data were rather fragmentary and 
preliminary. Mechanistic studies showed that the majority of these novel cytotoxic gold 
compounds induce evident signs of apoptosis in treated human tumor cells but their actual 
modes of action were not univocally identified. However, as gold compounds manifested, 
on the whole, a far lower affinity for DNA than platinum(II) compounds, it was 
hypothesized that apoptotic cell death should be the result of DNA-independent processes. 
Accordingly, the new cytotoxic gold compounds were often found to overcome resistance 
to cisplatin confirming the occurrence of a substantially different mode of action. Pairwise, 
at variance with classical platinum(II) compounds, only very modest effects on the cell 
cycle were highlighted. These observations led researchers to postulate the existence of 
preferential protein targets for gold compounds. 
Interestingly, all the mechanistic studies and hypotheses formulated about the action 
of this metal compounds, suggest that mitochondria represent the most likely site for the 
                                                
186 Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Coord. Chem. Rev. 2009, 
253, 1692–1707. 
187 Messori, L.; Abbate, F.; Marcon, G.; Orioli, P.; Fontani, M.; Mini, E.; Mazzei, T.; Carotti, S.; O’Connell, 
T.; Zanello, P. J. Med. Chem. 2000, 43, 3541. 
188 Marcon, G.; Carotti, S.; Coronnello, M.; Messori, L.; Mini, E.; Orioli, P.; Mazzei, T.; Cinellu, M.A.; 
Minghetti, G. J. Med. Chem. 2002, 45, 1672. 
189 Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Maccà, C.; Trevisan, A.; Fregona, D. J. 
Med. Chem. 2006, 49, 1648. 
190 Gabbiani, C.; Casini, A.; Messori, L.; Guerri, A.; Cinellu, M.A.; Minghetti, G.; Corsini M.; Rosani, C.; 
Zanello, P. Inorg. Chem. 2008, 47, 2368. 
191 Humphreys, A.S.; Filipovska, A.; Berners-Price, S.J.; Koutsantonis, G.A.; Skelton, B.W.; White, A.H. 
Dalton Trans. 2007, 21, 4943. 
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biological action of gold compounds; in other words, gold-based cytotoxic drugs should be 
primarily considered as selective antimitochondrial drugs. There is indeed much recent 
evidence suggesting that mitochondria play a critical role in the regulation of apoptosis 
(programmed cell death), making them an attractive target for the design of new anticancer 
drugs. This issue is of particular interest as mitochondria are critically involved in the 
regulation of the intracellular redox state. In addition, mitochondria contain a specific 
thioredoxin reductase, a selenzoenzyme that seems to be an optimal target for gold 
compounds. Strong inhibition of mitochondrial thioredoxin reductase (TrxR) would 
eventually lead to altered mitochondrial functions and to initiation of the apoptotic process. 
 
4.1.2 Inhibitors of thioredoxin reductases 
A few observations revealed that cancer cells often overexpress both thioredoxin and 
thioredoxin reductase192 implying that the thioredoxin system may have a crucial role in 
tumor onset and progression. Accordingly, both thioredoxin and thioredoxin reductase 
might be considered as suitable targets for the development of new anticancer agents 
(Figure 4.1).193 The view that thioredoxin reductase constitutes an effective druggable 
cancer target has received significant experimental support and validation. Indeed, Yoo et 
al.,194 by transfecting lung cancer cells with siRNA specifically directed against TrxR1, 
found that these cells largely reverse their tumor morphology and growth properties 
returning similar to normal cells. Moreover, some established antitumor agents used in 
clinic several years ago were retrospectively found to act as potent inhibitors of 
thioredoxin reductase as it will be shown in this section. 
It follows that targeting thioredoxin reductase may be an appropriate strategy in 
modern cancer drug research. Interestingly, TrxR contains a very accessible selenocysteine 
on its flexible C-terminal arm; thus the several electrophilic compounds that are capable of 
modifying – selectively and irreversibly – this active site residue might be well considered 
as potential enzyme inhibitors and candidate anticancer agents. 
                                                
192 Nakamura, H.; Masutani, Y.; Tagaya, A.; Yamauchi, T.; Inamoto, Y.; Nanbu, S.; Fuji, K.; Ozawa, J. 
Cancer 1992, 69, 2091. 
193 Urig, S.; Becker, K. Semin. Cancer Biol. 2006, 16, 452. 
194 Yoo, M.-H.; Xu, X.-M.; Carlson, B.A.; Gladyshev, V.N.; Hatfield, D.L. J. Biol. Chem. 2006, 281, 13005. 
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It is now well established that thioredoxin reductases can be easily and efficiently 
inhibited by a large array of compounds ranging from natural products to synthetic organic 
compounds (dinitrohalobenzenes, quinines, etc.), from simple metal ions (Ca, Zn, Mn, Cd, 
Tl) to structurally elaborated metal coordination compounds (Au, Pt, Ru, Gd). Several 
inhibitors of thioredoxin reductase, either of natural origin or synthetic, have been 
developed during the last decade and are of potential interest as anticancer agents. 
 
Figure 4.1 Mechanism of action of cell death induction by gold(I/III) compounds. 
 
The role of TrxR inhibitors with reference to cancer therapy was recently reviewed 
by Urig and Becker;193 a list of representative thioredoxin reductase inhibitors with their 
respective IC50 values is reported in Table 4.1.!
It is apparent that most of the above compounds will directly target the active site 
selenolate as this chemical group is characterised by an appreciably high reactivity. In the 
case of a few organic compounds, e.g. carmustine and curcumin, that are known to be 
efficient alkylating agents, inactivation of the selenolate group via alkylation has been 
proposed and documented. However, for other bulkier organic TrxR inhibitors such as 
quinoids, anthracyclines and naphthoquinones, a direct interaction at the FAD binding site 
is also conceivable. 
  
Chapter 4. TrxR as a target for anticancer drugs 
 126 
Table 4.1 TrxR inhibitors (MGD, Motexafin gadolinium). 
Substance class TrxR inhibition potency; in vitro data 
Nitrosoureas IC50 ! 50 µM for BCNU 
Platinum(II) complexes IC50 ! 15 µM for cisplatin 
Phosphole complexes IC50 ! 2 nM for Pt-phosphole 
Organocalchogenides IC50 ! 0.26 µM for diorganyl telluride 
Polyphenol flavonoids IC50 ! 3.6 µM for curcumin 
Texaphyrins (MGD) IC50 ! 6 µM for MGD 
Quinoid compounds IC50 ! 6.3 µM for 9,10-phenantrene quinone 
Naphtoquinones spirochetal derivatives IC50 ! 0.35 µM for palmarumycin 
 
Inorganic compounds will preferentially target the active site selenolate function. 
Thus, arsenic and organochalcogenides are believed to form direct As-Se and Te-Se 
bonds.195 Finally, as mentioned above, metal complexes of platinum and ruthenium were 
shown to be good inhibitors of thioredoxin reductase. Cisplatin (cis-
diamminedichloroplatinum(II)) was able to irreversibly inhibit thioredoxin reductase 
activity suggesting a covalent interaction with the thiol/selenol active site.196 A similar 
effect on TrxR was also observed with other platinum complexes such as terpyridine 
platinum(II).197 After the successful utilization of platinum complexes in cancer 
chemotherapy other metal complexes were considered and, in particular, ruthenium 
complexes were shown to present antitumor activity mainly against metastatic cancer.198 
Interestingly, several ruthenium(III) complexes were shown to markedly inhibit, although 
at different levels, the cytosolic isoform of thioredoxin reductase, while they are scarcely 
effective towards the mitochondrial isoform.199 This effect is similar to that of calcium ions 
that potently inhibit TrxR1, but are weak inhibitors of the mitochondrial isoform, 
indicating that the redox signalling stimulated by these complexes occurs primarily in the 
cytosolic compartment. The numerous studies appeared so far concerning the interactions 
                                                
195 Engman, L.; Al-Maharik, N.; McNaughton, M.; Birmingham, A.; Powis, G. Bioorg. Med. Chem. 2003, 
11, 5091. 
196 Arnér, E.S.J.; Nakamura, H.; Sasada, T.; Yodoi, J.; Holmgren, A.; Spyrou, G. Free Radic. Biol. Med. 
2001, 31, 1170. 
197 Becker, K.; Herold-Mende, C.; Park, J.J.; Lowe, G.; Schirmer, R.H. J. Med. Chem. 2001, 44, 2784. 
198 Clarke, M.J. Coord. Chem. Rev. 2003, 236, 209. 
199 Rigobello, M.P.; Vianello, F.; Folda, A.; Roman, C.; Scutari, G.; Bindoli, A. Biochem. Biophys. Res. 
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of gold compounds with thioredoxin reductase will be considered in detail in the next 
paragraph. 
 
 
4.2 Gold compounds as TrxR inhibitors: previous results 
Since the very first studies on the protein chemistry of thioredoxin reductases and the 
discovery of an essential selenocysteine residue in its active site, it was soon apparent that 
gold compounds (in particular gold(I) compounds) might behave as potent enzyme 
inhibitors. This hypothesis was initially grounded on the simple chemical consideration 
that gold compounds, especially those in the oxidation state +1, are “soft Lewis acids” and 
“thiol reactive species” with the ability to target, potently and selectively, thiol and selenol 
groups of proteins. 
Although the effects of numerous gold compounds on thioredoxin reductase activity 
were widely investigated during the last decade and potent enzyme inhibition highlighted 
in several cases, the actual mechanisms of interaction of gold compounds with this enzyme 
have been poorly explored at the molecular level. It was just assumed that the “soft”, 
catalytically relevant, selenolate group should constitute the common anchoring site for 
gold-based inhibitors; this assumption was grounded on the concept that “soft” gold ions, 
especially in the oxidation state +1, are able to form strong bonds with “soft” Lewis 
donors. Notably, important although indirect, support to this hypothesis was recently pro- 
vided by Deponte et al.200 who reported that gold phospholes inhibit native thioredoxin 
reductase orders of magnitude stronger than a mutant where the C-terminal selenol group 
is replaced by a cysteine. 
This substantial lack of molecular information prompted us to analyse in more detail 
the interactions taking place between gold compounds and thioredoxin reductase with the 
aid of a few specific biophysical and biochemical tools. In particular, we have exploited 
advanced mass spectrometry methods to explore the reactions of representative gold 
compounds with thioredoxin reductase. Some remarkable results emerging from our 
studies will be briefly described below. 
                                                
200 Deponte, M.; Urig, S.; Arscott, L.D.; Fritz-Wolf, K.; Réau, R.; Herold-Mende, C.; Koncarevic, S.; Meyer, 
M.; Davioud-Charvet, E.; Ballou, D.P.; Williams Jr., C.H.; Becker, K. J. Biol. Chem. 2005, 280, 20628. 
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Today’s mass spectrometry methods may allow a direct monitoring of the TrxR 
enzyme in spite of its relatively large size (!110 kDa for the homodimeric protein). A 
series of MALDI (Matrix-Assisted Laser Desorption Ionization) TOF (Time-of-Flight) 
spectra were thus recorded on TrxR1 samples, pre-reduced with NADPH, either alone or 
incubated with a stoichiometric excess of various gold complexes, for 1 h at 37 °C; a 
similar approach had been previously adopted by Deponte et al., when studying the 
reaction of gold phospholes with human glutathione reductase.200 Representative MALDI 
spectra for TrxR1 and for its auranofin adduct are shown in Figure 4.2. Interestingly, 
treatment of TrxR1 with gold compounds results into significant mass increases, whose 
extent clearly depends on the applied gold-to-protein molar ratios. For example, in the case 
of the auranofin-treated sample, the main peak is located at !56,600 Da, while the peak of 
untreated TrxR1 falls at !55,500Da, suggesting protein binding of !4 AuPEt3+ fragments. 
These observations provide direct evidence for extensive protein metallation and point out 
that a certain number of sites, beyond Sec, are available for gold binding on the protein 
surface, most likely Cys, Met and His residues. A similar situation, i.e. the presence of 
multiple gold binding sites on the protein surface, was recently hypothesized for the 
reaction of human serum albumin with antiarthritic gold(I) compounds and cytotoxic 
gold(III) compounds.201 
 
 
Figure 4.2 MALDI MS spectra of intact rat TrxR1, pre-reduced with NADPH, alone or after 1 h incubation 
with Auranofin, at 10:1 gold to protein molar ratio, and removal of unbound gold. 
  
                                                
201 Marcon, G.; Messori, L.; Orioli, P.; Cinellu, M.A.; Minghetti, G. Eur. J. Biochem. 2003, 270, 4655. 
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4.3 Reactions of gold compounds with the C-terminal motif of 
thioredoxin reductase 
 
4.3.1 Rationale of the study 
Thioredoxin reductases are important and widespread proteins playing a crucial role 
in the intracellular redox metabolism. Indeed, thioredoxin reductases (TrxRs) (EC 1.8.1.9) 
are the only known enzymes capable of reducing thioredoxin (Trx), a key molecule -
together with glutathione- in governing the intracellular redox balance.202,203 Thioredoxin 
reductase, comprised of two identical 316-residue subunits, catalyzes the reduction of 
thioredoxin using NADPH as a source of electrons (Figure 4.3). Notably, the mammalian 
enzyme contains a functionally relevant selenol group at its C-terminal extension.204 
 
Figure 4.3 Ribbon representation of the dimer of human TrxR (Sec2Cys) (PDB entry 2J3N). The two 
subunits are shown in blue or orange colors, respectively. Cys58/Cys63, Cys58'/Cys63', Cys497 and Cys 497' 
are shown in yellow, Cys498 and Cys498' in magenta. Bound FAD (red) and NADP+ (green) are shown as 
ball-and-stick models. 
 
Recent studies pointed out that thioredoxin reductase might constitute an effective 
biomolecular target for a variety of anticancer inorganic drugs. For instance, TrxR was 
claimed to represent the major target for the arsenic based drug Trisenox, recently 
                                                
202 Arnér, E.S.J. Biochim Biophys Acta. 2009, 6, 495-526. 
203 Arnér, E.S.J.; Holmgren, A. Eur. J. Biochem. 2000, 267, 6102–6109. 
204 Fritz-Wolf, K.; Urig, S.; Becker, K. J. Mol. Biol. 2007, 370, 116-127. 
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approved by FDA for the treatment of promyelocytic leukemia.205 In addition, gold(I) 
compounds, like the antiarthritic drug Auranofin (67), were shown to act as potent and 
selective thioredoxin reductase inhibitors.206 Potency and selectivity were tentatively 
associated to the pronounced “soft” character of the gold(I) center and to its high affinity 
for selenium. Very likely, gold(I) might block TrxR active site selenocysteine.206 Recently, 
the reaction of Auranofin (67) with the C-terminal peptide of TrxR was reproduced 
theoretically by DFT analysis and preferential gold coordination to selenol over the 
adjacent thiol strongly supported.207 Consistently, Millet et al.208 showed that an 
engineered mutant of TrxR, bearing a cysteine residue in the place of selenocysteine, is far 
less sensitive to inhibition by metallodrugs than the native protein. Moreover, a few 
gold(III) compounds were reported to be effective inhibitors of TrxR; in this latter case 
enzyme inhibition could arise either by oxidation of key enzyme residues or by gold 
coordination to C-terminal active site.186 In any case, no conclusive and direct evidence has 
been gained so far that gold compounds specifically target the selenol group of thioredoxin 
reductase. 
Scheme 4.2 The tetrapeptide (66); Auranofin (67) and AuOXO6 (62). 
 
These arguments led us, in collaboration with Prof. Luigi Messori, to design and 
synthetize a short peptide with the sequence Ac-Gly-[Cys-Sec]-Gly-NH2 (66); the 
                                                
205 Lu, J.; Chew, E.H.; Holmgren, A. Proc. Natl. Acad. Sci. U S A 2007, 104, 12288-12293. 
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Lewis, J.B.; Wataha, J.C. Toxicol. In Vitro 2006, 20, 882-890. 
207 Howell, J.A.S. J. Organomet. Chem. 2009, 694, 868–873. 
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sequence of this tetrapetide exactly matches that of TrxR C-terminus. The reactivity of 66 
toward Auranofin (67) and two representative gold(III) compounds i.e. the dinuclear 
AuOXO6 complex (62) and sodium tetra-chloroaurate (NaAuCl4) was tested by MS 
analysis.209 The peptide 66, and compounds 67 and 62 are schematically represented in 
Scheme 4.2. 
 
4.3.2 Chemical synthesis of TrxR fragment 
The synthesis of the peptide was not trivial. Selenocysteine was prepared starting 
from Selenocystine, in accordance with Moroder210 and Hondal,211 Fmoc-Sec(Mob)-OH 
was obtained with a bidimensional orthogonal protection scheme suitable for solid phase 
peptide synthesis. The peptide Ac-Gly-[Cys-Sec]-Gly-NH2 (66) was synthesized starting 
from Rink Amide MBHA resin. All the reactions were performed on a semi automatic 
synthesizer (MultiSyn Tech - Germany) following the standard SPPS method and using the 
orthogonal Fmoc/Trt/t-Bu protection scheme. The linear peptide-resin was acetylated on 
the -NH2 terminal group with a solution of acetic anhydride and NMM. 
Formation of S-Se bridge was obtained by changing the original method for Mob 
removal,212 while detaching the peptide from the resin (Scheme 4.3) using TFA 93%, TIS 
2.5%, Tioanisole 2.5% and H2O 2.5%, a cleavage cocktail with 1.0 equivalent of 2,23-
Dithiobis(5-nitropyridine) (DTNP) per selenium. On the ground of literature data, the 
rationale for this reaction is that the highly acidic solution of DTNP in TFA activates 
DTNP by protonation of the pyridine nitrogen atom. This creates a very good electron sink 
and enhances the electrophilicity of the disulfide bond of DTNP. The highly nucleophilic 
selenium atom attacks the DTNP to form a Sec(5-Npys) residue.  
Since there is a nearby Cys(Mob) residue, the sulphur atom of this aminoacid can 
attack the reactive selenilsulfide bond, with concomitant loss of the Mob group and the 
formation of cyclic peptide 66 (Scheme 4.3). 
                                                
209 Pratesi, A.; Gabbiani, C.; Ginanneschi, M.; Messori, L. Chem. Commun. 2010, 46, 7001–7003. 
210 Besse, D.; Moroder, L. J. Pept. Sci., 1997, 3, 442-453. 
211 Hondal, R.J.; Nilsson, B.L.; Raines, R.T. J. Am. Chem. Soc. 2001, 123, 5140-5141; Hondal, R.J.; Raines, 
R.T. Methods Enzymol. 2002, 347, 70-83. 
212 Harris, K.; Flemer Jr, S.; Hondal, R.J. J. Pept. Sci. 2007, 13, 81-93. 
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The crude peptide was prepurified by solid phase extraction (SPE) with a RP-8 
LiChroprep silica. The purification of the peptide was performed by semipreparative RP-
HPLC. 
Scheme 4.3 Supposed mechanism of DTNP mediated S-Se bond formation. 
 
4.3.3 MS analysis of TrxR-gold compounds 
The peptide 66 was reduced by adding 5.0 equivalents of DTT and then reacted with 
1.1 equivalents of the various gold drugs for 30 min at room temperature. The reaction 
products were analysed through ESI mass spectrometry, in the positive ion mode. ESI-MS 
spectra were recorded by direct injection at a 5 µl/min flow rate in a LCQ Advantage ion 
trap (Thermo, San Jose, California), equipped with a conventional ESI source. The specific 
conditions used for these experiments were as follows: the spray voltage was 4.5 kV, the 
capillary voltage was 1.5 V and the capillary temperature was kept at 270 °C. Sheath gas 
was set at 35 (arbitrary units) whereas auxiliary gas was kept at 0 (arbitrary units). The 
MS/MS was acquired on peak 742.00 m/z with an isolation width ±1.0 m/z, source 
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fragmentation collision energy set at 15 V and 30% of Normalized Collision Energy. All 
ESI spectra were elaborated using Xcalibur software (Thermo). 
Notably, no reaction takes place in the absence of reducing agents. At variance, when 
the peptide was pre-reduced with DTT and treated with the various gold drugs a number of 
new peaks of greater molecular mass appeared that could be assigned to well defined 
metal-peptide species. A representative ESI-MS spectrum of the reaction with Auranofin 
(67) is shown in Figure 4.4. The main product shows a signal at m/z 741.84, peak (A), 
whose molecular mass exactly matches the tetrapeptide with a bound AuPEt3+ group. 
Another intense peak is detected at m/z 1055.86 (B) corresponding to the tetrapeptide 
bearing two AuPEt3+ groups. Both peaks show the characteristic isotopic pattern of 
selenium, as reported in Figure 4.5. 
Figure 4.4 Mass spectra of the reduced peptide (66) with Auranofin (67). 
Figure 4.5 Isotopic pattern for mono- and di-Au(I) peptide complexes, single ion monitoring experiment. 
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At variance, peak (C) just corresponds to a peculiar rearrangement of Auranofin (67), 
previosuly described.213 
The reported ESI-MS results are in nice agreement with expectations. Auranofin (67) 
binds the peptide tightly; apparently, enzyme binding takes place through replacement of 
the thiosugar moiety while the phosphine ligand is kept. It can be proposed that gold 
binding preferentially occurs at the level of the selenocysteine, in fact the MS/MS 
spectrum (Figure 4.6) for peak (A) in Figure 4.4, just shows a signal at m/z 536.40 
corresponding to the loss of the fragment [Ac-Gly-Cys-] with no evidence of bound gold 
atoms. However, the binding of two AuPEt3+ fragments to Ac-Gly-Cys-Sec-Gly-NH2 was 
also observed (Scheme 4.4, compounds 68, 69). Instead, any evidence was obtained for 
one gold center bridging the adjacent selenocysteine and cysteine residues nor for peptide 
binding of bare gold(I) ions. 
 
Figure 4.6 MS/MS spectra for the mono-Au(I) peptide complex. 
 
                                                
213 Shoeib, T.; Atkinson, D.W.; Sharp, B.L. Inorganica Chimica Acta 2010, 363, 184-192. 
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Scheme 4.4 Auranofin complexes revealed in ESI-MS spectra 
 
Afterward, the reactions of Ac-Gly-Cys-Sec-Gly-NH2 with the above mentioned 
gold(III) compounds, namely 62 and NaAuCl4, were investigated. The resulting ESI-MS 
profiles are shown in Figure 4.7. Interestingly, treatment of the tetrapetide with these two 
gold(III) compounds invariantly afforded quantitative transformation of the original 
species into two main adducts of greater molecular mass. Notably, the same products were 
obtained in the two cases ruling out that any gold(III) ligands are eventually incorporated 
in the final species. Both adducts contain selenium as witnessed by their isotopic patterns. 
Figure 4.7 ESI-MS spectra with the two gold(III) compounds. 
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Analysis of the spectra led us to propose that peak (A) located at 971.80 m/z 
corresponds to the tetrapeptide bearing two bare Au+ ions. Linear coordination is probably 
completed by a macrochelate DTT molecule as tentatively depicted in Scheme 4.5, 
(structure 70). The parent peak (B) and its Na+ form (C), reported in Figure 4.7, are due to 
association of two molecules of the tetrapeptide through formation of a S-S (not Se-Se) 
bond (structure 71). 
 
 
Scheme 4.5 Adducts formed during the complexation with AuOXO6 and NaAuCl4. 
 
Excess of DTT in solution is known to cause oxidation of SH to S-S.214 This reaction 
occurs because the redox potential of the selenol group is far higher than that of the thiol 
group. Peak (D) at m/z 448.00 was assigned to the free peptide in its oxidised state 
([M+Na]+). Remarkably, selenol or thiol oxidation by gold(III) to the respective selenenic 
or sulfenic species may be ruled out as the characteristic peaks of the oxidised tetrapeptide 
incorporating one or more oxygen atoms were not detected at all. 
 
 
4.3.4 Conclusions 
The synthetic tetrapeptide Ac-Gly-[Cys-Sec]-Gly-NH2 is a suitable model for the C-
terminal site of the selenoenzyme TrxR. We have shown here that Ac-Gly-Cys-Sec-Gly-
NH2, in its reduced form, reacts eagerly with a few gold compounds, either gold(I) or 
gold(III). Such reactions are likely to reproduce closely the interactions taking place 
between the selenoenzyme and its gold-based inhibitors. Notably, the reaction with 
Auranofin (67) leads to predominant formation of a gold(I)-selenolate complex through 
                                                
214 Li, Y.; Rothwarf, D.M.; Scheraga, H.A. J. Am. Chem. Soc. 1998, 120, 2668-2669. 
H
N CH C
H
NH2
O
H
N CH C
CH2
O
Se
H
N CH C
CH2
O
S
N
H
CH C
H
O
O
Au Au
S
S
OH
OH
H
N CH C
H
NH2
O
H
N CH C
CH2
O
SeH
H
N CH C
CH2
O
S
N
H
CH C
H
O
O
H
N CH C
H
NH2
O
H
N CH C
CH2
O
SeH
H
N CH C
CH2
O
S
H
N CH C
H
O
O
70 71
Chapter 4. TrxR as a target for anticancer drugs 
 137 
replacement of the thiosugar ligand (while the triethyl phosphine ligand is retained). On 
the other hand, reactions of Ac-Gly-Cys-Sec-Gly-NH2 with two distinct gold(III) 
compounds -AuOXO6 and AuCl4-- afforded the same products. The main product was 
identified as a DTT/Au(I)2/tetrapeptide species implying that gold(III) reduction has taken 
place. At variance, any evidence was obtained for extensive oxidation of the selenol/thiol 
groups by gold(III) to the respective selenenic/sulfenic species. Detailed information is 
thus inferred on the likely mechanisms of interaction of gold drugs with the enzyme. 
Apparently, in both cases, gold(I) coordination to the active site selenol group seems to be 
the crucial event leading to strong enzyme inhibition. Notably, these findings are roughly 
consistent with recently published ESI-MS results for the reaction of Auranofin (67) with 
cysteine and selenocysteine213 though showing a few significant differences. In any case, 
we believe that the Ac-Gly-[Cys-Sec]-Gly-NH2, tetrapeptide, characterised by the presence 
of adjacent thiol and selenol groups, is a far better model for the “real” enzyme.
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Chapter 5 
EXPERIMENTAL METHODS 
 
5.1 Radiolabeling 
5.1.1 Radiolabeling of MonoDOTA 
90YCl3 in hydrochloric acid (0.04 M) was purchased from AEA Technology 
(Harwell, UK). Radiolabeling was carried out at a specific activity of 37 MBq 90Y/10 µg of 
MonoDOTA (1), buffering with 1 M ammonium acetate pH 7.0. After being heated for 25 
min at 85 °C, the mixture was diluted to 1 mL with saline. The labeling yield was 
determined by Instant Thin Layer Chromatography (ITLC SG, Gelman Science, Ann 
Arbor, MI) in saline, adding a molar excess of Av and EDTA to an aliquot of the 
radiolabeled mixture. In this system, Av/biotin derivative complex remains at the starting 
point while free 90Y (bound to EDTA) migrates with the solvent front. The strip was cut in 
two halves and counted in a #-counter (Tri-Carb 2900TR Liquid Scintillation Analyzer, 
Packard). 
 
5.1.2 Radiolabeling of BisDOTA and BisBiotin 
Radiolabeling general procedure was performed using the three derivatives 
BisDOTA-Lys-C3 (7), and BisDOTA-Lys-(pAB)-C3 (11), BisBiotinMonoDOTA-C3 (21), 
BisBiotinMonoDOTA-(pAB)-C6 (34) and BisBiotinBisDOTA-(PEG6)-C3 (44) at a 
concentration of 3 mg/mL in saline. Equal volumes of 1.0 M sodium acetate buffer (pH 
5.0) and of the radionuclide chloride solution were used. In each experiment, biotin 
solution was added to the buffer and transferred into the radionuclide supplier vial. The 
mixture was then mixed and heated at 95 °C for 30 min. RCP was assayed in triplicate for 
each radiolabeled sample by ITLC. An aliquot (usually 0.05 mL) of the radiolabeling 
solution was mixed with 0.2 mL of an avidin-DTPA solution (0.4 mM Av and 2.5 mM 
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DTPA, final pH 6.0) and kept at room temperature for 5 min. Subsequently, an amount of 
5 µL of the radioactive mixture was spotted on a silica gel ITLC paper strip and then 
developed in saline solution. In this chromatographic system, Av-radio-biotin complex 
remains at the origin whereas free radiometal, bound to DTPA, migrates to the solvent 
front. The radiochromatographic profile was determined by an autoradiographic system 
using high performance storage phosphor screen and RCP consequently calculated. 
Labelling yields greater than 97% were routinely achieved. 
 
5.1.3 High specific activity (SA) radiolabeling 
To determine the achievable SA (expressed as MBq/nmol), the derivatives 7, 11, 21, 
34 and 44 were radiolabeled with 90Y at the following increasing of SA: 2.6, 5.2, 10.6, 
51.2, 212, 530 MBq/nmol. RCP was determined in each sample as previously described. 
 
5.2 Studies of binding 
5.2.1 Studies of Binding on MonoDOTA 
Different molar ratios of 90Y-labeled MonoDOTA (1) toward Av were studied. The 
same amount of radiolabeled MonoDOTA (1 µg) was reacted with decreasing amounts of 
Av (Mw 66 kDa), to obtain 1:2, 1:4, 1:8, 1:16, and 1:32 Av/1 molar ratios. The mixtures 
were incubated at 37 °C and analysed at 2 and 24 h using Centricon YM-10 concentrators 
(Millipore, Bedford, MA, 10kDa Mw cutoff). Aliquots from the top and bottom parts of 
the Centricon were counted in the #-counter as previously described (see above). To 
evaluate the activity aspecifically bound to the Centricon, an 90Y-labeled MonoDOTA 
aliquot was centrifuged without adding Av. All runs were performed in duplicate. 
 
5.2.2 Studies of Binding on BisDOTA and BisBiotin 
HABA Assay. Preliminary experiments were performed by varying the 
concentration of HABA (from 3 mM to 0.3 µM) and avidin (15.1, 7.6, and 3.8 µM) to 
calculate their optimal concentrations in the competitive binding studies. In the final 
experiments, carried out in 1 mL sample cuvettes, various concentrations of competitors 
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[(+)-biotin and BisDOTA or BisBiotin derivatives] were added to the HABA/Av complex, 
obtained by mixing avidin and HABA to a final concentration of 7.6 and 0.25 µM, 
respectively. Changes in absorbance were measured at 500 nm. All experiments were in 
triplicate, and the % inhibition was calculated as {[(absorbance with competitor) - 
(absorbance without HABA)/(Av complex)]/[(absorbance without competitor) - 
(absorbance without HABA)/(Av complex)]}'100. 
 
CD Assay on Avidin/BisDOTA and BisBiotin Complexes Stability. Each 
spectrum (195-260 nm) was obtained from averaging three scans and subtracting the 
contribution from the buffer solution. Other experimental settings were as follows: 20 nm 
min scan speed, 2.0 nm bandwidth, 0.2 nm resolution, 50 mdeg sensitivity, and 4 s 
response. Melting curves of wild type avidin, with or without 4 eq. of (+)-biotin and its 
BisDOTA derivatives, were recorded by following the decrease of dichroic signal at 225 
nm, keeping the temperature in the range 25-95 °C. Instrument settings were as follows: 
bandwidth 1 nm, response 0.5 s, data pitch 1 °C, temperature slope 10 °C/min. At every 
temperature increment of 5 °C, a far-UV CD spectrum was collected, assay utilizes the 
observation that HABA shows dramatic spectral changes when it binds to avidin. Free 
HABA has an absorption peak at 348 nm, while the HABA/avidin complex has strong 
absorption at 500 nm. Since the affinity between HABA and avidin is relatively weak (Kd 
= 5.8 10-6 M) compared to the affinity between (+)-biotin and avidin (Kd = 1 10-15 M), (+)-
biotin can easily replace HABA from the HABA/avidin complex, resulting in a decrease of 
absorption at 500 nm. To estimate the apparent avidin binding affinity of biotin and 
BisDOTA derivatives, several competitive binding studies have been performed adding 
(+)-biotin and corresponding BisDOTA derivatives to the HABA/avidin sample and 
measuring any change in absorbance. 
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5.3 Stability studies 
5.3.1 Stability Studies on MonoDOTA 
Aliquots from the labelling mixture were diluted with saline or human serum/saline 
1:1 solution alternatively. After 2, 6, 12, 24, 36, and 48 h of incubation at 37 °C, two 
aliquots (10 µL) of both the mixtures were drawn: one was added to Av molar excess and 
the other was added to saline. The samples were centrifuged in Centricon YM-10 and 
subsequently washed with 3 ' 200 µL saline. The presence of 90Y-labeled MonoDOTA/Av 
complex, free 90Y ion, and biotinidase-cleaved 90Y-DOTA, potentially generated during 
incubation, was determined by the activity counts of the top and bottom parts of the 
Centricon with and without Av excess. 
 
5.3.2 Stability studies on BisDOTA and BisBiotin 
Serum Stability. Normal mouse serum, freshly collected just before each 
experiment, was used as the source of biotinidase activity. Each experiment was carried 
out by mixing 50 µL of NMS with 10-25 µL of samples (BisDOTA derivatives or 
Biocytin). The volume was adjusted to 500 µL with reaction buffer (100 mM sodium 
acetate, pH 5.5), and each sample was incubated at 37 °C in water bath up to 2 h. To stop 
the reaction, an amount of 50 µL of each sample was diluted 10-fold with 0.08% TFA (v/v) 
in water, either before and after incubation, and 40 µL of this solution was applied to the 
HPLC columns. The chromatographic separations were carried out at a flow rate of 0.2 
mL/min and by applying a gradient from 2% to 60% of B in 20 min. Main settings of ESI 
source were the following: spray voltage, 4.2 kV; capillary temperature, 300 °C; capillary 
voltage, 6 V. 
 
5.4 Materials and methods 
DOTA was purchased from Macrocyclics (Richardson, Texas, USA), Fmoc-
Lys(MTT)-Wang resin (100-200 mesh) was from Novabiochem AG (Laufelfingen, 
Switzerland), 6Cl-HOBt was from Luxembourg (Israel), HATU was from PerSeptive 
Biosystem, TBTU was from Chem Impex International. Peptide-synthesis grade DMF was 
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from Scharlau (Barcelona, Spain). HPLC-grade MeCN was purchased from Carlo Erba 
(Italy). Dry solvents were distilled immediately before use: THF over 
sodium/benzophenone. All other chemicals were commercial compounds and were used as 
received. 
1H-NMR spectra were recorded on a Varian Gemini 200 MHz spectrometer or 
Varian Inova 400 MHz. Chemical shifts (4) are reported in ppm downfield from 
tetramethylsilane. The elemental analyses were performed on a Perkin Elmer 240 C 
Elemental Analyzer. 
Thin layer chromatographies (TLC) were carried out on SiO2 (Merck; 60 Å F254) 
and spots located with: UV light (254 and 366 nm), methanolic ninhydrin, Fluram (Fluka; 
fluorescamine, 4-phenyl-spyro[furan-2(3H),1’-isobenzofuran]-3,3’-dione) in acetone, 
Cl2/O-tolidine [O-tolidine (75 mg), AcOH (3 mL), and KI (21 mg) in water (47 mL)]. 
Semi-preparative purification via HPLC were performed by a Supelco C18 180Å 
(250 ' 10 mm, 5µm, metals < 10 ppm) column at 28 °C using a Beckman Gold Noveau 
instrument (detector diode array). Analytical HPLC were performed using a Phenomenex 
Jupiter column 5µ C18 300Å (250 ! 4.6 mm). The solvent systems used were: A (0.1% 
TFA in H2O) and B (0.1 % TFA in CH3CN). The flow rates were 1 mL/min for analytical 
HPLC and 4 mL/min for semi-preparative HPLC, with the indicated linear gradients. 
Electrospray ionization mass spectra (ESI-MS) were acquired on a LCQ-Advantage ESI 
ion trap spectrometer (ThermoFinnigan) for positive and negative ions detection. 
LC-ESI MS analyses were performed on a Phenomenex Aqua C18 column (5 µm, 
250 ' 4.6 mm) (flow rate: 1000 µL/min), on a ThermoFinnigan Surveyor HPLC system 
coupled to the ESI-MS, using the solvent systems reported above.  
LC was performed in automatic with a Biotage Isolera One. 
The peptide syntheses were performed using a semi-automatic synthesizer from 
MultiSyn Tech (German) and the microwave-assisted steps were carried out with a CEM 
Explorer microwave reactor. 
 
All the in vitro were experiments were performed at the Division of Nuclear 
Medicine of the European Institute of Oncology (Milano, Italy). 
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5.5 Chemical synthesis 
5.5.1 Fmoc-Lys(H)-OtBu 
 
 
Scheme 5.1 Synthesis of 17 
 
2.0 g of Fmoc-L-Lys(Boc)-OH (72) were added with 2.33 g of di-terbuthyl 
dicarbonate, Boc2O, and 156.5 mg of 4-dimethylaminopiridine, DMAP, in 30 ml of 
anhydrous ter-buthanol. The reaction was stirred for 30 min at 35°C and for 15 h at room 
temperature. At the end of the reaction the product, 73, was checked by TLC 
(AcOEt/exane 2:1), Rf = 0.75. 
The solvent was removed under vacuum and the solid residue was dissolved 30 ml of 
ethyl acetate and 5 ml of water; the organic layer was washed with a saturated solution of 
NaHCO3 (20 ml for 3 times), and with water (20 ml for 3 times). The organic phase was 
dried with anhydrous Na2SO4, the solvent was removed under vacuum and the crude 
product was purified by direct-phase LC on silica gel using AcOEt/exane 30:70. 
1.70 g of the purified product 73 were dissolved in 56 ml of solution containing 28% 
of TFA in AcOEt. The solution was stirred at 45 °C for 1 h. After, another 10 ml of TFA 
were added. The reaction was stirred for 2h and at the end, TFA was removed under 
nitrogen flow. The crude compound 17, was solubilized in 10 ml of CH3CN/H2O 2:3 and 
purified by solid phase extraction on reverse-phase C18 silica gel, obtaining the pure 
compound Fmoc-Lys(H)-OtBu, 17 (311 mg, 57% yield). ESI-MS: calculated m/z 425.5 
[M+H]+; found 425.5. 
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5.5.2 SPPS synthesis: general procedures 
The products were synthesized using classical SPPS method. The coupling was 
checked by the Kaiser test. The products were synthesized on Fmoc-Lys(MTT)-Wang 
resin (50 mg, 0.03 mmol or 500 mg, 0.3 mmol as specified for each compound) using the 
semiautomatic synthesizer. Before the synthesis the resin was swelled for 20 min in DMF. 
Step 1: Fmoc deprotection was performed by 20% piperidine in DMF (2 ' n mL) for 
10 min. The resin was twice washed with DMF, one time with DCM and twice with DMF. 
Step 2: coupling reactions. 
Method 1: TBTU/HOBt/NMM method with formation of active esters. The 
coupling reaction was performed by using the reagent (2.5 eq), HOBt (2.5 eq), TBTU (2.5 
eq) and NMM (5 eq) in DMF, under vortex mixing for 45 min. The resin was then washed 
with DMF (3 ' n mL) and DCM (2 ' n mL). Coupling reactions were controlled by the 
Kaiser test. 
Method 2: HATU/NMM method; the coupling reaction was performed by using the 
reagent (2.5 eq), HATU (2.5 eq), and NMM (5 eq) in DMF, under vortex mixing for 45 
min. The resin was then washed with DMF (3 ' n mL) and DCM (2 ' n mL). 
Step 3: removal of MTT protecting group was performed by a solution containing 
2% TFA, 2.5% TIS and 95.5% DCM. (20 ' n mL) for 3 min. Initially the solution became 
fluorescent yellow, indicating the presence of MTT. Washing was continued until the 
solution became colourless again. 
Step 4: cleavage the resin and removal of the tert-butyl protection was performed 
with 2.5% TIS, 2.5% H2O and 95% TFA for 3 h. The resin was filtered off and the solution 
was concentrated by flushing with N2. The peptide was precipitated from cold Et2O, 
centrifuged and lyophilized. The purification of the crude products was performed by 
semipreparative reverse-phase HPLC. Eluents: A (0.1% TFA in H2O) and B (0.1% TFA in 
CH3CN). Characterization of the products was performed by using ESI-MS and LC-ESI-
MS. 
The volume of solvents, n, used in washes was calculated with the general principle: 
1 mL for 100 mg of resin. 
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5.5.3 BisDOTA-Lys-C3 
2,2',2''-(10-(15-carboxy-2,9,17-trioxo-21-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)-7-(3-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-
yl)acetamido)propyl)-3,7,10,16-tetraazahenicosyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid 
 
Compound (4) 
After Fmoc deprotection (step 1), the biotin residue was introduced according to the 
TBTU/HOBt/NMM method (step 2, method 1): biotin (13.18 mg, 0.054 mmol), HOBt (7.3 
mg, 0.054 mmol), TBTU (17.3 mg, 0.054 mmol) and NMM (9 µL, 0.081 mmol) in DMF 
(0.5 mL). Coupling reaction was controlled by the Kaiser test. MTT deprotection was 
performed following step 3. HPLC (5 to 30% of B in 20 min): tR = 9.6 min; ESI-MS: m/z 
calcd [M+H]+ 373.2, found 373.3. 
 
Compound (6) 
Spacer C3 conjugation to the lysine side chain was performed using step 2, method 1: 
spacer C3, 5 (41.6 mg, 0.054 mmol), HOBt (7.3 mg, 0.054 mmol), TBTU (17.3 mg, 0.054 
mmol) and NMM (9 µL, 0.081 mmol) in DMF (0.5 mL). We were used three couplings to 
obtain a negative Kaiser test. HPLC (10 to 90% of B in 20 min): tR = 17.7 min; ESI-MS: 
m/z calcd [M+H]+ 988.46, found 988.72. 
 
BisDOTA-Lys-C3 (7) 
After Fmoc deprotection (step 1), for the DOTA conjugation (step 2, method 1) was 
used: DOTA-tris(tert-butyl) ester (20) (61.8 mg, 0.108 mmol), HOBt (14.6 mg, 0.108 
mmol), TBTU (34.6 mg, 0.108 mmol) and NMM (18 µL, 0.162 mmol) in DMF (0.5 mL). 
Coupling reaction was controlled by the Kaiser test. Cleavage from the resin and removal 
of the tert-butyl protection was performed using step 4. The crude product was purified by 
semipreparative RP-HPLC to give pure 7 (13 mg, 35% yield). HPLC (5 to 30% of B in 20 
min): tR = 11.1 min; ESI MS: m/z calcd [M+H]+, 1316.68, found 1316.5. Elemental 
analysis. Found: C, 38.38; H, 5.42; N, 10.02%. Calculated: C56H97N15O19S*6H2O*6TFA: C, 
38.73; H, 5.50; N, 9.96%.  
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5.5.4 BisDOTA-Lys-(pAB)-C3 
 
Compound (9) 
4-Aminobenzoic acid with primary amino-group Fmoc-protected 8 was conjugated 
to the lysine side chain using step 2, method 1: pAB acid 8 (19.4 mg, 0.054 mmol), HOBt 
(7.3 mg, 0.054 mmol), TBTU (17.3 mg, 0.054 mmol) and NMM (9 µL, 0.081 mmol) in 
DMF (0.5 mL). One coupling was necessary to obtain a negative Kaiser test. HPLC (10 to 
90% of B in 20 min): tR = 16.3 min; ESI MS: m/z calcd [M+H]+, 714.29, found 714.8. 
 
Compound (10) 
After Fmoc deprotection (step 1), the spacer C3 5 residue was introduced according 
to the HATU/NMM method (step 2, method 2): spacer C3 5 (52 mg, 0.067 mmol), HATU 
(25.67 mg, 0.067 mmol), and NMM (15 µL, 0.135 mmol) in DMF (0.5 mL). Coupling 
reaction was controlled by Kaiser test. Four couplings were necessary. HPLC (10 to 90% 
of B in 20 min): tR = 17.8 min; ESI-MS: m/z calcd [M+H]+, 1107.49, found 1107.3. 
 
BisDOTA-Lys-(pAB)-C3 (11) 
Coupling was carried out with a mixture of DOTA-tris(tert-butyl) ester (20) (61.8 
mg, 0.108 mmol), HOBt (14.6 mg, 0.108 mmol), TBTU (34.6 mg, 0.108 mmol) and NMM 
(18 µL, 0.162 mmol) in DMF (0.5 mL). Coupling reaction was controlled by the Kaiser 
test. Cleavage from the resin and removal of the tert-butyl protection was performed using 
step 4. The crude product was purified by semipreparative RP-HPLC to give pure 11 (8 
mg, 20%). HPLC (5 to 30% of B in 20 min): tR = 12.967 min; ESI-MS: m/z calcd [M+H]+, 
1435.72, found 1436.6. Elemental analysis. Found: C, 37.70; H, 4.49; N, 10.92%. 
Calculated: C63H102N16O20S*10H2O*7TFA: C, 38.31; H, 5.39; N, 9.28%.  
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5.5.5 BisBiotinMonoDOTA-C3 
16-(2-(1-carboxy-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-
yl)acetamido)pentylamino)-2-oxoethyl)-8,11,21,24-tetraoxo-2,30-bis(5-(2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-7,12,16,20,25-pentaazahentriacontane-
1,31-dioic acid 
 
Compound (12) 
After Fmoc deprotection from Fmoc-Lys(MTT)-Wang resin, (2) (500 mg, 0.3 mmol) 
(step 1), the spacer C3 conjugation to the lysine side chain was performed using step 2, 
method 2: spacer C3, 5 (2.5 eq, 577 mg), HATU (2.5 eq, 285 mg) and NMM (5 eq, 166 
0L). in DMF. HPLC (10 to 90% of B in 20 min): tR = 17.7 min; ESI-MS: m/z calcd 
[M+H]+ 988.46, found 988.72. 
 
Compound (15) 
Fmoc group removal was performed by treating the resin 13 with 20% piperidine in 
DMF (step 1). The succinic anhydride (14) (20 eq, 600 mg) and NMM (40 eq, 1.33 mL) 
were introduced, with the resin in anhydrous THF, in a microwave reactor. Program: 20 
cycles (60 Watt for 1 min and cooling for 30 sec), Tmax = 65°C. 
 
Compound (18) 
Fmoc-Lys-OtBu (17) was introduced by activation of the carboxyl function on resin 
15. HOBt (2.5 eq, 115 mg), TBTU (2.5 eq, 241 mg) and NMM (4.5 eq, 149 0L) in DMF 
were added on the resin and vortexed for 1 min. Building-block, 17 (2.5 eq, 318 mg) in 
DMF was then added an vortexed for 1 h. Coupling reaction was controlled by the Kaiser 
test and micro cleavage. Two couplings were necessary. 
 
Compound (19) 
Biotin residue was introduced according to the TBTU/HOBt/NMM method (step 2, 
method 1): biotin (3) (4 eq, 293 mg), HOBt (4 eq, 184 mg), TBTU (4 eq, 385 mg) e NMM 
(8 eq, 265 0L) in DMF. 
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BisBiotinMonoDOTA-C3 (21) 
MTT deprotection was performed following step 3. Coupling was carried out with a 
mixture of DOTA-tris(tert-butyl) ester (20) (2 eq, 344 mg), HOBt (2 eq, 92 mg), TBTU (2 
eq, 193 mg) and NMM (3 eq, 100 0L) in DMF. Coupling reaction was controlled by the 
Kaiser test. Cleavage from the resin and removal of the tert-butyl protection was 
performed using step 4. The crude product was purified by semipreparative RP-HPLC to 
give pure 21 (90 mg, 19%). HPLC (10 to 90% of B in 15 min): tR = 6.94 min; ESI-MS: m/z 
calcd [M+H]+, 1612.80, found 1612.62. Elemental analysis. Found: C, 38.54; H, 5.32; N, 
10.11%. Calculated C70H117N17O22S2*9H2O*7TFA, C, 39.21; H, 5.56; N, 9.25%. 
 
5.5.6 Spacer-C6 
 
2,2'-(iminodi-6,1-hexanediyl)bis-1H-isoindole-1,3(2H)-dione (24) 
N-(6-aminohexyl)-1,6-hexanediamine (22) (2.00 g, 9.28 mmol) was dissolved in 
warm toluene (10 mL) in a Dean-Stark. A solution of phthalic anhydride (23) 
(recrystallized from CHCl3) (2.83 g, 19.1 mmol) in warm toluene (20 mL) was added. The 
reaction mixture was monitored by TLC analysis (MeOH/CHCl3 1:10) and heated to reflux 
for 8 h. The precipitated phthalic acid was filtered off and the filtrate concentrated under 
reduced pressure to give 24 (4.2 g, 95 %) as an orange-brown oil which was used in the 
next step without further purification. 1H-NMR (200 MHz, CDCl3): + (ppm) 7.81-7.77 (m, 
4H), 7.68-7.64 (m, 4H), 3.62 (t, 4H), 2.57 (t, 4H), 2.20 (s, 1H), 1.75-1.55 (m, 4H), 1.5-1.4 
(m, 8H), 1.35-1.2 (m, 4H); ESI-MS: m/z calcd [M+H]+ 476.3, found 476.5. 
 
N,N-bis[6-(1,3-dihydro-1,3-dioxo-2H-isoindole-2-yl)hexyl]glycine ethyl ester (25) 
DIPEA (275 µL, 1.57 mmol) was added to a warm solution of 24 (350 mg, 0.73 
mmol) in DMF (5 mL) and the reaction mixture was heated at 75-80 °C. Ethyl brome 
acetate (105 µL, 0.95 mmol) in DMF (1 mL) was added dropwise during 1 h. The solution 
was stirred and monitored by TLC (MeOH/CH2Cl2 1:20). After 16 h the solvent was 
evaporated under reduced pressure. The orange-brown oil was purified by FCC (silica gel 
60, 40-63 µm; eluent: AcOEt/petroleum ether 1:1) affording pure 25 as an yellow-orange 
oil (150 mg, 44 %). RP-HPLC (30 to 80% of B in 20 min), tR = 15.6 min; 1H-NMR (200 
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MHz, CDCl3): + (ppm) 7.81-7.75 (m, 4H), 7.70-7.64 (m, 4H), 4.10 (q, 2H), 3.62 (t, 4H), 
3.24 (s, 2H), 2.49 (t, 4H), 1.66-1.56 (m, 4H), 1.44-1.26 (m, 15H); ESI-MS: m/z calcd 
[M+H]+ 562.3, found 562.4. 
 
N,N-bis(6-aminohexyl)glycine (26) 
Compound 25 was dissolved in HCl (6 M, 10 mL); the reaction mixture was heated 
to reflux for 3 days and monitored by TLC (AcOEt/ petroleum ether 1:1). HCl (12 M, 4 
mL) was added and the solution was refluxed for 19 h, and then allowed to cool at room 
temperature. The phthalic acid produced was filtered off and the aqueous phase lyophilized 
to give quantitatively 26. RP-HPLC (20 to 60% of B in 20 min): tR = 6.47 min; 1H-NMR 
(200 MHz, DMSO-d6): + (ppm) 10.22 (br s, 1H), 8.18 (br s, 4H), 4.06 (s, 2H), 3.13-3.08 
(m, 4H), 2.8-2.55 (m, 4H), 1.58-1.55 (m, 8H), 1.4-1.15 (m, 8H); ESI-MS: m/z calcd 
[M+H]+ 274.3, found 274.3. 
 
N,N-bis[[[6-(9H-fluoren-9-ylmethoxy)carbonyl]amino]hexyl]glycine (27) 
Compound 26 (394 mg, 1.03 mmol) was dissolved in dioxane (9.5 mL) and H2O (2.5 
mL) and Fmoc-Succinimide ester (729.6 mg, 2.16 mmol) in dioxane was added. The 
resulting mixture was stirred at room temperature and the pH adjusted to 8 with 2 M 
NaOH. The reaction was monitored by TLC analysis (CHCl3/MeOH 3:1) and stirred for 1 
h. The mixture was treated with H2O and 3 M HCl and the suspension extracted with 
CHCl3 (3 ' 20 ml). The combined organic layers were dried (Na2SO4), filtered and 
concentrated. The crude product was purified by FCC (silica gel 60, 40-63 µm; eluent: 
CHCl3/MeOH 3:1) to provide compound 27 (248 mg, 34% yield). RP-HPLC (30 to 100% 
of B in 20 min): tR = 17.92 min; 1H-NMR (200 MHz, CDCl3): + (ppm) 7.71 (d, 4H), 7.56 
(d, 4H), 7.38-7.22 (m, 8H), 4.33-4.29 (m, 2H), 4.16 (d, 4H), 3.60-3.44 (m, 2H), 3.3-2.95 
(m, 8H), 1.72-1.20 (m, 16H); ESI-MS: m/z calcd [M+H]+ 718.4, found 718.4. 
! !
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5.5.7 BisBiotinMonoDOTA-(pAB)-C6 
2,2',2''-(10-(13-carboxy-9-(6-(4-(4-(5-carboxy-5-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)pentylamino)-4-oxobutanamido)benzamido)hexyl)-1-(4-(4-
(5-carboxy-5-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)pentylamino)-4-oxobutanamido)phenyl)-1,11,19-trioxo-2,9,12,18-
tetraazaicosan-20-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid 
 
Compound (28) 
The Fmoc-Lys(MTT)-Wang resin (2) (500 mg, 0.3 mmol) was swelled for 20 min in 
DMF and deprotected from Fmoc (step 1). The spacer C6 conjugation to the lysine side 
chain was performed using step 2, method 2: spacer C6, 27 (2 eq, 430 mg), HATU (2 eq, 
228 mg) and NMM (4 eq, 133 µL) in DMF. Reaction time: 1 h. HPLC (10 to 90% of B in 
20 min): tR = 11.21 min; ESI-MS: m/z calcd [M+H]+ 402.59, found 402.50. 
 
Compound (30) 
The product 28 was deprotected from Fmoc (step 1). 4-Aminobenzoic acid with 
primary amino-group Fmoc-protected 8 was conjugated to the lysine side chain using step 
2, method 1: pAB acid 8 (4 eq, 432 mg), HOBt (4 eq, 184 mg), TBTU (4 eq, 385 mg) and 
NMM (8 eq, 266 µL) in DMF. Reaction time: 45 min. The coupling was checked by 
Kaiser test and microcleavage. HPLC (10 to 50% of B in 20 min): tR = 6.65 min; ESI-MS: 
m/z calcd [M+H]+, 640.83, found 640.64. 
 
Compound (31) 
Fmoc group removal was performed by treating the resin 30 with 20% piperidine in 
DMF (step 1). The succinic anhydride (14) (20 eq, 600 mg) and NMM (40 eq, 1.33 mL) 
were introduced, with the resin in anhydrous THF, in a microwave reactor. Program: 20 
cycles (60 Watt for 1 min and cooling for 30 sec), Tmax = 65 °C. 
The coupling was controlled with Kaiser test and microcleavage. HPLC (10 to 70% 
of B in 20 min): tR = 7.12 min; ESI-MS: m/z calcd [M+H]+, 840.44, found 840.50. 
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Compound (32) 
The intermediate 31 was vortexed for 30 sec with THF containing 10% of 0.25 M 
NaOH in aqueous solution. Then, the compound 31, was activated on resin by adding 
HOBt (3 eq, 138 mg), TBTU (3 eq, 289 mg) and NMM (5 eq, 166 0L) in DMF and 
vortexing for 1 min. Subsequently, building-block 17 (3 eq, 382 mg) in DMF was added to 
the mixture. Reaction time 1 h. HPLC-MS (10 to 90% of B in 20 min): tR = 5.78 min; m/z 
calcd [M+H]+ 1098.29, found 1098.08. 
 
Compound (33) 
Compound 32 was deprotected from Fmoc (step 1) and Biotin was introduced 
according to the TBTU/HOBt/NMM method (step 2, method 2): biotin (3) (2.5 eq, 183 
mg), HATU (2.5 eq, 285 mg) and NMM (4 eq, 133 µL) in DMF. Coupling reaction was 
controlled by the Kaiser test and microcleavage. Compound 33 was characterized by 
HPLC-MS (10 to 90% of B in 20 min): tR = 6.37 min; m/z calcd [M+H]+ 1549.91, found 
1549.86. 
 
BisBiotinMonoDOTA-(pAB)-C6 (34) 
MTT deprotection was performed following step 3. Coupling was carried out with a 
mixture of DOTA-tris(tert-butyl) ester (20) (2.5 eq, 430 mg), HOBt (2.5 eq, 115 mg), 
TBTU (2.5 eq, 241 mg) and NMM (5 eq, 166 0L) in DMF. Coupling reaction was 
controlled by the Kaiser test. Cleavage from the resin and removal of the tert-butyl 
protection was performed using step 4. The crude product was purified by semipreparative 
RP-HPLC to give pure 34 (85 mg, 18%). HPLC (35 to 45% of B in 20 min): tR = 7.56 min; 
ESI-MS: m/z calcd [M+H]+, 1936.31, found 1935.87; [M+2H]2+, 968.27. Elemental 
analysis. Found: C, 43.34; H, 5.12; N, 10.11%. Calculated C90H139N19O24S2 *10H2O*6TFA: 
C, 43.76; H, 5.94; N, 9.51%. 
  
Chapter 5. Expermental methods 
 152 
5.5.8 BisBiotinBisDOTA-(PEG6)-C3 
 
The procedure for the first intermediate was already described for compound 12. 
 
Compound (36) 
Fmoc group removal was performed by treating the resin 12 with 20% piperidine in 
DMF (step 1). The coupling was performed following method 2, with 1-Fmoc-amino-
3,6,9,12,15,18-esaossaenicosan-21-oic acid (Fmoc-NH-PEG6-COOH, 35) (4 eq, 553 mg), 
HOBt (4 eq, 147 mg), TBTU (4 eq, 308 mg) and NMM (6 eq, 159 µL) in DMF and the 
mixture was vortexed for 1h. Coupling reaction was controlled by the Kaiser test and 
microcleavage. Compound 36 was analyzed by HPLC-MS (10 to 90% of B in 20 min): tR 
= 12.43 min; m/z calcd [M+H]+ 989.21, found 989.38. 
 
Compound (38) 
The product 36 was deprotected from Fmoc (step 1). Fmoc-#-aminobutyric acid, 
(Fmoc-L-Abu-OH, 37) was conjugated to the terminal PEG amino group using step 2, 
method 1: Fmoc-L-Abu-OH (37) (5 eq, 391 mg), HOBt (5 eq, 184 mg), TBTU (5 eq, 385 
mg) and NMM (8 eq, 212 µL) in DMF. Reaction time: 45 min. The coupling was checked 
by Kaiser test and microcleavage. Two couplings were necessary to obtain a negative 
Kaiser test. HPLC (10 to 90% of B in 20 min): tR = 8.87 min; ESI MS: m/z calcd [M+H]+, 
1159.42, found 1159.12. 
 
Compound (39) 
Compound 38 was deprotected from Fmoc (step 1) and Biotin was introduced 
according to the HATU/NMM method (step 2, method 2): biotin 3 (3 eq, 176 mg), HATU 
(3 eq, 274 mg) and NMM (5 eq, 133 µL) in DMF. Coupling reaction was controlled by the 
Kaiser test and microcleavage. Compound 39 was analysed by HPLC-MS (10 to 90% of B 
in 20 min): tR = 7.53 min; m/z calcd [M+H]+ 1612.01, found 1612.45. 
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Compound (41) 
MTT deprotection of 39 was performed following step 3. Bis-Fmoc-3,5-
diaminobenzioc acid (40) (2.5 eq, 358 mg) was introduced (step 2, method 1) with HOBt 
(2.5 eq, 92 mg), TBTU (2.5 eq, 193 mg) and NMM (5 eq, 133 µL) in DMF. Reaction time: 
45 min. Two couplings were necessary in order to obtain a negative Kaiser test. HPLC-MS 
(10 to 90% of B in 20 min): tR = 9.21 min; m/z calcd [M+H]+ 1746.15, found 1746.63. 
 
Compound (43) 
The intermediate 41 was deprotected from Fmoc, using the step 1. Fmoc-!Ala-OH, 
(42) (5 eq, 374 mg) was introduced, in accordance with the method 1, by using HOBt (5 
eq, 184 mg), TBTU (5 eq, 385 mg) and NMM (8 eq, 212 µL) in DMF. Reaction time: 45 
min. only one coupling was necessary in order to obtain a negative Kaiser test. HPLC-MS 
(10 to 90% of B in 20 min): tR = 11.54 min; m/z calcd [M+2H]2+ 1166.89, found 1167.04. 
 
BisBiotinBisDOTA-(PEG6)-C3 (44) 
Fmoc deprotection was performed following step 3. Coupling was carried out with a 
mixture of DOTA-tris(tert-butyl) ester (20) (5 eq, 688 mg), HATU (5 eq, 457 mg) e NMM 
(8 eq, 212 µL) in DMF (method 2). Coupling reaction was controlled by the Kaiser test. 
Cleavage from the resin and removal of the tert-butyl protection was performed using step 
4. The crude product was purified by semipreparative RP-HPLC to give pure 44 (94 mg, 
20%). HPLC (20 to 40% of B in 20 min): tR = 15.79 min; ESI-MS: m/z calcd [M+2H]2+, 
1331.05, found 1330.52. Elemental analysis. Found: C, 42.01; H, 6.34; N, 9.02%. 
Calculated: C117H199N25O40S2*8H2O*8TFA: C, 42.98; H, 6.05; N, 9.42%. 
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5.5.9 BisBiotin-(PEG6)-Abu-SCN (45) 
34-ethyl-6-(28-ethyl-5,27,30-trioxo-34-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
8,11,14,17,20,23-hexaoxa-4,26,29-triazatetratriacontyl)-2-(4-isothiocyanatobutyl)-
4,11,33,36-tetraoxo-40-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
14,17,20,23,26,29-hexaoxa-3,6,10,32,35-pentaazatetracontan-1-oic acid 
 
The starting point was the compound 39, and the synthetic procedures were the same 
described for compounds 36, 38 and 39. 
The MTT protecting group was removed from 39 by using the step 3, and the 
compound 39a was obtained. The amino group was transformed in isothiocyanate by 
adding to the resin 39a (150 mg, 0.09 mmol) CS2 (100 eq, 543 µL) and triethyl amine (10 
eq, 125 µL). The mixture was stirred for 15 min at r.t. After this time, a solution of di-tert-
buthyl dicarbonate (10 eq, 196 mg) and dimethyl amino pyridine (3 mol%, 0.33 mg) was 
added and the reaction was cooled in an ice bath for 10 min and then reacted for other 30 
min at r.t. The solution was filtered off and the resin was washed three times with DMF 
and two times with DCM. Cleavage from the resin was performed using step 4. The crude 
product was purified by semipreparative RP-HPLC to give pure 45 (10.8 mg, 8% overall 
yield). HPLC (20 to 40% of B in 20 min): tR = 12.91 min; ESI-MS: m/z calcd [M+H]+, 
1653.07, found 1652.72. Elemental analysis. Found: C, 41.56; H, 6.98; N, 7.02%. 
Calculated: C73H129N13O23S3*9H2O*5TFA: C, 41.79; H, 6.42; N, 7.63%. 
 
5.5.10 BisBiotin-(PEG6)-Asp-SCN 
31-(2-((1-carboxy-5-isothiocyanatopentyl)amino)-2-oxoethyl)-4,26,36,58-tetraoxo-2-(5-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-60-(5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-
8,11,14,17,20,23,39,42,45,48,51,54-dodecaoxa-5,27,31,35,57-pentaazahenhexacontane-
1,61-dioic acid 
 
Compound (47) 
The starting point was the compound 36 (300 mg, 0.18 mmol). The Fmoc removal 
was achieved following the step 1. Fmoc-Asp-OtBu (46) was conjugated to the terminal 
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PEG amino group using step 2, method 1: Fmoc-Asp-OtBu (46) (5 eq, 370 mg), HOBt (5 
eq, 138 mg), TBTU (5 eq, 289 mg) and NMM (8 eq, 160 µL) in DMF. Reaction time: 45 
min. The coupling was checked by Kaiser test and microcleavage. Two couplings were 
necessary to obtain a negative Kaiser test. HPLC (10 to 50% of B in 20 min): tR = 12.34 
min; ESI-MS: m/z calcd [M+H]+, 1218.39, found 1218.56. 
 
Compound (47a) 
Compound 47 was deprotected from Fmoc (step 1) and Biotin was introduced 
according to the HATU/NMM method (step 2, method 2): biotin (3) (3 eq, 132 mg), 
HATU (3 eq, 206 mg) and NMM (5 eq, 99.5 µL) in DMF. Coupling reaction was 
controlled by the Kaiser test and microcleavage. Compound 47a was analysed by HPLC-
MS (10 to 90% of B in 20 min): tR = 6.65 min; m/z calcd [M+H]+ 1670.98, found 1670.50. 
 
BisBiotin-(PEG6)-Abu-SCN (48) 
The MTT protecting group was removed from 47a (250 mg, 0.15 mmol) by using the 
step 3. The amino group was transformed in isothiocyanate by adding to the resin CS2 (100 
eq, 904 µL) and triethyl amine (10 eq, 209 µL). The mixture was stirred for 15 min at r.t. 
After this time, a solution of di-tert-buthyl dicarbonate (10 eq, 327 mg) and dimethyl 
amino pyridine (3 mol%, 0.55 mg) was added and the reaction was cooled in an ice bath 
for 10 min and then reacted for other 30 min at r.t. The solution was filtered off and the 
resin was washed three times with DMF and two times with DCM. Cleavage from the 
resin was performed using step 4. The crude product was purified by semipreparative RP-
HPLC to give pure 45 (35 mg, 14% overall yield). HPLC (20 to 40% of B in 20 min): tR = 
11.00 min; ESI-MS: m/z calcd [M+H]+, 1713.04, found 1712.42. Elemental analysis. 
Found: C, 40.21; H, 6.64; N, 7.74%. Calculated: C73H125N13O27S3*9H2O*5TFA: C, 40.77; 
H, 6.10; N, 7.45%. 
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5.5.11 BisBiotin-(PEG2)-pAB-Abu-SCN 
16-(1,11-dioxo-1-(4-(3-(2-(2-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)ethoxy)ethoxy)propanamido)phenyl)-5,8-dioxa-2,12-diazapentadecan-
15-yl)-1,11,18-trioxo-1-(4-(3-(2-(2-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)ethoxy)ethoxy)propanamido)phenyl)-20-(4-((3-
thiocyanatopropyl)amino)butyl)-5,8-dioxa-2,12,16,19-tetraazahenicosan-21-oic acid 
 
Compound (50) 
The on resin compound 12 (350 mg, 0.189 mmol) was swelled for 20 min in DMF 
and deprotected from Fmoc (step 1). Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-
PEG-COOH, 49) was conjugated using step 2, method 2: Fmoc-NH-PEG-COOH (49) (4 
eq, 291.3 mg), HATU (4 eq, 287.5 mg) and NMM (8 eq, 167 µL) in DMF. Reaction time: 
40 min. The coupling was checked by Kaiser test and microcleavage. HPLC (05 to 50% of 
B in 20 min): tR = 9.55 min; ESI-MS: m/z calcd [M+H]+, 608.74, found 608.51. 
 
Compound (51) 
The product 50 was deprotected from Fmoc (step 1). 4-Aminobenzoic acid with 
primary amino-group Fmoc-protected 8 was conjugated to the PEG amino group using 
step 2, method 2: Fmoc-pAB-OH (8) (5 eq, 339.6 mg), HATU (5 eq, 359.3 mg) and NMM 
(10 eq, 208.9 µL) in DMF. Reaction time: 45 min. The coupling was checked by Kaiser 
test and microcleavage. HPLC (10 to 90% of B in 20 min): tR = 17.70 min; ESI-MS: m/z 
calcd [M+H]+ 846.98, found 846.38. 
 
Compound (52) 
The compound 51 was deprotected from Fmoc (step 1). Fmoc-8-amino-3,6-
dioxaoctanoic acid (Fmoc-NH-PEG-COOH, 49) was conjugated using step 2, method 2: 
Fmoc-NH-PEG-COOH (49) (4 eq, 291.3 mg), HATU (4 eq, 287.5 mg) and NMM (8 eq, 
167 µL) in DMF. Reaction time: 45 min. The coupling was checked by Kaiser test and 
microcleavage. HPLC (10 to 90% of B in 20 min): tR = 9.21 min; ESI-MS: m/z calcd 
[M+H]+ 1136.29, found 1136.43. 
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Compound (53) 
Compound 52 was deprotected from Fmoc (step 1) and Fmoc-Abu-OH was introduced 
according to the HATU/NMM method (step 2, method 2): Fmoc-Abu-OH (37) (5 eq, 
307.5 mg), HATU (5 eq, 359.3 mg) and NMM (10 eq, 208.9 µL) in DMF. Reaction time: 
45 min. Coupling reaction was controlled by the Kaiser test and microcleavage. Compound 
47a was analysed by HPLC-MS (10 to 90% of B in 20 min): tR = 11.49 min; m/z calcd 
[M+H]+ 1307.50, found 1307.21. 
 
Compound (54) 
Compound 53 was deprotected from Fmoc (step 1) and Biotin was introduced 
according to the HATU/NMM method (step 2, method 2): biotin (3) (3 eq, 138.5 mg), 
HATU (3 eq, 215.6 mg) and NMM (6 eq, 125.4 µL) in DMF. Coupling reaction was 
controlled by the Kaiser test and microcleavage. The reaction intermediate 53a was 
analysed by HPLC-MS (10 to 90% of B in 20 min): tR= 12.26 min; m/z calcd [M+H]+ 
1759.09, found 1758.61. 
The intermediate 53a was deprotected from MTT, using the step 3. Fmoc-!Ala-OH, 
(42) (2.5 eq, 147.10 mg) was introduced, in accordance with the method 2, by using 
HATU (2.5 eq, 179.8 mg) and NMM (5 eq, 212 µL) in DMF. Reaction time: 45 min. 
Coupling reaction was controlled by the Kaiser test and microcleavage. The compound 54 
was analysed by HPLC-MS (10 to 90% of B in 20 min): tR = 12.24 min; m/z calcd [M+H]+ 
1830.17, found 1829.64. 
 
BisBiotin-(PEG2)-pAB-Abu-SCN (55) 
The Fmoc protecting group was removed from 54 by using the step 1. The amino 
group was transformed in isothiocyanate by adding to the resin CS2 (100 eq, 1.2 mL) and 
triethyl amine (10 eq, 263 µL). The mixture was stirred for 15 min at r.t. After this time, a 
solution of di-tert-buthyl dicarbonate (10 eq, 413 mg) and dimethyl amino pyridine (3 
mol%, 0.66 mg) was added and the reaction was cooled in an ice bath for 10 min and then 
reacted for other 30 min at r.t. The solution was filtered off and the resin was washed three 
times with DMF and two times with DCM. Cleavage from the resin was performed using 
step 4. The crude product was purified by semipreparative RP-HPLC to give pure 55 (42 
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mg, 11% overall yield). HPLC (20 to 60% of B in 20 min): tR = 13.85 min; ESI-MS: m/z 
calcd [M+H]+ 1872.23, found 1871.63. Elemental analysis. Found: C, 40.89; H, 5.31; N, 
8.59%. Calculated: C84H130N18O24S3*10H2O*6TFA: C, 42.13; H, 5.75; N, 9.21%. 
 
5.5.12 Fmoc-His(trityl-resin)-OAl 
 
 
Scheme 5.2 Synthesis of Fmoc-L-His(Trityl-Resin)-OAl (77). 
 
Compound (75) 
A solution of DCC (400 mg, 1.94 mmol) in allyl alcohol (1.0 ml, 14.7 mmol) was 
slowly added at 0 °C to a stirred suspension of Fmoc-His(Trt)-OH (74) (1.0 g, 1.6 mmol) 
in dry DCM (20 mL). The mixture was stirred at room temperature for 16 h, and the 
reaction monitored by TLC (DCM/MeOH 10:1; Rf = 0.90). The white precipitate was 
filtered off and the excess of DCC was eliminated with AcOH (0.5 mL). The filtered 
solution was concentrated to dryness, and the residue recrystallized from EtOAc/hexane 
(780 mg, 74% yield). 1H-NMR (CDCl3, 200 MHz), 4 (ppm): 2.86–3.16 (2 H, m, !-H2), 
4.20 (1 H, t, Fmoc 9-H), 4.3–4.7 (3 H, #-H and Fmoc 10-H2), 4.65 (2 H, d, allyl O-CH2), 
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5.20–5.34 (2 H, CH2=CH), 5.8–6.0 (2 H, NH and CH2=CH), 7.32 (4 H, m, Fmoc 2-H, 3-H, 
6-H and 7-H), 7.57 (2 H, d, Fmoc 1-H and 8-H), 7.73 (2 H, d, Fmoc 4-H and 5-H). 
 
Compound (76) 
The product 75 was treated with TFA (7 mL) in 20 ml of DCM at 0 °C and stirred 
for 2 h, monitoring deprotection by TLC (DCM/MeOH 10:1; Rf = 0.35). The solution was 
evaporated to dryness and at the residue was added water (2 mL) and lyophilized. The 
crude oil was treated with Et2O to obtain a white powder (450 mg, 93% yield). 1H-NMR 
(CDCl3, 200 MHz), 4 (ppm): 3.49-3.09 (2 H, m, !-H2), 4.26 (2 H, m, Fmoc CH2), 4.50 (1 
H, His #-H), 4.58 (2 H, m, All 1-H2), 5.29 (2 H, m, All 3-H), 5.79 (1 H, All 2-H), 6.34 (1 
H, d, His NH), 6.97 (1 H, s, His 5-H), 7.71-7.19 (8 H, d, Fmoc Ar), 7.71 (2 H, m, Fmoc 
CH2). 
 
Fmoc-His(trityl-resin)-OAl (77) 
The chloro-trityl resin (2.57 g, 1.35 mmol/g) was dried under vacuum and then 
swollen with dry DCM. A solution of Fmoc-His-OAl (76) (0.868 g, 0.41 mmol) and 
DIPEA (1.54 mL, 8.34 mmol) in dry DCM (20 mL) was added to the resin. After 2 h, the 
resin was washed with DMF (3 times ' 2 min) and DCM (2 times ' 2 min), and then 
endcapped with DCM/MeOH/DIPEA (17:2:1) (2 times ' 2 min). After washing with DCM 
(2 times ' 2 min), DMF (2 times ' 2 min) and DCM (2 times ' 2 min), the resin was dried 
under vacuum and the resin loading was determined from the Fmoc release, monitored by 
UV absorbance. 
 
5.5.13 c(!3homoLys-DHis-!Ala-His), DK14 (56) 
(3R,7S,10S)-3,10-bis((1H-imidazol-4-yl)methyl)-7-(4-aminobutyl)-1,4,8,11-
tetraazacyclotetradecane-2,5,9,12-tetraone 
 
The tetracyclopeptide 56 was synthesized starting from Fmoc-His(trityl-resin)-OAl (77) 
(500 mg, 0.46 mmol/g), on semi automatic synthesizer (MultiSyn Tech – Germany) and 
following the SPPS method by using the orthogonal Fmoc/Trt/allyl protection scheme. 
Deprotection of amino acids were performed by 20% piperidine in DMF. The amino acids 
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residues (!-Ala; DHis and !3homoLys, respectively) were introduced according to the 
TBTU/HOBt/NMM method with formation of active esters. The coupling reactions were 
performed by using excess of the amino acids, HOBt and TBTU (4 eq.) and of NMM (8 
eq.) in DMF, under vortex mixing for 40 min. After each coupling, the resin was washed 
with DMF and DCM. Coupling reactions were controlled by the Kaiser test. 
The obtained peptide-resin was dried under vacuum and swollen in dry DCM under Ar. 
The resin was shaken for 5 min with a solution of PhSiH3 (24 eq) in dry DCM under Ar, 
and then a solution of Pd(PPh3)4 (0.25 eq.) in dry DCM was added for the allyl group 
cleavage (total volume of DCM should be 5 mL). After 40 min the resin was washed with 
dry DCM. The treatment with PhSiH3/Pd(PPh3)4 was repeated once again. The resin was 
washed with DCM, with a solution of 0.5% sodium diethyldithiocarbamate in DMF, DMF 
and DCM. The Fmoc group on the !3homoLys terminus was then removed with 20% 
piperidine in DMF and washed with DMF, DCM and DMF. The on-resin linear peptide 
was vortexed at r.t. for 2 h with a solution of the coupling reagents, TBTU (1 eq.) and base 
DIPEA (2 eq.), in DMF. After the cyclization, the resin was washed with DMF, and DCM. 
The reaction was checked by the Kaiser test. Peptide cleavage from the resin and 
deprotection from the trityl groups were carried out during 2.5 h with TFA/H2O/TIS 
(95:2.5:2.5). The resin was washed with TFA and the filtrate was partially evaporated. The 
crude product was precipitated with cold diethyl ether, collected by centrifugation, 
dissolved in H2O and lyophilized. After cleavage and lyophilization, the peptide 56 was 
pre-purified by solid phase extraction (SPE) and purified with RP-HPLC (0% to 20% of B 
in 30 min) affording the product 56 (14 mg, HPLC purity >98%, cyclization yield >90%, 
16% overall yield). HPLC (03 to 15% of B in 10 min): tR = 5.61 min; ESI-MS: m/z calcd 
[M+H]+ 419.2, found 419.6. Elemental analysis. Found: C, 40.19; H, 4.14; N, 15.08%. 
Calculated: C22H33N9O4*1H2O*3TFA: C, 39.67; H, 4.52; N, 14.87%. 
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5.5.14 Fmoc-Lys(trityl-resin)-OAl 
 
 
Scheme 5.3 Synthesis of Fmoc-L-Lys(Trityl-Resin)-OAl (81). 
 
Compound (79) 
Product 79 was prepared starting from Fmoc-Lys(Boc)-OH (78) (2.01 g, 4.29 mmol), 
following the same steps and ratios described for 75. The reaction was monitored by TLC 
(DCM/MeOH 10:1; Rf = 0.8), and the product (1.9 g, 87% yield) analysed by 1H-NMR 
(CDCl3, 200 MHz), 4 (ppm): 1.18-1.94 (15 H, m, 3'CH2 e tBu), 3.18-2.85 (2 H, m, 
CH2NH), 4.40-4.0 (4 H, m, #-CH, 9-H Fmoc, CH2 Fmoc), 4.62-4.43 (2 H, m, allyl O-
CH2), 5.14–5.30 (2 H, m, CH=CH2), 5.94-5.70 (1 H, m, CH2=CH), 6.70 (1 H, s br, #-NH), 
7.30 (4 H, m, Fmoc 2-H, 3-H, 6-H e 7-H), 7.59 (2 H, d, J = 7.4, Fmoc 1-H e 8-H), 7.69 (2 
H, d, J = 7.4, Fmoc 4-H e 5-H). 
 
Compound (80) 
Product 80 was obtained by Boc removal from product 79, following the same steps 
and ratios described for 76. The complete Boc removal was monitored by TLC 
(DCM/MeOH 10:1; Rf = 0.59), and the final product (1.506 g, 96% yield) analysed by 1H-
NMR (CDCl3, 200 MHz), 4 (ppm): 1.18-1.94 (6 H, m, 3'CH2), 3.14-2.81 (2 H, m, 
CH2NH), 4.40-4.0 (4 H, m, #-CH, 9-H Fmoc, CH2 Fmoc), 4.62-4.43 (2 H, m, allyl O-
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CH2), 5.14-5.30 (2 H, m, CH=CH2), 5.94-5.70 (1 H, m, CH2=CH), 6.70 (1 H, s br, 1#-NH), 
7.30 (4 H, m, Fmoc 2-H, 3-H, 6-H e 7-H), 7.59 (2 H, d, J =7.4, Fmoc 1-H e 8- H), 7.69 (2 
H, d, J =7.4, Fmoc 4-H e 5-H). 
 
Fmoc-Lys(trityl-resin)-OAl (81) 
The building-block was prepared as described for 77, and the resin loading was 
determined from the Fmoc release, monitored by UV absorbance. 
 
5.5.15 c(Lys-LHis-!Ala-His) (LK13) (57) 
(3S,6S,9S)-3,9-bis((1H-imidazol-4-yl)methyl)-6-(4-aminobutyl)-1,4,7,10-
tetraazacyclotridecane-2,5,8,11-tetraone 
 
Compound 57 was prepared following the same procedure for compound 56. Amino 
acids residues (!-Ala; LHis and Lys, respectively) were introduced according to the 
TBTU/HOBt/NMM method with formation of active esters. The coupling reactions were 
performed by using excess of the amino acids, HOBt and TBTU (4 eq.) and of NMM (8 
eq.) in DMF, under vortex mixing for 40 min. After deprotection and cyclization the crude 
57 was pre-purified by solid phase extraction (SPE) and semi-preparative RP-HPLC (0% 
to 20% of B in 30 min.). Analytical HPLC (03% to 20% of B in 5 min.; flow 600 µL/min) 
tR = 1.47 min; (65 mg, 16% overall yield) ESI-MS: m/z calcd [M+H]+, 474.53, found 
474.42. Elemental analysis. Found: C, 39.09; H, 4.46; N, 15.21%. Calculated: 
C21H31N9O4*1H2O*3TFA: C, 38.90; H, 4.35; N, 15.12%. 
 
5.5.16 c(Lys-DHis-!Ala-His) (DK13) (58) 
(3R,6S,9S)-3,9-bis((1H-imidazol-4-yl)methyl)-6-(4-aminobutyl)-1,4,7,10-
tetraazacyclotridecane-2,5,8,11-tetraone 
 
Compound 58 was prepared following the same procedure for compound 56. Amino 
acids residues (!-Ala; DHis and Lys, respectively) were introduced according to the 
TBTU/HOBt/NMM method with formation of active esters. The coupling reactions were 
Chapter 5. Expermental methods 
 163 
performed by using excess of the amino acids, HOBt and TBTU (4 eq.) and of NMM (8 
eq.) in DMF, under vortex mixing for 40 min. After deprotection and cyclization the crude 
58 was pre-purified by solid phase extraction (SPE) and semi-preparative RP-HPLC (0% 
to 20% of B in 30 min.). Analytical HPLC (03% to 20% of B in 5 min.; flow 600 µL/min) 
tR = 1.17 min; (60 mg, 15% overall yield) ESI-MS: m/z calcd [M+H]+, 474.53, found 
474.41. Elemental analysis. Found: C, 39.11; H, 4.39; N, 15.46%. Calculated: 
C21H31N9O4*1H2O*3TFA: C, 38.90; H, 4.35; N, 15.12%. 
 
5.5.17 c(Gly-!Ala-Gly-Lys) (GK13) (59) 
(S)-6-(4-aminobutyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetraone 
!
Compound 59 was prepared following the same procedure for compound 56 but, in 
this case, the starting material was Fmoc-Lys(Trityl-Resin)-OAl (81). Amino acids 
residues (Gly; !-Ala and Gly, respectively) were introduced according to the 
TBTU/HOBt/NMM method with formation of active esters. The coupling reactions were 
performed by using excess of the amino acids, HOBt and TBTU (4 eq.) and of NMM (8 
eq.) in DMF, under vortex mixing for 40 min. After deprotection and cyclization the crude 
59 was pre-purified by solid phase extraction (SPE) and semi-preparative RP-HPLC (0% 
to 20% of B in 30 min.). Analytical HPLC (03% to 20% of B in 5 min.; flow 600 µL/min) 
tR = 1.09 min; (58 mg, 14% overall yield) ESI-MS: m/z calcd [M+H]+, 314.35, found 
314.40. Elemental analysis. Found: C, 39.95; H, 5.31; N, 15.02%. Calculated: 
C13H23N5O4*H2O*TFA: C, 40.45; H, 5.88; N, 15.72%. 
!
5.5.18 Synthesis of Copper/Cyclopeptide complexes 
The purified cyclopeptide (obtained as trifluoroacetate salt) DK13*3TFA (58) 
(815.22 g/mol; 18.7 mg) was dissolved in 0.5 mL of water (MilliQ grade). In order to 
avoid the presence of free copper(II), the complex was prepared with DK13/Cu ratio of 
1:0,8 respectively, so 2.94 mg of anhydrous CuSO4 were added to the solution and the pH 
was adjusted to 12,0 with diluted NaOH. The resulting solution was lyophilized and the 
solid obtained stored under argon. The same methods and quantities were used also for 
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LK13*3TFA (57) (815.22 g/mol; 18.7 mg). Instead, for GK13*1TFA (59) (427.17 g/mol; 
18.7 mg) were used 1.54 mg of anhydrous CuSO4 in order to maintain the same 
cyclopeptide/Copper ratio. 
The preparation of the sample for the measurements was done in to a glove box 
under argon atmosphere, because of the presence of small particle of solid NaOH in the 
sample; it was very hygroscopic and deliquescent. The solid sample was then milled in a 
mortar and applied in a thin layer between two Kapton films. 
 
5.5.19 Synthesis of Sodium Ditelluratocuprate(III) 
The synthesis of the internal standard compound Ditelluratocuprate(III) 
Na5[Cu{TeO4(OH)2}2]*16H2O (DTC) was performed in accordance with the method 
reported by Sen Gupta et al. 
Copper sulphate (0.78 g) was added to a mixture of telluric acid (1.43 g), potassium 
persulfate (2.11 g), and potassium hydroxide (4.0 g) in water (40 mL). The mixture was 
heated until the solution was an intense red. The boiling was continued for another 30 min 
to ensure the complete removal of persulfate. The ditelluratecuprate(III) was crystallized 
by the solution, cooled at r.t. and 10 mL of saturated NaNO3 solution were added. Almost 
immediately deep red crystals started appearing and crystallisation is complete (ca. 12 h) 
when the supernatant liquid is colourless. The crystals were filtered and washed several 
times with demineralised water and dried under vacuum. 
The final product was characterized by X-Ray structure analysis, and the results are 
in complete agreements with those reported in literature. 
!
5.5.20 Ac-Gly-[Cys-Sec]-Gly-NH2 (66) 
7-(2-acetamidoacetamido)-N-(2-amino-2-oxoethyl)-6-oxo-1,2,5-thiaselenazocane-4-
carboxamide 
 
Selenocysteine was prepared starting from Selenocystine, in accordance with Moroder and 
Hondal (for the references see chapter 4.3.2), Fmoc-Sec(Mob)-OH was obtained with a 
bidimensional orthogonal protection scheme suitable for solid phase peptide synthesis. The 
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peptide Ac-Gly-[Cys-Sec]-Gly-NH2 (66) was synthesized starting from Rink Amide 
MBHA resin (500 mg; 0,4 mmol/g). All the reactions were performed on a semi automatic 
synthesizer (MultiSyn Tech - Germany) following the standard SPPS method and using the 
orthogonal Fmoc/Trt/t-Bu protection scheme. 
The resin was swelled in DMF for 20 minutes and the removal of the Fmoc amino acids 
protecting group was performed by 20% piperidine in DMF. The amino acids Fmoc-Gly-
OH, Fmoc-Sec(Mob)-OH, Fmoc-Cys(Mob)-OH; according to the reported sequence, were 
introduced following the TBTU/HOBt/NMM method with formation of active esters. The 
coupling reactions were performed by using an excess of the amino acids, of the activating 
agents HOBt and TBTU (2.5 eq.) and of NMM (5 eq.) in DMF, vortexing for 40 min at 
room temperature. After each coupling, the resin was washed with DMF and DCM. 
Coupling reactions efficiency was controlled by the Kaiser test. 
The linear peptide was deprotected with 20% piperidine in DMF and the -NH2 terminal 
group was acetylated with a solution of acetic anhydride (20 eq.) and NMM (20 eq.). The 
resin-containing mixture was then swollen at room temperature for 30 min. The reaction 
was repeated once again with fresh solutions. After deprotection, the resin was washed 
with DMF, DCM and dried under vacuum. 
Formation of S-Se bridge was obtained by changing the original method for Mob removal, 
while detaching the peptide from the resin was achieved by using TFA 93%, TIS 2.5%, 
Tioanisole 2.5% and H2O 2.5%, a cleavage cocktail with 1.0 equivalent of 2,23-
Dithiobis(5-nitropyridine) (DTNP) per selenium. 
The crude peptide 66 was purified by solid phase extraction (SPE) and by semi-preparative 
RP-HPLC (20% to 60% of B in 20 min). Analytical HPLC (20% to 60% of B in 20 min.; 
flow 1000 µL/min) tR = 11.85 min; ESI-MS: m/z calcd [M+H]+, 425.33, found 425.95. 
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5.6 Abbreviations 
 
1H-NMR, Proton Nuclear Magnetic Resonance Spectroscopy; Ag, antigen; Av, 
avidin; t-Bu, tert-butyl; Cyclam, 1,4,8,11-tetraazacyclotetradecane; Cyclen, 1,4,7,10-
tetraazacyclododecane; DCC, N,N’-dicyclohexylcarbodiimide; DCM, dichloromethane; 
DCI, diisopropylcarbodimide; DCU, N,N’-dicyclohexylurea; DMF, N,N-
dimethylformamide; EDT, 1,2-ethanedithiol; EtOAc, ethyl acetate; DMSO, 
dimethylsulfoxide; Fmoc, 9H-fluoren-9-ylmethyloxycarbonyl; MeCN, acetonitrile; MeOH, 
methanol; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; EDC, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; ELISA, Enzyme-Linked 
Immunosorbent Assay; ESI-MS, electron spray-ionization mass spectrometry; FCC, Flash 
Column Chromatography; Fmoc, 9-fluorenylmethyloxycarbonyl; GHG, glioma high grade; 
HATU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazole(4,5-b)pyridinium 3-oxide 
hexafluorophosphate; HCTU, 1-[bis(dimethylamino)methylene]-5-chloro-1H-
benzotriazolium 3-oxide hexafluorophosphate; HOAt, 1-hydroxy-7-azabenzotriazole; 
HOBt, 1-hydroxybenzotriazole; HOSu hydroxysuccinimide; HPLC, high performance 
liquid chromatography; HSA, human serum albumin; Ig, immunoglobuline; i.v., 
intravenous; ITLC-SG, silica gel instant layer chromatography; LC-MS liquid 
chromatography-mass spectrometry; MoAb, monoclonal antibody; MTT, methyltrityl; 
NMM, N-methylmorpholine; NMP, 1-methyl-2-pyrrolidinone; RCP, radiochemical purity; 
Rf, retention factor; RIT, radioimmunotherapy; RP-CC, reverse phase column 
chromatography; RP-HPLC, reverse phase high-performance liquid chromatography; tR, 
retention time; Sav, streptavidin; SPE, solid phase extraction; SPECT, single photon 
emission computed tomography; SPPS, solid-phase peptide synthesis; sulfo-NHS, N-
hydroxysulfosuccinimide sodium salt monosodium 1-hydroxy-2,5-dioxo-3-
pyrrolidinesulfonate; TBTU, 1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-
oxide tetrafluoroborate; TFA, trifluoroacetic acid; TETA, 1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid; TIS, triisopropylsilane; TLC, thin layer 
chromatography; UPLC, ultra performance liquid chromatography. 
 
